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A B S T R A C T
Background
Vascular closure devices (VCDs) are widely used to achieve haemostasis after procedures requiring percutaneous common femoral artery
(CFA) puncture. There is no consensus regarding the beneﬁts of VCDs, including potential reduction in procedure time, length of
hospital stay or time to patient ambulation. No robust evidence exists that VCDs reduce the incidence of puncture site complications
compared with haemostasis achieved through extrinsic (manual or mechanical) compression.
Objectives
To determine the efﬁcacy and safety of VCDs versus traditional methods of extrinsic compression in achieving haemostasis after
retrograde and antegrade percutaneous arterial puncture of the CFA.
Search methods
The Cochrane Vascular Trials Search Co-ordinator searched the Specialised Register (April 2015) and the Cochrane Central Register
of Controlled Trials (CENTRAL) (2015, Issue 3). Clinical trials databases were searched for details of ongoing or unpublished studies.
References of articles retrieved by electronic searches were searched for additional citations.
Selection criteria
We included randomised and quasi-randomised controlled trials in which people undergoing a diagnostic or interventional procedure
via percutaneous CFA puncture were randomised to one type of VCD versus extrinsic compression or another type of VCD.
Data collection and analysis
Two authors independently extracted data and assessed the methodological quality of trials. We resolved disagreements by discussion
with the third author. We performed meta-analyses when heterogeneity (I2) was < 90%. The primary efﬁcacy outcomes were time to
haemostasis and time to mobilisation (mean difference (MD) and 95% conﬁdence interval (CI)). The primary safety outcome was
a major adverse event (mortality and vascular injury requiring repair) (odds ratio (OR) and 95% CI). Secondary outcomes included
adverse events.
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Main results
We included 52 studies (19,192 participants) in the review. We found studies comparing VCDs with extrinsic compression (sheath
size ≤ 9 Fr), different VCDs with each other after endovascular (EVAR) and percutaneous EVAR procedures and VCDs with surgical
closure after open exposure of the artery (sheath size ≥ 10 Fr). For primary outcomes, we assigned the quality of evidence according to
GRADE (Grades of Recommendation, Assessment, Development and Evaluation) criteria as low because of serious imprecision and
for secondary outcomes as moderate for precision, consistency and directness.
For time to haemostasis, studies comparing collagen-based VCDs and extrinsic compression were too heterogenous to be combined.
However, both metal clip-based (MD -14.81 minutes, 95% CI -16.98 to -12.63 minutes; ﬁve studies; 1665 participants) and suture-
based VCDs (MD -14.58 minutes, 95% CI -16.85 to -12.32 minutes; seven studies; 1664 participants) were associated with reduced
time to haemostasis when compared with extrinsic compression.
For time to mobilisation, studies comparing collagen-, metal clip- and suture-based devices with extrinsic compression were too
heterogeneous to be combined. No deaths were reported in the studies comparing collagen-based, metal clip-based or suture-based
VCDs with extrinsic compression. For vascular injury requiring repair, meta-analyses demonstrated that neither collagen (OR 2.81,
95% CI 0.47 to 16.79; six studies; 5731 participants) nor metal clip-based VCDs (OR 0.49, 95% CI 0.03 to 7.95; three studies; 783
participants) were more effective than extrinsic compression. No cases of vascular injury required repair in the study testing suture-
based VCD with extrinsic compression.
Investigators reported no differences in the incidence of infection between collagen-based (OR 2.14, 95% CI 0.88 to 5.22; nine
studies; 7616 participants) or suture-based VCDs (OR 1.66, 95% CI 0.22 to 12.71; three studies; 750 participants) and extrinsic
compression. No cases of infection were observed in studies testing suture-based VCD versus extrinsic compression. The incidence
of groin haematoma was lower with collagen-based VCDs than with extrinsic compression (OR 0.46, 95% CI 0.40 to 0.54; 25
studies; 10,247 participants), but no difference was evident when metal clip-based (OR 0.79, 95% CI 0.46 to 1.34; four studies; 1523
participants) or suture-based VCDs (OR 0.65, 95% CI 0.41 to 1.02; six studies; 1350 participants) were compared with extrinsic
compression. The incidence of pseudoaneurysm was lower with collagen-based devices than with extrinsic compression (OR 0.74, 95%
CI 0.55 to 0.99; 21 studies; 9342 participants), but no difference was noted when metal clip-based (OR 0.76, 95% CI 0.20 to 2.89;
six studies; 1966 participants) or suture-based VCDs (OR 0.79, 95% CI 0.25 to 2.53; six studies; 1527 participants) were compared
with extrinsic compression. For other adverse events, researchers reported no differences between collagen-based, clip-based or suture-
based VCDs and extrinsic compression.
Limited data were obtained when VCDs were compared with each other. Results of one study showed that metal clip-based VCDs were
associated with shorter time to haemostasis (MD -2.24 minutes, 95% CI -2.54 to -1.94 minutes; 469 participants) and shorter time
to mobilisation (MD -0.30 hours, 95% CI -0.59 to -0.01 hours; 469 participants) than suture-based devices. Few studies measured
(major) adverse events, and those that did found no cases or no differences between VCDs.
Percutaneous EVAR procedures revealed no differences in time to haemostasis (MD -3.20 minutes, 95% CI -10.23 to 3.83 minutes;
one study; 101 participants), time to mobilisation (MD 1.00 hours, 95% CI -2.20 to 4.20 hours; one study; 101 participants) or major
adverse events between PerClose and ProGlide. When compared with sutures after open exposure, VCD was associated with shorter
time to haemostasis (MD -11.58 minutes, 95% CI -18.85 to -4.31 minutes; one study; 151 participants) but no difference in time to
mobilisation (MD -2.50 hours, 95% CI -7.21 to 2.21 hours; one study; 151 participants) or incidence of major adverse events.
Authors’ conclusions
For time to haemostasis, studies comparing collagen-based VCDs and extrinsic compression were too heterogeneous to be combined.
However, bothmetal clip-based and suture-based VCDs were associated with reduced time to haemostasis when compared with extrinsic
compression. For time to mobilisation, studies comparing VCDs with extrinsic compression were too heterogeneous to be combined.
No difference was demonstrated in the incidence of vascular injury or mortality when VCDs were compared with extrinsic compression.
No difference was demonstrated in the efﬁcacy or safety of VCDs with different mechanisms of action. Further work is necessary to
evaluate the efﬁcacy of devices currently in use and to compare these with one other and extrinsic compression with respect to clearly
deﬁned outcome measures.
P L A I N L A N G U A G E S U M M A R Y
Effectiveness and safety of devices designed to close femoral artery puncture sites
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Background
Endovascular procedures require access to the inside of an artery. A small hole is made in the artery at the groin, and a catheter is
guided along to the site of interest. Once the procedure is complete, the hole in the artery must be closed and the bleeding stopped
(haemostasis). Traditionally, the main method of closing the artery is compression, during which up to 30 minutes of manual pressure
or mechanical clamps is applied directly to the patient’s groin. This manual pressure can be painful and requires up to eight hours of
bedrest. The process of closing the artery can lead to complications such as damage to the artery and bleeding, ranging from minor to
life-threatening. Pressure applied to the artery also affects the nearby vein and may cause blood clots (deep vein thrombosis). Vascular
closure devices (VCDs) are designed to close the hole and stop bleeding. VCDs were developed in the 1990s in an attempt to reduce the
time to stop bleeding, to enable earlier walking after a procedure and to improve patient comfort. Four main types of VCDs are based
on the material used: collagen plugs, suture-based, disc-based and metal clips. No consensus has been reached on the effectiveness of
VCDs in reducing procedure time, length of stay or time to mobilisation, and it is unknown whether they confer a cost beneﬁt when
compared with compression.
Study characteristics
This review measures the effectiveness and safety of these VCDs compared with one other and with manual or mechanical compression.
After searching for relevant studies, we found 52 studies with a combined total of 19,192 participants (current until April 2015). Studies
compared different VCDs with manual or mechanical compression and/or with one other. The main measures of effectiveness were
time to haemostasis and time to mobilisation. The main safety outcomes included adverse events such as bleeding, arterial damage,
infection and development of clots in the adjacent vein.
Key results
This review showed that for time to haemostasis and time to mobilisation, the studies were too different to be combined in a statistical
analysis when VCDs are compared with compression. For safety outcomes, no robust evidence shows that VCDs reduce the number
of serious puncture site complications, when compared with manual or mechanical compression. Furthermore, this review showed no
difference in effectiveness or safety for one type of VCD versus another, but few studies made these comparisons. Further good quality
studies are required before ﬁrm conclusions can be drawn.
Quality of the evidence
For time to haemostasis and time to mobilisation, the studies were too different to be combined and therefore were judged to provide
low-quality evidence. The quality of the evidence for the other outcomes was judged as moderate for precision, consistency and
directness.
B A C K G R O U N D
Description of the condition
Percutaneous puncture of the common femoral artery is performed
to enable sheath access to the arterial system for diagnostic catheter
angiography and arterial intervention. Percutaneous arterial access
carries risks of damage to the artery and adjacent vein, including
haematoma and pseudoaneurysm formation and arterial dissec-
tion (Koreny 2004). If the adjacent vein is damaged at the time
of the puncture, arteriovenous ﬁstula formation is also possible
(Merriweather 2012).
On completion of the procedure, haemostasis can be achieved by
external compression of the artery against the underlying bone,
either manually or with a mechanical compression device. After
haemostasis has been achieved in this way, the patient is required
to rest in bed, normally for four to six hours (Schwartz 2010). Suc-
cessful and persistent haemostasis reduces the incidence of arterial
bleeding and decreases the incidence of haematoma and pseudoa-
neurysm formation. Deep vein thrombosis has been reported af-
ter prolonged extrinsic compression of the adjacent artery (Zahn
1997).
Description of the intervention
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Percutaneously deployed vascular closure devices (VCDs) are ad-
juncts to haemostasis that are deployed at the time of sheath re-
moval. VCDs are suitable for use in many patients to provide in-
stant haemostasis, obviating the need for extrinsic compression
and prolonged bedrest. Over the past two decades, VCD use has
been widely accepted by practitioners of endovascular medicine.
VCDs fall into four main categories: clip-based (e.g. StarClose;
Abbott), suture-based (e.g. PerClose, ProStar; both Abbott), disc-
based (e.g. Cardiva Catalyst II; Cardiva Medical) and plug-based
(e.g. AngioSeal; St Jude Medical; ExoSeal; Cordis), in which the
plugs are predominantly collagen in composition, except for Ex-
oSeal, which is Polyglycolic Acidsee (Table 1). Indications forVCD
use are device-speciﬁc and depend on patient characteristics, cal-
ibre and quality of the arterial wall and arteriotomy size. Most
devices are licenced to close 6 to 8 Fr puncture sites in non-dis-
eased arteries for patients without signiﬁcant obesity. Recently, so-
called “pre-closure” devices have become available (e.g. ProStar
XL;, Abbott) that can close larger arteriotomies and can be used in
large-calibre arterial interventions such as percutaneous endovas-
cular aortic aneurysm repair (EVAR) or transcatheter aortic valve
implantation (TAVI). Device selection should be consistent with
instructions for use. Operator and unit preference and device cost
also play a signiﬁcant role in device selection.
Why it is important to do this review
VCDs are thought to reduce time to haemostasis, but no consen-
sus indicates whether they affect the incidence of complications at
the arteriotomy site compared with haemostasis achieved through
extrinsic compression (Smilowitz 2012). Furthermore, introduc-
tion of a delivery system and a foreign body into a patient could
further damage the artery, and little is known about potentially
increased incidence of complications arising directly from closure
device use. This review compares the beneﬁts and complications
of different types of VCD with one other and with extrinsic com-
pression.
O B J E C T I V E S
To determine the efﬁcacy and safety of VCDs versus traditional
methods of extrinsic compression in achieving haemostasis after
retrograde and antegrade percutaneous arterial puncture of the
common femoral artery (CFA).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all randomised and quasi-randomised controlled
clinical trials comparing vascular closure devices (VCDs) against
manual compression (MC) or mechanical compression devices
(MCDs), or both, for achieving common femoral artery (CFA)
puncture site haemostasis. The review also encompasses compar-
isons between different vascular closure devices.
Types of participants
All studies involving people of both genders undergoing a diag-
nostic or interventional procedure in which vascular access was
achieved through percutaneous puncture of the common femoral
artery.
Types of interventions
• Haemostasis after diagnostic or interventional endovascular
procedures (sheath size ≤ 9 Fr).
◦ Vascular closure device (VCD) versus manual
compression (MC) or mechanical compression device (MCD),
or both.
◦ One type of VCD versus another.
• Haemostasis after percutaneous EVAR (sheath size ≥ 10
Fr).
◦ One type of VCD versus another.
• Haemostasis after EVAR with open exposure of CFA
(sheath size ≥ 10 Fr).
◦ One type of VCD versus another.
◦ Surgical suture-based closure versus VCD.
Types of outcome measures
Primary outcomes
Primary end point: efficacy
• Time to haemostasis: Haemostasis is deﬁned as no or
minimal subcutaneous bleeding and absence of expanding or
developing haematoma.
• Time to mobilisation: This was deﬁned as the time between
sheath removal and when the participant was able to mobilise
without recurrence of bleeding.
• Major adverse event (occurring at any time).
◦ Mortality.
◦ Vascular injury requiring vascular repair by surgical or
non-surgical techniques.
4Vascular closure devices for femoral arterial puncture site haemostasis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Secondary outcomes
• Adverse events (occurring up to 30 days after arterial
closure).
◦ Infection.
◦ Groin haematoma.
◦ Retroperitoneal haemorrhage.
◦ Pseudoaneurysm.
◦ Arterial dissection.
◦ Arteriovenous ﬁstula.
◦ Embolisation resulting in loss of distal pulse.
◦ Deep vein thrombosis.
◦ Limb ischaemia.
◦ Femoral artery thrombosis.
• Technical failure of VCDs.
• Time spent in angiography suite.
• Length of hospital stay.
• Participant satisfaction.
• Costs of VCD and extrinsic compression.
Search methods for identification of studies
Electronic searches
The Cochrane Vascular Trials Search Co-ordinator (TSC)
searched the Specialised Register (April 2015). In addition, the
TSC searched the Cochrane Register of Studies (CRS) at http:/
/www.metaxis.com/CRSWeb/Index.asp (the Cochrane Central
Register of Controlled Trials (CENTRAL) (2015, Issue 3)). See
Appendix 1 for details of the search strategy used to search the
CRS. The Specialised Register is maintained by the TSC and
is constructed from weekly electronic searches of MEDLINE,
EMBASE, CINAHL, AMED, and through handsearching rele-
vant journals. The full list of the databases, journals and con-
ference proceedings which have been searched, as well as the
search strategies used are described in the Specialised Register sec-
tion of the Cochrane Vascular module in The Cochrane Library (
www.cochranelibrary.com).
The TSC searched the following trial databases in April 2015
for details of ongoing and unpublished studies using the terms
’vascular’ and ’closure’.
• World Health Organization International Clinical Trials
Registry (http://apps.who.int/trialsearch/).
• ClinicalTrials.gov (http://clinicaltrials.gov/).
• International Standard Randomized Controlled Trial
Number (ISRCTN) register (http://www.isrctn.com/).
Searching other resources
We searched citations within identiﬁed studies and contacted au-
thors of identiﬁed studies to ask about unpublished studies. We
applied no restrictions on language.
Data collection and analysis
All randomised and quasi-randomised trials that compared the sa-
fety and efﬁcacy of vascular closure devices with manual compres-
sion or mechanical compression methods, or both, were eligible
for inclusion.
Selection of studies
Two review authors (LR and AA) independently assessed studies
identiﬁed for inclusion in the reviewusing the criteria stated above.
They resolved disagreements by discussion or by consultation with
a third review author (FC).
Data extraction and management
Two review authors (LR and AA) independently extracted data
from the included studies using a standard data extraction form
created for the review. Disagreements between the two review au-
thors were resolved by discussion or by consultation with a third
review author (FC).
Assessment of risk of bias in included studies
Two review authors (LR and AA) assessed the risk of bias for each
study as described in theCochraneHandbook for Systematic Reviews
of Interventions 5.1.0 (Higgins 2011) for each of the following
domains.
• Randomisation sequence generation.
• Allocation concealment.
• Blinding (of participants, personnel and outcome assessors).
• Completeness of data.
• Selective outcome reporting.
• Other sources of bias.
The review authors evaluated each criterion as ’Low risk’ of bias
or ’High risk’ of bias according to Higgins 2011. If these criteria
were not discussed in the publication, the review authors assessed
risk of bias as ’Unclear’. Disagreements between the two review
authors were resolved by discussion or by consultation with a third
review author (FC).
Measures of treatment effect
Whendealingwith dichotomous outcomemeasures, we calculated
a pooled estimate of the treatment effect for each outcome across
trials using the odds ratio (OR) (the odds of an outcome among
treatment-allocated participants to the corresponding odds of the
same outcome among participants in the control group) and es-
timated the 95% conﬁdence interval (CI). For continuous out-
comes, we recorded either the mean change from baseline for each
group or mean post-intervention values and standard deviation
(SD) for each group. When appropriate, we calculated a pooled
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estimate of the treatment effect by calculating the mean difference
(MD) and the SD.
Unit of analysis issues
The unit of analysis was the individual participant. We did not in-
clude cross-over trials in the review because only a single treatment
was designated to each group. In the case of cluster-randomised
trials, when the unit of randomisation was not the same as the unit
of analysis, we performed appropriate adjustment for clustering,
as outlined in the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011).
Dealing with missing data
The review authors requested missing data from the original inves-
tigators, if appropriate. When these could not be obtained, an in-
tention-to-treat (ITT) analysis was carried out. For the ITT analy-
sis, we used data on the number of participants with each outcome
event by allocated treatment group, irrespective of compliance and
whether or not the participant was later thought to be ineligible
or otherwise excluded from treatment or follow-up.
Assessment of heterogeneity
If ameta-analysis was possible, we assessed statistical heterogeneity
by using the I2 statistic to quantify inconsistencies among included
studies. A guide to interpretation of the I2 statistic is provided
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011) as follows: 0% to 40% might not be important;
30% to 60%may represent moderate heterogeneity; 50% to 90%
may represent substantial heterogeneity; 75% to 100% represents
considerable heterogeneity. For the purposes of this review, 90%
was the cutoff point for considerable heterogeneity. If considerable
heterogeneity was observed (I2 ≥ 90%), the data were not pooled
into a meta-analysis. If heterogeneity was observed, we planned to
conduct a subgroup analysis to explore possible causes.
Assessment of reporting biases
We investigated publication bias by using funnel plots if we were
able to include a sufﬁcient number of studies (≥ 10), as recom-
mended by the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011; Sterne 2001). If we detected asymme-
try, we explored causes other than publication bias. Asymmetrical
funnel plots can indicate outcome reporting bias (ORB) or het-
erogeneity. If we suspected ORB, we contacted trialists. Outcome
reporting bias can be assessed by comparing the Methods section
of a published trial with the Results section when the original pro-
tocol is not available.
Data synthesis
We used a ﬁxed-effect model in our analysis (Higgins 2011). If we
detected heterogeneity (I2 > 75%), we reassessed the signiﬁcance
of the treatment effect by using and reporting a random-effects
model.
Subgroup analysis and investigation of heterogeneity
The original protocol stipulated that the following analyses should
be performed.
• VCD for the conventional interventional vascular
procedure using introducer sheaths up to 9 Fr versus VCD
requiring larger introducer sheaths (e.g. for EVAR).
• Comparison between antegrade and retrograde punctures.
However, data from the included studies did not permit these
subgroup analyses.
In the presence of heterogeneity, we used a random-effects model.
To investigate heterogeneity further, we performed analyses com-
paring type of procedure (diagnostic or interventional) and brand
of VCD when possible.
Sensitivity analysis
We planned to perform a sensitivity analysis to assess the impact
of trials with high risk of bias on the overall outcome of pooling
of data. However, most studies were classiﬁed as having low or
unclear risk of bias; therefore, this was not possible.
Quality of evidence
We graded the quality of the evidence according to the GRADE
(Grades ofRecommendation, Assessment,Development andEval-
uation) principles described in Higgins 2011 and GRADE 2004.
R E S U L T S
Description of studies
Results of the search
See Figure 1.
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Figure 1. Study flow diagram.
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Included studies
See Characteristics of included studies.
We included in the review 52 studies involving a total of 19,192
participants (Amin 2000; Amine 1999; Ansel 2006; Behan 2007;
Brachmann 1998; Camenzind 1994; Carere 2000; Castañeda
2003; Chen 2013; Deuling 2008; Diaz 2001; Doneaux 2001;
Fargen 2011; Gerckens 1998; Gwechenberger 1997; Hattab
2012; Hermanides 2010; Hermiller 2005; Hermiller 2006; Holm
2014; Jensen 2008; Juergens 2004; Kalsch 2008; Kussmaul 1995;
Legrand 2005; Machnik 2012; Magosaki 1999; Martin 2008;
Michalis 2002;Nelson2014;Noguchi 2000; Park 2005; Perlowski
2011; Rastan 2008; Reddy 2004; Rickli 2002; Sanborn 1993;
Schräder 1992; Schulz-Schüpke 2014; SEAL Trial Study Team;
Seidelin 1997; Shammas 2002; Silber 1998; Sun 2009; Tron 2003;
Upponi 2007; Veasey 2008; von Hoch 1995; Ward 1998; Wetter
2000; Wong 2009; Yadav 2003).
In all, 51 studies assessed the effectiveness of VCDs after diag-
nostic or interventional endovascular procedures (sheath size ≤
9 Fr). One study compared the effectiveness of VCDs in people
undergoing percutaneous EVAR and in those with open exposure
of the common femoral artery (both sheath size ≥ 10 Fr) (Nelson
2014).
Eleven studies looked at the effectiveness of VCDs after diagnos-
tic catheterisation procedures (Amine 1999; Behan 2007; Fargen
2011; Hermiller 2005; Holm 2014; Jensen 2008; Reddy 2004;
Schulz-Schüpke 2014; Seidelin 1997; Veasey 2008; Ward 1998),
and 15 studies assessed interventional procedures (Amin 2000;
Camenzind 1994; Chen 2013; Doneaux 2001; Hattab 2012;
Hermiller 2006; Juergens 2004; Legrand 2005; Machnik 2012;
Martin 2008; Rickli 2002; Silber 1998; Tron 2003; von Hoch
1995; Wetter 2000). Twenty-four studies looked at both diag-
nostic and interventional procedures (Ansel 2006; Brachmann
1998; Carere 2000; Castañeda 2003; Deuling 2008; Diaz 2001;
Gerckens 1998; Gwechenberger 1997; Kalsch 2008; Kussmaul
1995; Magosaki 1999; Michalis 2002; Noguchi 2000; Park 2005;
Perlowski 2011; Rastan 2008; Sanborn 1993; Schräder 1992;
SEALTrial Study Team; Shammas 2002; Sun 2009;Upponi 2007;
Wong 2009; Yadav 2003). One study (Nelson 2014) measured
the effectiveness of two VCDs after percutaneous EVAR; the same
study also compared devices with surgical suture-based closure ver-
sus VCDs after EVAR with open exposure of the CFA.
Collagen-based VCD versus manual or mechanical
compression
Thirty studies measured the effectiveness of a collagen-based
vascular closing device versus manual or mechanical compres-
sion (Amin 2000; Behan 2007; Brachmann 1998; Camenzind
1994; Castañeda 2003;Deuling 2008;Diaz 2001;Doneaux 2001;
Gwechenberger 1997; Hermanides 2010; Holm 2014; Jensen
2008; Juergens 2004; Kussmaul 1995; Legrand 2005; Machnik
2012; Magosaki 1999; Martin 2008; Reddy 2004; Sanborn 1993;
Schräder 1992; Schulz-Schüpke 2014; SEAL Trial Study Team;
Seidelin 1997; Silber 1998; Upponi 2007; von Hoch 1995; Ward
1998; Wong 2009; Yadav 2003). Seventeen trials studied the An-
gioSeal device (Amin 2000; Behan 2007; Deuling 2008; Diaz
2001; Doneaux 2001; Hermanides 2010; Jensen 2008; Juergens
2004; Kussmaul 1995; Legrand 2005; Machnik 2012; Magosaki
1999; Martin 2008; Reddy 2004; Seidelin 1997; Upponi 2007;
Ward 1998) - seven in diagnostic procedures (Behan 2007;
Deuling 2008;Doneaux 2001; Jensen 2008; Reddy 2004; Seidelin
1997; Ward 1998), six in interventional procedures (Amin 2000;
Hermanides 2010; Juergens 2004; Legrand 2005; Machnik 2012;
Martin 2008) and four (Diaz 2001; Kussmaul 1995; Magosaki
1999; Upponi 2007) in both diagnostic and interventional proce-
dures. Seven studies tested the VasoSeal device (Brachmann 1998;
Camenzind 1994; Gwechenberger 1997; Sanborn 1993; Schräder
1992; Silber 1998; von Hoch 1995) - three (Camenzind 1994;
Silber 1998; von Hoch 1995) in interventional procedures and
four (Brachmann 1998; Gwechenberger 1997; Sanborn 1993;
Schräder 1992) in both diagnostic and interventional procedures.
One study (SEAL Trial Study Team) tested the Duett device,
which is a liquid collagen and thrombin device, two studied
QuickSeal (Castañeda 2003; Yadav 2003), two studied FemoSeal
(Holm 2014; Schulz-Schüpke 2014) and two studied ExoSeal
(Schulz-Schüpke 2014; Wong 2009), a device that uses a polygly-
colic acid plug. Schulz-Schüpke 2014 tested ExoSeal in interven-
tional procedures, and Wong 2009 tested ExoSeal in both diag-
nostic and interventional procedures.
Metal clip-based VCD versus manual or mechanical
compression
Six studies measured the effectiveness of a metal clip-based device
versusmanual compression (Ansel 2006;Deuling 2008;Hermiller
2005; Hermiller 2006; Perlowski 2011; Sun 2009). Four studied
the StarClose device (Deuling 2008; Hermiller 2005; Hermiller
2006; Perlowski 2011) - one (Hermiller 2005) in diagnostic pro-
cedures, one (Hermiller 2006) in interventional procedures and
two (Deuling 2008; Perlowski 2011) in both diagnostic and in-
terventional procedures. Sun 2009 was a three-armed trial that
compared StarClose, PerClose and manual compression in partic-
ipants undergoing both diagnostic and interventional procedures.
Finally, one study measured the effectiveness of the Angiolink EVS
closure device (Ansel 2006) with both diagnostic and interven-
tional procedures.
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Suture-based VCD versus manual or mechanical
compression
Ten studies (Amine 1999; Carere 2000; Gerckens 1998; Jensen
2008; Martin 2008; Noguchi 2000; Rickli 2002; Sun 2009; Tron
2003; Wetter 2000) measured the effectiveness of a suture-based
device versus manual compression. Seven studies (Amine 1999;
Jensen 2008; Martin 2008; Rickli 2002; Sun 2009; Tron 2003;
Wetter 2000) looked at PerClose - two (Amine 1999; Jensen 2008)
in diagnostic participants, four (Martin 2008; Rickli 2002; Tron
2003; Wetter 2000) in interventional participants and one (Sun
2009) in both types of procedures. Three studies (Carere 2000;
Gerckens 1998; Noguchi 2000) tested ProStar in participants un-
dergoing diagnostic and interventional procedures.
Collagen-based VCD versus metal clip-based VCD:
AngioSeal versus StarClose
Three studies compared AngioSeal versus StarClose (Deuling
2008; Rastan 2008; Veasey 2008). Veasey 2008 tested the device
after diagnostic procedures, and Deuling 2008 and Rastan 2008
looked at both diagnostic and interventional procedures.
Collagen-based VCD versus suture-based VCD
Five studies (Hattab 2012; Jensen 2008; Kalsch 2008; Martin
2008; Park 2005) compared a collagen-based VCD with a suture-
based VCD. Three studies (Jensen 2008; Kalsch 2008; Martin
2008) compared AngioSeal with PerClose - one (Jensen 2008) in
diagnostic participants, one (Martin 2008) in interventional par-
ticipants and one (Kalsch 2008) in both diagnostic and interven-
tional participants. One study (Park 2005) compared AngioSeal
with Closure S in diagnostic and interventional participants, and
Hattab 2012 compared ExoSeal with ProGlide in participants un-
dergoing intervention. Park 2005 included participants with sev-
eral femoral artery punctures. Outcomes are based on the number
of punctures rather than on the number of individual participants.
After personal communication with the study author, it was de-
cided that although this study was relevant and met the inclusion
criteria, data would not be included in the analyses, as they were
not comparable with data based on individuals from the other in-
cluded studies.
Metal clip-based VCD versus suture-based VCD: StarClose
versus PerClose
One study (Sun 2009) compared the metal clip-based StarClose
with the suture-based PerClose in participants undergoing diag-
nostic and interventional procedures.
Disc-based VCD versus suture-based VCD: Boomerang
versus PerClose
One study (Chen 2013) compared a disc-based device
(Boomerang) with a suture-based device (PerClose) in 60 partici-
pants undergoing coronary intervention.
Collagen-based VCD versus collagen-based VCD: AngioSeal
versus VasoSeal
Two studies (Michalis 2002; Shammas 2002) compared the colla-
gen-based devices AngioSeal and VasoSeal in both diagnostic and
interventional procedures.
Collagen-based VCD versus collagen-based VCD: AngioSeal
versus Mynx
One study (Fargen 2011) measured vascular injury requiring re-
pair, infection, groin haematoma and patient satisfaction in diag-
nostic participants treated with the AngioSeal or another collagen
device, Mynx.
Collagen-based VCD versus collagen-based VCD: AngioSeal
versus Duett
Michalis 2002 was a three-armed trial that tested the collagen
devicesAngioSeal andDuett in participants undergoingdiagnostic
and interventional procedures.
Collagen-based VCD versus collagen-based VCD: VasoSeal
versus Duett
Michalis 2002 also tested the VasoSeal and Duett collagen devices.
Collagen-based VCD versus collagen-based VCD: FemoSeal
versus ExoSeal
One study (Schulz-Schüpke 2014) compared the collagen devices
FemoSeal and ExoSeal in participants undergoing diagnostic pro-
cedures.
PerClose ProGlide versus ProStar XL after percutaneous
EVAR (sheath size ≥ 10 Fr)
One study (Nelson 2014) compared PerClose ProGlide with
ProStar XL in participants undergoing percutaneous EVAR.
PerClose ProGlide and ProStar XL versus suture-based
closure after EVAR with open exposure of CFA (sheath size
≥ 10 Fr)
Nelson 2014 also compared the PerClose ProGlide and ProStar
XL devices with surgical suture-based closure in participants un-
dergoing open femoral exposure of the CFA.
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Excluded studies
See Characteristics of excluded studies.
We excluded 14 studies (Baim 2000; Beyer-Enke 1996; Chalmers
2007; Chevalier 2000; Jean-Baptiste 2008; Kuraklio lu 2008;
Larzon 2015; Leinbudgut 2013; Lupi 2012; Neudecker 2003;
Ratnam 2007; Slaughter 1995; Smilowitz 2012; Starnes 2003).
Seven were not randomised controlled trials (Jean-Baptiste 2008;
Kuraklio lu 2008; Lupi 2012; Ratnam 2007; Neudecker 2003;
Ratnam 2007; Smilowitz 2012), two (Baim 2000; Starnes 2003)
used 7 to 10 Fr sheath sizes and did not present data by sheath
size and one (Chalmers 2007) used EVICEL and another (Larzon
2015) used the fascia suture technique (neither of which are
VCDs); another study (Chevalier 2000) measured adverse events
included in this review but did not present data, one (Leinbudgut
2013) randomised people by the drug they received to prevent
bleeding rather than by VCD and another study (Beyer-Enke
1996) was not clear on whether access for the procedure was at-
tained through the femoral artery. For studies on which we had
queries regarding data (Baim 2000; Beyer-Enke 1996; Chevalier
2000; Starnes 2003), we wrote to the study authors but received
no response and therefore had to exclude these studies from the
review.
Risk of bias in included studies
See Figure 2 and Figure 3.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
11Vascular closure devices for femoral arterial puncture site haemostasis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Random sequence generation: Of the 52 studies included in
this review, 10 were deemed to be at low risk of bias (Amine
1999; Castañeda 2003;Hermanides 2010; Holm 2014; Kussmaul
1995; Legrand 2005; Nelson 2014; Schulz-Schüpke 2014; SEAL
Trial Study Team; Wong 2009). Three studies (Legrand 2005;
Schulz-Schüpke 2014; Wong 2009) reported that randomisation
was computer-assisted, and another seven studies (Amine 1999;
Castañeda 2003;Hermanides 2010; Holm 2014; Kussmaul 1995;
Nelson 2014; SEAL Trial Study Team) reported using a block de-
sign to generate the random sequence. Two studies were judged to
be at high risk of bias, as participants were assigned to treatment
not randomly but rather on order of presentation (Deuling 2008)
or by odd and even numbers (Diaz 2001). The remaining 40 stud-
ies did not provide enough information about the randomisation
process to permit judgement on the risk of bias.
Allocation concealment: One study was deemed to be at high risk
of bias as allocation was based on alternation (Diaz 2001). Eleven
studies were at low risk of bias, as they reported using sealed en-
velopes (Amine 1999; Castañeda 2003; Fargen 2011; Kussmaul
1995; Nelson 2014; Noguchi 2000; Rastan 2008; SEAL Trial
Study Team; Wong 2009) or a computer-based system (Holm
2014; Schulz-Schüpke 2014) to conceal allocation of treatment.
The remaining 40 did not provide enough information about al-
location concealment to permit judgement on the risk of selection
bias.
Blinding
Blinding of study participants and personnel was not possible.
However, we determined that outcomes of the review were not
likely to be inﬂuenced by lack of blinding and therefore judged all
studies to be at low risk of performance bias.
Blinding of outcome assessors was possible, and eight studies (
Behan 2007; Brachmann 1998; Camenzind 1994; Fargen 2011;
Hermanides 2010; Juergens 2004; Schulz-Schüpke 2014; SEAL
Trial Study Team) were judged to be at low risk of detection bias
as study authors reported that outcome assessors were blinded to
treatment assignment. No study was found to be at high risk of
detection bias. In the remaining 44 studies included in this review,
risk of detection bias was deemed to be unclear because reporting
of blinding of outcome assessors was inadequate.
Incomplete outcome data
Thirty-six of the 52 included studies were judged to be at
low risk of attrition bias (Amin 2000; Amine 1999; Ansel
2006; Camenzind 1994; Carere 2000; Castañeda 2003; Chen
2013; Fargen 2011; Gwechenberger 1997; Hermanides 2010;
Hermiller 2005; Hermiller 2006; Holm 2014; Jensen 2008;
Juergens 2004; Kalsch 2008; Legrand 2005; Machnik 2012;
Martin 2008;Michalis 2002;Nelson2014;Noguchi 2000; Rastan
2008; Rickli 2002; Sanborn 1993; Schulz-Schüpke 2014; Seidelin
1997; Shammas 2002; Silber 1998; Tron 2003; Upponi 2007;
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von Hoch 1995; Ward 1998; Wetter 2000; Wong 2009; Yadav
2003). Two studies were judged to be at high risk of attrition bias:
SEALTrial Study Team reported that only 227 of 392 participants
treated with the Duett device completed the seven-day and 30-
day quality of life study and did not explain the reason for this
large loss to follow-up and Behan 2007 reported that only 72%
of AngioSeal and 71% of manual compression participants com-
pleted follow-up at one week. The remaining 14 studies did not
provide enough information about incomplete outcome data to
permit judgement on the risk of attrition bias.
Selective reporting
One study (SEAL Trial Study Team) was judged to be at high risk
of reporting bias, as study authors reported quality of life results at
seven days and 30 days post procedure, but quality of life was not
a clearly speciﬁed outcome of the study. Thirty-one studies ade-
quately reported data on all pre-speciﬁed outcomes and therefore
were judged to be at low risk of reporting bias (Amin 2000; Ansel
2006; Behan 2007; Camenzind 1994; Carere 2000; Castañeda
2003; Chen 2013; Fargen 2011; Hermanides 2010; Hermiller
2005;Hermiller 2006;Holm2014; Juergens 2004; Legrand 2005;
Martin 2008;Michalis 2002;Nelson2014;Noguchi 2000; Rastan
2008; Rickli 2002; Sanborn 1993; Schulz-Schüpke 2014; Seidelin
1997; Shammas 2002; Silber 1998; Tron 2003; von Hoch 1995;
Ward 1998;Wetter 2000; Wong 2009; Yadav 2003). The remain-
ing 20 studies did not provide enough information to permit
judgement on low or high risk of reporting bias; therefore, the risk
was deemed unclear.
Other potential sources of bias
Twenty-eight studies appeared to be free from other sources of bias
(Amin 2000; Ansel 2006; Behan 2007; Carere 2000; Castañeda
2003; Chen 2013; Diaz 2001; Fargen 2011; Hermanides 2010;
Hermiller 2005; Hermiller 2006; Holm 2014; Juergens 2004;
Legrand 2005; Machnik 2012; Martin 2008; Michalis 2002;
Nelson 2014; Rastan 2008; Rickli 2002; Sanborn 1993; Schulz-
Schüpke 2014; Seidelin 1997; Silber 1998; Tron 2003; von Hoch
1995; Wong 2009; Yadav 2003). No study was deemed to be at
high risk of bias. The remaining 24 studies included in the review
did not provide enough information; therefore, risk of bias was
unclear.
Effects of interventions
Haemostasis after diagnostic or interventional
endovascular procedures (sheath size ≤ 9 Fr)
Collagen-based VCD versus manual or mechanical
compression
Thirty studies measured the effectiveness of a collagen-based
vascular closing device versus manual or mechanical compres-
sion (Amin 2000; Behan 2007; Brachmann 1998; Camenzind
1994; Castañeda 2003;Deuling 2008;Diaz 2001;Doneaux 2001;
Gwechenberger 1997; Hermanides 2010; Holm 2014; Jensen
2008; Juergens 2004; Kussmaul 1995; Legrand 2005; Machnik
2012; Magosaki 1999; Martin 2008; Reddy 2004; Sanborn 1993;
Schräder 1992; Schulz-Schüpke 2014; SEAL Trial Study Team;
Seidelin 1997; Silber 1998; Upponi 2007; von Hoch 1995; Ward
1998; Wong 2009; Yadav 2003).
Time to haemostasis
Nineteen studies that compared a collagen-based VCDwith man-
ual compression measured time to haemostasis (Brachmann 1998;
Castañeda 2003; Diaz 2001; Doneaux 2001; Gwechenberger
1997; Holm 2014; Juergens 2004; Kussmaul 1995; Magosaki
1999;Martin 2008; Reddy 2004; Sanborn 1993; Schulz-Schüpke
2014; SEAL Trial Study Team; Seidelin 1997; Silber 1998; Ward
1998; Wong 2009; Yadav 2003). Data from 12 studies were en-
tered into a meta-analysis (Brachmann 1998; Castañeda 2003;
Diaz 2001;Gwechenberger 1997; Juergens 2004; Kussmaul 1995;
Magosaki 1999; Reddy 2004; Sanborn 1993; Seidelin 1997; Silber
1998; Wong 2009). Seven studies were not included in the meta-
analysis: Four studies (Doneaux 2001; Martin 2008; Ward 1998;
Yadav 2003) did not report standard deviations for mean time
to haemostasis, and three studies (Holm 2014; Schulz-Schüpke
2014; SEAL Trial Study Team) presented time to haemostasis as
a median and as an interquartile range.
When the 12 studies were combined in a meta-analysis, consid-
erable heterogeneity was evident (I2 = 98%) (Analysis 1.1). Sub-
group analyses by type of procedure, brand of VCD and quality
of the included studies revealed no differences between groups.
Individually, 11 of the 12 studies showed that the collagen-based
VCD was associated with signiﬁcantly shorter time to haemosta-
sis when compared with manual compression (Brachmann 1998;
Castañeda 2003; Diaz 2001; Gwechenberger 1997; Juergens
2004; Kussmaul 1995; Magosaki 1999; Sanborn 1993; Seidelin
1997; Silber 1998;Wong 2009).Only one study showed no signif-
icant improvement between the collagen-based VCD and manual
compression (Reddy 2004). Juergens 2004 reported a signiﬁcantly
longer time to haemostasis for both VCD and manual compres-
sion participants than was reported in other included studies. We
contacted the study author, who did not reply to clarify whether
results reported in the paper were correct. Exclusion of this study
from the meta-analysis had little impact on heterogeneity.
Time to mobilisation
Thirteen studies were included in a meta-analysis (Behan 2007;
Brachmann 1998; Castañeda 2003; Diaz 2001; Holm 2014;
Juergens 2004; Legrand 2005; Machnik 2012; Magosaki 1999;
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Sanborn 1993; Schräder 1992; Seidelin 1997; Wong 2009).
Doneaux 2001;Martin 2008; SEALTrial StudyTeam;Ward1998;
and Yadav 2003 reported time to ambulation but did not provide
standard deviations; the SEAL Trial Study Team reported time to
ambulation as median and as interquartile range. We contacted
the authors of these studies but did not obtain requested data.
Meta-analysis of the 13 studies indicated heterogeneity (I2 =
100%) (Analysis 1.2). Subgroup analyses by type of procedure,
brand of VCD and quality of included studies showed no differ-
ences between groups. All 13 studies individually showed that the
collagen-based VCDwas associated with signiﬁcantly shorter time
to mobilisation than was seen with manual compression (Behan
2007; Brachmann 1998;Castañeda 2003;Diaz 2001;Holm2014;
Juergens 2004; Legrand 2005; Machnik 2012; Magosaki 1999;
Sanborn 1993; Schräder 1992; Seidelin 1997; Wong 2009).
Major adverse events
Mortality
Only one study (Castañeda 2003) presented data onmortality and
reported no deaths in 141 participants (Analysis 1.3).
Vascular injury requiring vascular repair by surgical or non-
surgical techniques
Five studies (Sanborn 1993; Schulz-Schüpke 2014; Seidelin 1997;
Ward 1998; Yadav 2003) reported on this outcome (Analysis 1.3).
Of 3727 participants treated with a collagen-based VCD, ﬁve
(0.1%) had vascular injury requiring repair compared with none
of 2004 manual compression participants (OR 2.81, 95%CI 0.47
to 16.79; P value = 0.26).
Adverse events
Infection
Nine studies (Behan 2007; Castañeda 2003; Deuling 2008; Holm
2014; Sanborn 1993; Schulz-Schüpke 2014; SEAL Trial Study
Team; Seidelin 1997; von Hoch 1995) recorded puncture site
infection (Analysis 1.4). Of 4674 participants treated with a
VCD, 15 (0.3%) experienced infection compared with six of 2942
(0.2%) participants treated with manual compression (OR 2.14,
95% CI 0.88 to 5.22; P value = 0.09). However, ﬁve of the nine
included studies (Behan 2007; Castañeda 2003; Deuling 2008;
Schulz-Schüpke 2014; SEAL Trial Study Team) found no cases
of infection, and another study (Seidelin 1997) included only 50
people.
Groin haematoma
A total of 25 studies (Amin 2000; Camenzind 1994; Castañeda
2003; Deuling 2008; Diaz 2001; Doneaux 2001; Gwechenberger
1997; Hermanides 2010; Holm 2014; Jensen 2008; Juergens
2004; Kussmaul 1995; Legrand 2005; Machnik 2012; Magosaki
1999; Reddy 2004; Sanborn 1993; Schräder 1992; Schulz-
Schüpke 2014; Seidelin 1997; Silber 1998; Upponi 2007; Ward
1998; Wong 2009; Yadav 2003) measured groin haematoma
(Analysis 1.5). Haematoma occurred in 327 of 6019 (5.4%) par-
ticipants treatedwith a collagen-basedVCDcomparedwith 456 of
4228 (10.8%)participants treatedwithmanual compression, lead-
ing to an OR of 0.46 (95% CI 0.40 to 0.54; P value < 0.00001).
Retroperitoneal haemorrhage
Three studies (Behan 2007; Martin 2008; Wong 2009), based on
a total of 744 participants, found retroperitoneal haemorrhage in
three of 444 (0.7%) VCD participants and one of 300 (0.3%)
manual compression participants (OR 1.5, 95%CI 0.22 to 11.42;
P value = 0.65) (Analysis 1.6).
Pseudoaneurysm
Twenty-one studies (Amin 2000; Behan 2007; Camenzind 1994;
Deuling 2008; Doneaux 2001; Gwechenberger 1997; Holm
2014; Juergens 2004; Legrand 2005; Machnik 2012; Magosaki
1999;Martin 2008; Reddy 2004; Sanborn 1993; Schulz-Schüpke
2014; SEAL Trial Study Team; Silber 1998; Upponi 2007; von
Hoch 1995; Ward 1998; Yadav 2003) reported pseudoaneurysm
as an outcome (Analysis 1.7). Meta-analysis showed that pseudoa-
neurysm occurred in 92 of 5573 (1.6%) VCD participants and in
83 of 3769 (2.2%) manual compression participants, leading to
an OR of 0.74 (95% CI 0.55 to 0.99; P value = 0.04).
Arterial dissection
None of the included studies measured arterial dissection as an
outcome.
Arteriovenous ﬁstula
Meta-analysis of eight studies (Gwechenberger 1997; Hermanides
2010;Machnik 2012; Martin 2008; Schulz-Schüpke 2014; SEAL
Trial Study Team; Upponi 2007; von Hoch 1995) showed that
arteriovenous ﬁstula occurred in 14 of 3868 (0.4%) VCD partic-
ipants and in nine of 2285 (0.4%) manual compression partici-
pants (OR 0.98, 95% CI 0.43 to 2.21; P value = 0.96) (Analysis
1.8).
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Embolisation resulting in loss of distal pulse
None of the included studies measured this as an outcome.
Deep vein thrombosis
Among three studies (Camenzind 1994; Sanborn 1993; Seidelin
1997), deep vein thrombosis (DVT) occurred in four of 332
(1.2%) VCD participants and in one of 297 (0.3%) manual com-
pression participants, leading to an OR of 2.41 (95% CI 0.46 to
12.50; P value = 0.30) (Analysis 1.9).
Limb ischaemia
Three studies (Behan 2007; Machnik 2012; Schulz-Schüpke
2014) measured limb ischaemia as an outcome (Analysis 1.10).
No cases occurred in the 3242 VCD participants nor in the 1728
participants treated with manual compression.
Femoral artery thrombosis
One study (Upponi 2007) measured femoral artery thrombosis
but found no cases in VCD nor manual compression participants
(Analysis 1.11).
Technical failure of VCDs
In 24 studies (Amin 2000; Behan 2007; Castañeda 2003;
Deuling 2008; Doneaux 2001; Gwechenberger 1997; Jensen
2008; Juergens 2004; Kussmaul 1995; Legrand 2005; Machnik
2012; Magosaki 1999; Martin 2008; Reddy 2004; Sanborn 1993;
Schräder 1992; SEAL Trial Study Team; Seidelin 1997; Silber
1998; Upponi 2007; von Hoch 1995; Ward 1998; Wong 2009;
Yadav 2003) with a combined total of 3033 participants treated
with a collagen-based VCD, 118 unsuccessful device deployments
led to a technical failure rate of 3.9%.
Time spent in angiography suite
None of the included studies reported on this outcome.
Length of hospital stay
Eight studies (Castañeda 2003; Juergens 2004; Machnik 2012;
Magosaki 1999; Silber 1998; Ward 1998; Wong 2009; Yadav
2003) measured length of hospital stay. However, Ward 1998
and Yadav 2003 did not report standard deviations for the mean
stay and therefore could not be included in the meta-analysis.
Meta-analysis of the six studies based on a random-effects model
showed considerable heterogeneity (I2 = 90%) (Analysis 1.12).
Subgroup analyses that excluded two studies (Magosaki 1999;
Silber 1998) with signiﬁcantly longer hospital stay than the other
studies showed no differences between groups.
Patient satisfaction
Six studies (Amin 2000; Holm 2014; Juergens 2004; Legrand
2005; Martin 2008; Schräder 1992) reported on patient satis-
faction. However, these studies used different measurement tools
and scales; therefore, the results could not be meta-analysed.
Five studies reported that collagen-based devices were associated
with less pain and bedrest than were seen with manual compres-
sion (Amin 2000; Juergens 2004; Legrand 2005; Martin 2008;
Schräder 1992). However, in one study (Holm 2014), participants
in the VCD group reported greater pain and discomfort during
the closure procedure when compared with participants in the
manual compression group.
Cost of VCD and extrinsic compression
None of the included studies compared the cost of VCD versus
manual compression.
Metal clip-based VCD versus manual or mechanical
compression
Six studies measured the effectiveness of a metal clip-based device
versusmanual compression (Ansel 2006;Deuling 2008;Hermiller
2005; Hermiller 2006; Perlowski 2011; Sun 2009).
Time to haemostasis
Five studies (Ansel 2006; Hermiller 2005; Hermiller 2006;
Perlowski 2011; Sun 2009)measured time to haemostasis, four us-
ing StarClose (Hermiller 2005; Hermiller 2006; Perlowski 2011;
Sun 2009) and one using Angiolink (Ansel 2006). Ansel 2006
presented results according to type of procedure and therefore
provided data on both diagnostic and interventional participants.
Meta-analysis using a random-effects model indicated that the
metal clip-basedVCDwas associatedwith statistically signiﬁcantly
less time to haemostasis than manual compression (MD -14.81
minutes, 95%CI -16.98 to -12.63; participants = 1665; I2 = 84%;
P value < 0.00001) (Analysis 2.1).
Time to mobilisation
Three studies (Ansel 2006; Hermiller 2005; Sun 2009) including
a total of 1303 participants measured time to haemostasis with
Angiolink (Ansel 2006) or StarClose (Hermiller 2005; Sun 2009).
Ansel 2006 presented results according to type of procedure, in-
cluding data on both diagnostic and interventional participants.
Meta-analysis using a random-effects model indicated substantial
heterogeneity (I2 = 100%), and subgroup analysis performed by
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type of procedure and brand of VCD showed no differences be-
tween groups (Analysis 2.2). Individually, all three studies (Ansel
2006; Hermiller 2005; Sun 2009) showed that the metal clip-
based VCD was associated with signiﬁcantly reduced time to mo-
bilisation when compared with manual compression.
Major adverse event
Three studies (Hermiller 2005; Hermiller 2006; Perlowski 2011)
with a combined total of 564 participants reported no deaths in
either treatment group (Analysis 2.3). Three studies (Deuling
2008; Hermiller 2005; Hermiller 2006) with a combined total
of 783 participants reported no differences in the incidence of
vascular injury requiring repair (OR 0.49, 95% CI 0.03 to 7.95;
P value = 0.62).
Adverse events
Infection
No cases of infection were reported in the 470 VCD and 313
manual compression participants among three studies reporting
on infection (Deuling 2008; Hermiller 2005; Hermiller 2006)
(Analysis 2.4).
Groin haematoma
Four studies (Deuling 2008; Hermiller 2005; Hermiller 2006;
Sun 2009) determined that the incidence of groin haematoma
was 30 of 939 (3.2%) and 28 of 584 (4.8%) VCD and manual
compression participants, respectively (OR 0.79, 95% CI 0.46 to
1.34; P value = 0.38) (Analysis 2.5).
Retroperitoneal haemorrhage
None of the studies comparing metal clip-based VCDs with man-
ual compression measured retroperitoneal haemorrhage as an out-
come.
Pseudoaneurysm
Pseudoaneurysm was reported in six of the included studies (Ansel
2006; Deuling 2008; Hermiller 2005; Hermiller 2006; Perlowski
2011; Sun 2009) (Analysis 2.6). The combined incidence was four
of 1221 (0.3%)metal clip-basedVCDparticipants comparedwith
three of 745 (0.4%) manual compression participants (OR 0.76,
95% CI 0.20 to 2.89; P value = 0.69).
Arterial dissection
None of the studies comparing metal clip-based VCDs with man-
ual compression measured arterial dissection as an outcome.
Arteriovenous ﬁstula
No cases of arteriovenous ﬁstula were reported in 564 participants
in three studies (Hermiller 2005;Hermiller 2006; Perlowski 2011)
(Analysis 2.7).
Embolisation resulting in loss of distal pulse
None of the studies comparing metal clip-based VCDs with man-
ual compression measured embolisation with loss of distal pulse
as an outcome.
Deep vein thrombosis
No cases of DVT were reported among 483 participants in two
studies (Hermiller 2005; Hermiller 2006) (Analysis 2.8).
Limb ischaemia
None of the 320 VCD participants nor 163 manual compression
participants in two studies developed limb ischaemia (Hermiller
2005; Hermiller 2006) (Analysis 2.9).
Femoral artery thrombosis
None of the studies comparing metal clip-based VCDs with man-
ual compression measured femoral artery thrombosis as an out-
come.
Technical failure of VCDs
In six studies (Ansel 2006; Deuling 2008; Hermiller 2005;
Hermiller 2006; Perlowski 2011; Sun 2009) on a combined to-
tal of 1039 participants treated with a metal clip-based VCD, 71
unsuccessful device deployments occurred, leading to a technical
failure rate of 6.8%.
Time spent in angiography suite
Time spent in the angiography suite was not measured in any of
the studies comparing metal clip VCDs and manual compression.
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Length of hospital stay
Length of hospital stay was not measured in any of the studies
comparing metal clip VCDs and manual compression.
Patient satisfaction
One study (Hermiller 2006) measured pain on a scale of 0 to 10
and found StarClose to be non-inferior to manual compression.
A pain scale of 0 to 3 was reported by 87.3% of StarClose versus
93.3% of manual compression participants. Pain scales of 8 to 10
were seen in 2.2% of StarCose and 3.3% of compression partici-
pants.
Cost of VCD and extrinsic compression
No studies considered the costs of the different treatments.
Suture-based VCD versus manual or mechanical
compression
Ten studies (Amine 1999; Carere 2000; Gerckens 1998; Jensen
2008; Martin 2008; Noguchi 2000; Rickli 2002; Sun 2009; Tron
2003; Wetter 2000) measured the effectiveness of a suture-based
device versus manual compression.
Time to haemostasis
Eight studies (Amine 1999; Gerckens 1998; Martin 2008;
Noguchi 2000; Rickli 2002; Sun 2009; Tron 2003; Wetter 2000)
measured time to haemostasis. However, Martin 2008 did not
report standard deviations and therefore was not included in the
meta-analysis. Pooled analysis of the seven studies using a ran-
dom-effects model showed that suture-based VCDs were associ-
atedwith a statistically signiﬁcant reduction in time to haemostasis
when compared with manual compression (MD -14.58 minutes;
95% CI -16.85 to -12.32; participants = 1664; I2 = 86%; P value
< 0.0001) (Analysis 3.1).
Time to mobilisation
Eight studies (Amine 1999; Carere 2000; Gerckens 1998; Martin
2008; Noguchi 2000; Rickli 2002; Sun 2009; Wetter 2000) mea-
sured time to mobilisation. Martin 2008 did not report standard
deviations and therefore was not included in the meta-analysis.
Pooled analysis of the seven studies (Amine 1999; Carere 2000;
Gerckens 1998; Noguchi 2000; Rickli 2002; Sun 2009; Wetter
2000) showed signiﬁcant heterogeneity (I2 = 98%), and subgroup
analysis performed by type of procedure and by brand of VCD
showed no differences between groups (Analysis 3.2). Individu-
ally, all seven studies (Amine 1999; Carere 2000; Gerckens 1998;
Noguchi 2000; Rickli 2002; Sun 2009; Wetter 2000) showed that
the suture-based VCD was associated with signiﬁcantly reduced
time to mobilisation when compared with manual compression.
Major adverse event
Only one study (Noguchi 2000) measured mortality and vascular
injury requiring repair but reported no cases in either treatment
group (Analysis 3.3).
Adverse events
Infection
Three studies (Amine 1999; Gerckens 1998; Noguchi 2000) with
750 participants reported the incidence of infection, describing
two cases of infection in the VCD groups compared with one in
themanual compression groups (OR 1.66, 95%CI 0.22 to 12.71;
P value = 0.63) (Analysis 3.4).
Groin haematoma
Six studies (Amine 1999; Carere 2000; Gerckens 1998; Jensen
2008; Noguchi 2000; Sun 2009) including a total of 1350 par-
ticipants measured the incidence of groin haematoma and found
an incidence of 5.4% (34/633) among suture-based VCD partici-
pants compared with 7.2% (52/717) among manual compression
participants (OR 0.65, 95% CI 0.41 to 1.02; P value = 0.06)
(Analysis 3.5).
Retroperitoneal haemorrhage
One studymeasured the incidence of retroperitoneal haemorrhage
in 63 suture-based VCD (0/63) and 67 manual compression par-
ticipants (1/67), reporting no association (OR 0.35, 95% CI 0.01
to 8.73) (Analysis 3.6).
Pseudoaneurysm
Six studies (Gerckens 1998; Martin 2008; Noguchi 2000; Rickli
2002; Sun 2009; Wetter 2000) measured this outcome. Pseudoa-
neurysm occurred in ﬁve of 720 (0.7%) suture-based VCD and
seven of 807 (0.9%) manual compression participants, leading to
an OR of 0.79 (95% CI 0.25 to 2.53; P value = 0.70) (Analysis
3.7).
Arterial dissection
Arterial dissectionwas not a reported outcome in any of the studies
comparing suture-based VCDs with manual compression.
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Arteriovenous ﬁstula
Four studies (Amine 1999;Gerckens1998;Martin 2008;Noguchi
2000) reported on the incidence of arteriovenous ﬁstula. Of the
441 VCD participants, none had an arteriovenous ﬁstula, and one
of the 439 (0.2%) manual compression participants experienced
this outcome (OR 0.33, 95% CI 0.01 to 8.02; P value = 0.49)
(Analysis 3.8).
Embolisation resulting in loss of distal pulse
One study (Noguchi 2000) measured distal embolisation but
reported no cases in the VCD or manual compression group
(Analysis 3.9).
Deep vein thrombosis
Deep vein thrombosis was not an outcome in any of the studies
examining suture-based VCDs and manual compression.
Limb ischaemia
Limb ischaemia was measured in two studies (Gerckens 1998;
Martin 2008); the combined incidence was one of 361 (0.3%)
VCD and one of 359 (0.3%) manual compression participants,
respectively (OR 1.02, 95% CI 0.14 to 7.22; P value = 0.98)
(Analysis 3.10).
Femoral artery thrombosis
None of the studies comparing suture-based VCDs with manual
compressionmeasured the incidence of femoral artery thrombosis.
Technical failure of VCDs
In 10 studies (Amine 1999; Carere 2000; Gerckens 1998; Jensen
2008; Martin 2008; Noguchi 2000; Rickli 2002; Sun 2009; Tron
2003;Wetter 2000) with a combined total of 843 participants who
received a suture-based VCD, 56 unsuccessful device deployments
were reported, leading to a technical failure rate of 6.7%.
Time spent in angiography suite
This was not a reported outcome in any of the included studies.
Length of hospital stay
Three studies (Carere 2000; Noguchi 2000; Tron 2003) based on
a total of 327 participants reported length of hospital stay. Meta-
analysis of the three studies using a random-effects model showed
that the suture-based VCD was associated with shorter hospital
staywhen comparedwithmanual compression (MD-11.66 hours,
95% CI -20.46 to -2.85; I2 = 85%; P value = 0.009) (Analysis
3.11).
Patient satisfaction
One study (Martin 2008) measured patient satisfaction in a ques-
tionnaire designed to address issues of discomfort and inconve-
nience at hospital discharge. On a 1 to 4 scale, mean groin dis-
comfort was rated at 1.7 with the PerClose device compared with
2.0 among manual compression participants. Mean scores for the
inconvenience of bedrest were 1.8 and 2.0 among VCD and man-
ual compression participants, respectively. Discomfort at the time
of sheath removal was 1.6 in both study arms.
Noguchi 2000 measured whether participants would be willing
to undergo another procedure with the ProStar device if a repeat
intervention was needed. Of 30 participants, 24 (80%) stated that
ProStar would be their preferred choice.
Another study (Carere 2000) measured participant perception of
the sheath removal procedure by questionnaire 24 hours after the
procedure. Participants treated with the ProStar-Plus device re-
ported a more acceptable duration of bedrest when compared
with those undergoing manual compression. Although discom-
fort during the procedure was similar between ProStar-Plus and
manual compression groups, discomfort after the procedure was
greater among ProStar-Plus participants. Overall, the 42 partici-
pants treated with ProStar reported that the procedure was very
acceptable compared with 24 participants undergoing haemosta-
sis by manual compression.
Participant comfort was reported on a visual analogue scale (VAS)
(0 best to 10 worst) by Rickli 2002. Mean pain at sheath removal
was 1.7 (SD 2.2) in PerClose and 2.9 (SD 2.7) in manual com-
pression groups, with back pain reported as 2.8 (SD 2.7) and 4.5
(SD 2.9) and groin pain during follow-up as 3.0 (SD 2.0) and 2.0
(SD 2.2), respectively.
Cost of VCD and extrinsic compression
Carere 2000 reported a total per-patient cost (incremental savings)
of $460.21 in the ProStar-Plus group compared with $759.16
in the manual compression group but did not provide standard
deviations for these means.
Noguchi 2000 reported that the hospital cost was $300 less in the
ProStar group than in the manual compression group ($1310 (SD
248) vs $1613 (SD 460)).
Rickli 2002 measured treatment costs and reported that post-per-
cutaneous coronary intervention (PCI) costs were reduced in the
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PerClose group (EURO469 (SD 145) vs EURO539 (SD 57))
compared with the manual compression group. Additional costs
of the PerClose device (EURO225) were exceeded by savings of
ward costs due to earlier discharge (PerClose EURO178 (SD 132)
vs manual compression EURO481 (SD 55)). PerClose was also
associated with less cardiologist time (13.8 (SD 5.4) minutes vs
32.9 (SD 13.9) minutes) and less nursing time (6.9 (SD 3.5) vs
11.5 (SD 7.0) minutes).
Collagen-based VCD versus metal clip-based VCD:
AngioSeal versus StarClose
Three studies compared AngioSeal versus StarClose (Deuling
2008; Rastan 2008; Veasey 2008).
Time to haemostasis
None of the studies comparing a collagen-basedVCDwith ametal
clip-based VCD measured time to haemostasis.
Time to mobilisation
Time to mobilisation was not a reported outcome in any of the
studies comparing collagen-based and metal clip-based VCDs.
Major adverse event
One study measured mortality and reported no deaths (Rastan
2008). Two studies (Deuling 2008; Rastan 2008) measured vas-
cular injury requiring repair and found no differences between the
two treatment groups (OR 0.33, 95% CI 0.01 to 8.22; P value =
0.50) (Analysis 4.1).
Adverse events
Infection
No cases of infection occurred in two studies reporting this out-
come (Deuling 2008; Veasey 2008) among a combined total of
701 participants (Analysis 4.2).
Groin haematoma
Two studies (Deuling 2008; Rastan 2008) compared AngioSeal
and StarClose devices among a combined total of 871 participants.
Meta-analysis using a random-effectsmodel showed no differences
in the incidence of groin haematoma between the two devices
(OR 0.84, 95% CI 0.43 to 1.65; P value = 0.61). The incidence
was 3.9% (17/435) and 4.6% (20/436) among collagen-based and
metal clip-based VCD participants, respectively (Analysis 4.3).
Retroperitoneal haemorrhage
Only one study (Veasey 2008)measured the incidence of retroperi-
toneal haemorrhage and reported no cases in the collagen VCD
(n = 208) nor metal clip VCD (n = 193) arms (Analysis 4.4).
Pseudoaneurysm
Pseudoaneurysm was measured in three studies (Deuling 2008;
Rastan 2008; Veasey 2008). The incidence was four of 643 (0.6%)
among collagen-basedVCDand eight of 629 (1.3%) amongmetal
clip-based VCD participants (OR 0.50, 95% CI 0.15 to 1.66; P
value = 0.26) (Analysis 4.5).
Arterial dissection
Arterial dissection was not reported in any of the included studies.
Arteriovenous ﬁstula
Only one study (Rastan 2008) measured arteriovenous ﬁstula.
Rastan 2008 reported one case in 285 collagen-based VCD par-
ticipants but no cases in 286 metal clip-based VCD participants
(OR 3.02, 95% CI 0.12 to 74.47) (Analysis 4.6).
Embolisation resulting in loss of distal pulse
This was not measured in any of the included studies.
Deep vein thrombosis
Deep vein thrombosis was not reported in any of the studies com-
paring collagen-based and clip-based VCDs.
Limb ischaemia
One study (Veasey 2008) measured limb ischaemia but reported
no cases in either treatment group (Analysis 4.7).
Femoral artery thrombosis
Femoral artery thrombosis was not reported in any of the studies
comparing collagen-based with clip-based VCDs.
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Technical failure of VCDs
Three studies (Deuling 2008; Rastan 2008; Veasey 2008) reported
the technical failure of AngioSeal versus StarClose devices. The
device failed in 22 of 643 (3.4%) AngioSeal participants compared
with 53 of 629 (8.4%) StarClose participants, suggesting that the
collagen-based device has a signiﬁcantly lower failure rate than
the StarClose device (OR 0.38, 95% CI 0.23 to 0.64; P value =
0.0003) (Analysis 4.8).
Time spent in angiography suite
Time spent in the angiography suite was not a reported outcome
in any of the included studies.
Length of hospital stay
Length of hospital stay was not measured in any of the studies
comparing collagen-based and metal clip-based VCDs.
Patient satisfaction
No study compared patient satisfaction with collagen-based versus
metal clip-based VCDs.
Cost of VCD and extrinsic compression
Cost of the device was not reported in any of the included studies.
Collagen-based VCD versus suture-based VCD
Five studies (Hattab 2012; Jensen 2008; Kalsch 2008; Martin
2008; Park 2005) compared a collagen-based VCD with a suture-
based VCD.
Time to haemostasis
Martin 2008 measured time to haemostasis among participants
treated with AngioSeal and PerClose ProGlide. Although investi-
gators reported themean time to haemostasis, they did not provide
standard deviations for the mean; therefore, it was not possible to
perform statistical analysis on mean differences. We attempted to
obtain these data, but study authors did not respond to our re-
quest. Martin 2008 did report that AngioSeal was associated with
signiﬁcantly reduced time to haemostasis compared with PerClose
(P value < 0.01).
Time to mobilisation
Martin 2008 also reported mean time to mobilisation but did not
present standard deviations; therefore, statistical tests on the mean
difference could not be performed. However, study authors re-
ported that AngioSeal was associated with reduced time to mobil-
isation when compared with the PerClose device (P value < 0.01).
Major adverse event
None of the ﬁve studies measured death or vascular injury requir-
ing repair (Hattab 2012; Jensen 2008; Kalsch 2008;Martin 2008;
Park 2005).
Adverse events
Infection
Kalsch 2008 measured the incidence of infection in 212 AngioSeal
and 154 PerClose participants, reporting no cases of infection in
either treatment group (Analysis 5.1).
Groin haematoma
Three studies (Hattab 2012; Jensen 2008; Kalsch 2008) measured
the incidence of groin haematoma in a combined total of 510 par-
ticipants. . Haematoma occurred in 34 of 284 (12.0%) AngioSeal
participants compared with 22 of 226 (9.7%) ExoSeal partici-
pants, resulting in an OR of 1.26 (95% CI 0.71 to 2.22; P value
= 0.43); therefore, neither AngioSeal nor ExoSeal was superior in
the prevention of haematoma (Analysis 5.2).
Retroperitoneal haemorrhage
Martin 2008 reported one case of retroperitoneal haemorrhage in
70 AngioSeal participants but no cases in 63 PerClose ProGlide
participants (OR 2.74, 95% CI 0.11 to 68.51; P value = 0.54)
(Analysis 5.3).
Pseudoaneurysm
Martin 2008 reportedno cases of pseudoaneurysm in70AngioSeal
participants but one case in 63 PerClose ProGlide participants
(OR 0.30, 95% CI 0.01 to 7.39; P value = 0.46) (Analysis 5.4).
Arterial dissection
This outcome was not measured in any of the studies included in
this review.
Arteriovenous ﬁstula
No cases of arteriovenous ﬁstula were reported among participants
treated with AngioSeal (n = 70) nor PerClose ProGlide (n = 63)
in the study by Martin 2008 (Analysis 5.5).
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Embolisation resulting in loss of distal pulse
Embolisation was not reported as an outcome in any study.
Deep vein thrombosis
Deep vein thrombosis was not measured in any of the studies
comparing collagen-based and suture-based VCDs.
Limb ischaemia
None of the studies comparing collagen-based and suture-based
VCDs reported limb ischaemia.
Femoral artery thrombosis
Femoral artery thrombosis was not a reported outcome in any
study.
Technical failure of VCDs
Three studies (Hattab 2012; Jensen 2008; Kalsch 2008) compared
the technical failure of a collagen-basedVCDversus a suture-based
VCD. Two studies (Jensen 2008; Kalsch 2008) compared An-
gioSeal with PerClose, and Hattab 2012 compared ExoSeal with
ProGlide. Meta-analyses showed no differences in the technical
failure of VCDs (OR 0.24, 95% CI 0.08 to 0.69; I2 = 74%; P
value = 0.008) (Analysis 5.6).
Time spent in angiography suite
Time spent in the angiography suite was not an outcome in any
of the included studies.
Length of hospital stay
Length of hospital stay was not measured in any studies comparing
collagen-based and suture-based VCDs.
Patient satisfaction
No study compared patient satisfaction with collagen-based versus
suture-based VCDs.
Cost of VCD and extrinsic compression
Cost of treatment was not measured in any of the studies compar-
ing collagen-based and suture-based VCDs.
Metal clip-based VCD versus suture-based VCD: StarClose
versus PerClose
One study (Sun 2009) compared the metal clip-based StarClose
with the suture-based PerClose.
Time to haemostasis
One study (Sun 2009) on 469 participants tested a metal clip-
based VCD (StarClose) against a suture-based VCD (PerClose).
Data on time to haemostasis were presented separately by type of
procedure. For the purposes of the review, the mean and standard
deviations for this outcome were combined according to the for-
mula given in Table 7.7.a in Chapter 7 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). This
study found that StarClose was associated with shorter time to
haemostasis than PerClose (MD -2.24 minutes, 95% CI -2.54 to
-1.94; P value < 0.00001) (Analysis 6.1).
Time to mobilisation
Sun 2009 also presented data on time to mobilisation separately
according to the type of procedure. As above, the mean and stan-
dard deviations for this outcome were combined according to the
formula given in Table 7.7.a in Chapter 7 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). This
study found that the StarClose device was associated with a reduc-
tion in the mean time to mobilisation (MD -0.30 hours, 95% CI
-0.59 to -0.01; P value = 0.05) (Analysis 6.2).
Major adverse event
Sun 2009 did not report mortality nor vascular injury requiring
repair.
Adverse events
Infection
Sun 2009 did not report infection.
Groin haematoma
Sun 2009 measured the incidence of haematoma at 0.3% (1/286)
in StarClose participants and 1.6% (3/183) in PerClose partici-
pants, leading to an OR of 0.21 (95% CI 0.02 to 2.04; P value =
0.18) (Analysis 6.3).
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Retroperitoneal haemorrhage
Sun 2009 did not report retroperitoneal haemorrhage.
Pseudoaneurysm
In the Sun 2009 study, pseudoaneurysm did not occur in any of
the StarClose participants, and one case was reported among the
183 (0.5%) PerClose participants (OR 0.21, 95%CI 0.01 to 5.24;
P value = 0.34) (Analysis 6.4).
Arterial dissection
This outcome was not measured in the Sun 2009 study.
Arteriovenous ﬁstula
Sun 2009 did not report arteriovenous ﬁstula.
Embolisation resulting in loss of distal pulse
Embolisation was not reported as an outcome in the Sun 2009
study.
Deep vein thrombosis
Sun 2009 did not report deep vein thrombosis.
Limb ischaemia
Sun 2009 did not report limb ischaemia.
Femoral artery thrombosis
Sun 2009 did not report femoral artery thrombosis.
Technical failure of VCDs
In the Sun 2009 study, the StarClose device demonstrated fewer
incidences of technical failure compared with the PerClose device
(OR 0.34, 95% CI 0.12 to 0.92; P value = 0.03) (Analysis 6.5)..
Time spent in angiography suite
Time spent in the angiography suite was not reported as an out-
come in the Sun 2009 study.
Length of hospital stay
Sun 2009 did not measure length of hospital stay.
Patient satisfaction
Sun 2009 did not measure patient satisfaction.
Cost of VCD and extrinsic compression
Cost of treatment was not measured in the Sun 2009 study.
Disc-based VCD versus suture-based VCD: Boomerang
versus PerClose
Chen 2013 compared a disc-based device (Boomerang) with a
suture-based device (PerClose).
Time to haemostasis
Chen 2013 measured time to haemostasis in participants treated
with the Boomerang and PerClose devices. The Boomerang device
was associated with signiﬁcantly longer time to haemostasis than
the PerClose device (MD 32.05 minutes, 95% CI 29.09 to 35.01;
P value < 0.00001) (Analysis 7.1).
Time to mobilisation
Chen 2013 also reported mean time to mobilisation but found no
difference between the two devices (MD -0.04 hours, 95% CI -
0.14 to 0.06 hours; P value = 0.41) (Analysis 7.2).
Major adverse event
Chen 2013 did not report mortality nor vascular injury requiring
repair.
Adverse events
Infection
Chen 2013 did not report infection.
Groin haematoma
Chen 2013 found no difference in the incidence of groin
haematoma between the Boomerang and PerClose devices (OR
10.36, 95% CI 0.53 to 201.45; P value = 0.12) (Analysis 7.3).
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Retroperitoneal haemorrhage
Chen 2013 did not report retroperitoneal haemorrhage.
Pseudoaneurysm
Chen 2013 did not report pseudoaneurysm.
Arterial dissection
This outcome was not measured in the Chen 2013 study.
Arteriovenous ﬁstula
Chen 2013 did not report arteriovenous ﬁstula.
Embolisation resulting in loss of distal pulse
Embolisation was not reported as an outcome in the Chen 2013
study.
Deep vein thrombosis
Chen 2013 did not report deep vein thrombosis.
Limb ischaemia
Chen 2013 did not report limb ischaemia.
Femoral artery thrombosis
Chen 2013 did not report femoral artery thrombosis.
Technical failure of VCDs
Chen 2013 found no difference in the rate of technical failure
between the Boomerang and PerClose devices (OR 2.07, 95% CI
0.18 to 24.15; P value = 0.56) (Analysis 7.4).
Time spent in angiography suite
Time spent in the angiography suite was not reported as an out-
come in the Chen 2013 study.
Length of hospital stay
Chen 2013 did not measure length of hospital stay.
Patient satisfaction
Chen 2013 measured pain on a scale of 0 to 10, with 0 repre-
senting no pain and 10 representing the worst possible pain. Re-
sults indicated that participants treated with the Boomerang de-
vice reported signiﬁcantly lower pain levels (mean 1.10, SD 1.71)
compared with participants treated with PerClose (mean 6.40, SD
2.92).
Cost of VCD and extrinsic compression
Cost of treatment was not measured in the Chen 2013 study.
Collagen-based VCD versus collagen-based VCD: AngioSeal
versus VasoSeal
Two studies (Michalis 2002; Shammas 2002) compared the col-
lagen-based devices AngioSeal and VasoSeal.
Time to haemostasis
Both studies (Michalis 2002; Shammas 2002) presented time to
haemostasis separately for diagnostic and interventional proce-
dures. When these studies were combined in a meta-analysis, con-
siderable heterogeneity was evident (I2 = 90%). When AngioSeal
was compared with VasoSeal, VasoSeal was associated with shorter
time to haemostasis for interventional procedures (MD8.63, 95%
CI 1.46 to 15.80; P value = 0.02; I2 = 86%) but not for diagnostic
procedures (MD 6.68, 95% CI -2.31 to 15.67; P value = 0.15; I2
= 96%) (Analysis 8.1).
Time to mobilisation
Both studies (Michalis 2002; Shammas 2002) compared the time
to mobilisation between AngioSeal and VasoSeal devices. An-
gioSeal was not associated with a difference in time tomobilisation
compared with VasoSeal, for both diagnostic (MD 0.01 hours,
95% CI -1.04 to 1.06; P value = 0.98; I2 = 90%) and interven-
tional procedures (MD 0.45, 95% CI -1.91 to 2.82; P value =
0.71; I2 = 74%) (Analysis 8.2).
Major adverse event
Shammas 2002 found no cases of mortality nor vascular injury
requiring repair (Analysis 8.3). Michalis 2002 did not measure
mortality nor vascular injury requiring repair.
Adverse events
Infection
Shammas 2002 reported no cases of infection (Analysis 8.4).
Michalis 2002 did not measure infection.
23Vascular closure devices for femoral arterial puncture site haemostasis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Groin haematoma
Both studies measured groin haematoma between collagen-based
devices (Michalis 2002; Shammas 2002). Shammas 2002 found
no haematoma, but the incidence of haematoma in Michalis
2002led to an OR of 0.49 (95% CI 0.16 to 1.47; P = 0.20)
(Analysis 8.5).
Retroperitoneal haemorrhage
Both studies (Michalis 2002; Shammas 2002) measured retroperi-
toneal haemorrhage as an outcome. They reported no cases in 367
AngioSeal-treated participants and only one case in 353 VasoSeal-
treated participants, leading to an OR of 0.36 (95% CI 0.01 to
9.09; P value = 0.54) (Analysis 8.6).
Pseudoaneurysm
Shammas 2002 reported just one case of pseudoaneurysm (OR
0.31, 95%CI 0.01 to 7.71; P value = 0.47) (Analysis 8.7).Michalis
2002 did not measure pseudoaneurysm.
Arterial dissection
Arterial dissection was not reported in the Michalis 2002 and
Shammas 2002 studies.
Arteriovenous ﬁstula
Shammas 2002 reported no cases of arteriovenous ﬁstula (Analysis
8.8). Michalis 2002 did not measure arteriovenous ﬁstula.
Embolisation resulting in loss of distal pulse
The studies by Michalis 2002 and Shammas 2002 did not report
on embolisation resulting in loss of distal pulse.
Deep vein thrombosis
Deep vein thrombosis was not an outcome of the Michalis 2002
and Shammas 2002 studies.
Limb ischaemia
Limb ischaemia was not an outcome of the Michalis 2002 and
Shammas 2002 studies.
Femoral artery thrombosis
Femoral artery thrombosis was not an outcome of the Michalis
2002 and Shammas 2002 studies.
Technical failure of VCDs
Michalis 2002 showed that the device failed in 19 of 290 An-
gioSeal participants compared with 26 of 280 VasoSeal partici-
pants, leading to an OR of 0.68 (95% CI 0.37 to 1.26; P value =
0.22) (Analysis 8.9). Shammas 2002 did not report on the tech-
nical failure of the VCD.
Time spent in angiography suite
NeitherMichalis 2002 nor Shammas 2002 reported on time spent
in the angiography suite.
Length of hospital stay
Length of hospital stay was not an outcome of the Michalis 2002
and Shammas 2002 studies.
Patient satisfaction
Patient satisfaction was not an outcome of the Michalis 2002 and
Shammas 2002 studies.
Cost of VCD and extrinsic compression
Device cost was not assessed in the two included studies (Michalis
2002; Shammas 2002).
Collagen-based VCD versus collagen-based VCD: AngioSeal
versus Mynx
One study compared AngioSeal versus Mynx (Fargen 2011).
Time to haemostasis
Fargen 2011 did not measure time to haemostasis as an outcome.
Time to mobilisation
Fargen 2011 did not measure time to mobilisation as an outcome.
Major adverse event
Fargen 2011 did not measure mortality and found no cases of
vascular injury requiring repair (Analysis 9.1).
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Adverse events
Infection
Fargen 2011 found no cases of infection (Analysis 9.2).
Groin haematoma
Fargen 2011 found no cases of groin haematoma (Analysis 9.3).
Retroperitoneal haemorrhage
Retroperitoneal haemorrhage was not reported as an outcome of
the Fargen 2011 study.
Pseudoaneurysm
Pseudoaneurysm was not reported as an outcome of the Fargen
2011 study.
Arterial dissection
Arterial dissection was not reported as an outcome of the Fargen
2011 study.
Arteriovenous ﬁstula
Arteriovenous ﬁstula was not reported as an outcome of the Fargen
2011 study.
Embolisation resulting in loss of distal pulse
Fargen 2011 did not report on embolisation resulting in loss of
distal pulse.
Deep vein thrombosis
Deep vein thrombosis was not reported as an outcome of the
Fargen 2011 study.
Limb ischaemia
Limb ischaemia was not reported as an outcome of the Fargen
2011 study.
Femoral artery thrombosis
Femoral artery thrombosis was not reported as an outcome of the
Fargen 2011 study.
Technical failure of VCDs
Fargen 2011 did not report technical failure of the VCDs.
Time spent in angiography suite
Fargen 2011 did not report on time spent in the angiography suite.
Length of hospital stay
Length of hospital stay was not reported as an outcome of the
Fargen 2011 study.
Patient satisfaction
Fargen 2011 measured pain at closure and pain increase from
baseline to closure, reporting that 88% of AngioSeal participants
reported closure as the most painful part compared with 34% of
Mynx participants.
Cost of VCD and extrinsic compression
Device cost was not assessed in the Fargen 2011 study.
Collagen-based VCD versus collagen-based VCD: AngioSeal
versus Duett
Michalis 2002 compared AngioSeal with Duett.
Time to haemostasis
Data regarding time to haemostasis were presented separately for
diagnostic and interventional procedures. The Duett device was
associated with shorter time to haemostasis when compared with
AngioSeal in both diagnostic (MD10.60minutes, 95%CI 9.74 to
11.46) and interventional procedures (MD 12.00 minutes, 95%
CI 9.57 to 14.43) (Analysis 10.1).
Time to mobilisation
Michalis 2002 showed that AngioSeal was associated with shorter
time to mobilisation when compared with the Duett device in
diagnostic procedures (MD -0.40 hours, 95% CI -0.51 to -0.29).
However, no difference was noted when AngioSeal was compared
with the Duett device in interventional procedures (MD -0.32
hours, 95% CI -0.71 to 0.07) (Analysis 10.2).
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Major adverse event
Michalis 2002 did not measure mortality nor vascular injury re-
quiring repair.
Adverse events
Infection
Michalis 2002 did not measure infection as an outcome.
Groin haematoma
Michalis 2002 reported the incidence of haematoma as 1.7% (5/
290) in AngioSeal participants compared with 1.8% (5/281) in
Duett participants (OR 0.97, 95% CI 0.28 to 3.38; P value =
0.97) (Analysis 10.3).
Retroperitoneal haemorrhage
Michalis 2002 measured retroperitoneal haemorrhage as an out-
come, reporting no cases in AngioSeal nor Duett participants
(Analysis 10.4).
Pseudoaneurysm
Michalis 2002 did not measure pseudoaneurysm as an outcome.
Arterial dissection
Arterial dissection was not reported as an outcome in theMichalis
2002 study.
Arteriovenous ﬁstula
Michalis 2002 did not measure arteriovenous ﬁstula as an out-
come.
Embolisation resulting in loss of distal pulse
Michalis 2002 did not report on embolisation resulting in loss of
distal pulse.
Deep vein thrombosis
Deep vein thrombosis was not reported as an outcome of the
Michalis 2002 study.
Limb ischaemia
Limb ischaemia was not reported as an outcome of the Michalis
2002 study.
Femoral artery thrombosis
Femoral artery thrombosis was not reported as an outcome of the
Michalis 2002 study.
Technical failure of VCDs
Michalis 2002 showed that the device failed in 19of 290AngioSeal
participants compared with 32 of 281 Duett participants, leading
to an OR of 0.54 (95% CI 0.30 to 0.99; P value = 0.04) (Analysis
10.5).
Time spent in angiography suite
Michalis 2002 did not report on time spent in the angiography
suite.
Length of hospital stay
Length of hospital stay was not reported as an outcome of the
Michalis 2002 study.
Patient satisfaction
Patient satisfaction was not reported as an outcome of theMichalis
2002 study.
Costs of VCD and extrinsic compression
Device costwas not assessed in the included study (Michalis 2002).
Collagen-based VCD versus collagen-based VCD: VasoSeal
versus Duett
One study compared VasoSeal and Duett (Michalis 2002).
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Time to haemostasis
Michalis 2002 presented data regarding time to haemostasis sepa-
rately for diagnostic and interventional procedures. No difference
was found when VasoSeal was compared with the Duett device in
diagnostic (MD -0.50 minutes, 95% CI -1.11 to 0.11) nor inter-
ventional (MD -1.00 minutes, 95% CI -3.15 to 1.15) procedures
(Analysis 11.1).
Time to mobilisation
Michalis 2002 showed that when VasoSeal was compared with the
Duett device, no differences in time to mobilisation were noted
for diagnostic (MD 0.08 hours, 95% CI 0.05 to 0.21) nor in-
terventional procedures (MD 0.16 hours, 95% CI -0.17 to 0.49)
(Analysis 11.2).
Major adverse event
Michalis 2002 did not measure mortality nor vascular injury re-
quiring repair.
Adverse events
Infection
Michalis 2002 did not measure infection as an outcome.
Groin haematoma
Michalis 2002 found no difference in the incidence of haematoma
when the VasoSeal was compared with theDuett device (OR 2.00,
95% CI 0.67 to 5.95; P value = 0.21) (Analysis 11.3).
Retroperitoneal haemorrhage
Michalis 2002 reported only one case of retroperitoneal haemor-
rhage in 280 VasoSeal participants and no cases in Duett partici-
pants (OR 2.77, 95% CI 0.11 to 69.59; P value = 0.54) (Analysis
11.4).
Pseudoaneurysm
Michalis 2002 did not measure pseudoaneurysm as an outcome.
Arterial dissection
Arterial dissection was not reported in the Michalis 2002 study.
Arteriovenous ﬁstula
Michalis 2002 did not measure arteriovenous ﬁstula as an out-
come.
Embolisation resulting in loss of distal pulse
Michalis 2002 did not report on embolisation resulting in loss of
distal pulse.
Deep vein thrombosis
Deep vein thrombosis was not reported as an outcome of the
Michalis 2002 study.
Limb ischaemia
Limb ischaemia was not reported as an outcome of the Michalis
2002 study.
Femoral artery thrombosis
Femoral artery thrombosis was not reported as an outcome of the
Michalis 2002 study.
Technical failure of VCDs
Michalis 2002 showed that the Duett device failed in 32 of 281
participants, leading to an OR of 0.80 (95% CI 0.46 to 1.30;
P value = 0.42) when compared with 26/280 failures with the
VasoSeal device (Analysis 11.5).
Time spent in angiography suite
Michalis 2002 did not report on time spent in the angiography
suite.
Length of hospital stay
Length of hospital stay was not reported as an outcome of the
Michalis 2002 study.
Patient satisfaction
Patient satisfaction was not reported as an outcome of theMichalis
2002 study.
Cost of VCD and extrinsic compression
Device cost was not assessed in the Michalis 2002 study.
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Collagen-based VCD versus collagen-based VCD: FemoSeal
versus ExoSeal
One study compared FemoSeal and ExoSeal (Schulz-Schüpke
2014).
Time to haemostasis
Schulz-Schüpke 2014 presented time to haemostasis as a median
and as an interquartile range. Time to haemostasis was 0.5 minute
(IQR 0.5 minute to 1 minute) in the group treated with FemoSeal
and 2 minutes (IQR 1 minute to 2 minutes) in the group treated
with ExoSeal.
Time to mobilisation
Schulz-Schüpke 2014 did not measure time to mobilisation.
Major adverse event
Schulz-Schüpke 2014 did not report onmortality and reported no
cases of vascular injury requiring repair in either group (Analysis
12.1).
Adverse events
Infection
Schulz-Schüpke 2014 found no cases of infection in the group
treated with ExoSeal and only one case in the group treated with
FemoSeal (OR 3.00, 95% CI 0.12 to 73.60; P value = 0.50) (
Analysis 12.2).
Groin haematoma
Schulz-Schüpke 2014measured the incidence of groinhaematoma
as 4.3% (65/1509) and 5.3% (80/1506) in the two groups, respec-
tively (OR 0.80, 95% CI 0.57 to 1.12; P value = 0.20) (Analysis
12.3).
Retroperitoneal haemorrhage
Schulz-Schüpke 2014 did not report on retroperitoneal haemor-
rhage.
Pseudoaneurysm
Schulz-Schüpke 2014 reported that the incidence of pseudoa-
neurysm was 1.5% (22/1509) in FemoSeal and 2.1% (31/1506)
in ExoSeal participants (OR 0.70, 95% CI 0.41 to 1.22; P value
= 0.21) (Analysis 12.4).
Arterial dissection
Arterial dissection was not reported in the Schulz-Schüpke 2014
study.
Arteriovenous ﬁstula
Schulz-Schüpke 2014 reported the incidence of arteriovenous ﬁs-
tula as 0.3% (4/1509) in FemoSeal and 0.5% (8/1506) in ExoSeal
participants, respectively (OR 0.50, 95% CI 0.15 to 1.66; P value
= 0.26) (Analysis 12.5).
Embolisation resulting in loss of distal pulse
Schulz-Schüpke 2014 did not report on embolisation resulting in
loss of distal pulse.
Deep vein thrombosis
Deep vein thrombosis was not reported as an outcome of the
Schulz-Schüpke 2014 study.
Limb ischaemia
Schulz-Schüpke 2014 found no cases of limb ischaemia in the
FemoSeal nor the ExoSeal group (Analysis 12.6).
Femoral artery thrombosis
Femoral artery thrombosis was not reported as an outcome of the
Schulz-Schüpke 2014 study.
Technical failure of VCDs
Schulz-Schüpke 2014 reported that the FemoSeal device failed to
close in 5.3% (80/1509) of participants compared with 12.2%
(184/1506) of ExoSeal participants, leading to an OR of 0.40
(95% CI 0.31 to 0.53; P value < 0.00001) (Analysis 12.7).
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Time spent in angiography suite
Schulz-Schüpke 2014 did not report on time spent in the angiog-
raphy suite.
Length of hospital stay
Length of hospital stay was not reported as an outcome of the
Schulz-Schüpke 2014 study.
Patient satisfaction
Patient satisfaction was not an outcome of the Schulz-Schüpke
2014 study.
Cost of VCD and extrinsic compression
Device cost was not assessed in the included study (Schulz-
Schüpke 2014).
Haemostasis after percutaneous EVAR (sheath size ≥
10 Fr)
One study compared PerClose ProGlide with ProStar XL in par-
ticipants undergoing percutaneous EVAR (Nelson 2014).
Time to haemostasis
Nelson 2014 measured time to haemostasis between the PerClose
ProGlide and ProStar XL devices in participants undergoing per-
cutaneous EVAR. They found no differences between the two de-
vices (MD -3.20 minutes, 95% CI -10.23 to 3.83; P value = 0.37)
(Analysis 13.1).
Time to mobilisation
Nelson 2014 also measured time to mobilisation between the Per-
Close ProGlide and ProStar XL devices in participants undergoing
percutaneous EVAR. They found no differences between the two
devices (MD 1.00 hour, 95% CI -2.20 to 4.20; P value = 0.54)
(Analysis 13.2).
Major adverse event
Nelson 2014 also measured major adverse events between the Per-
Close ProGlide and ProStar XL devices in participants undergoing
percutaneous EVAR. They found no differences in the effective-
ness of the devices in preventing death (OR 0.33, 95% CI 0.01
to 8.38; P value = 0.50) nor vascular injury requiring repair (OR
0.33, 95% CI 0.03 to 3.25; P value = 0.34) (Analysis 13.3).
Adverse events
Infection
Nelson 2014 measured infection between the PerClose ProGlide
and ProStar XL devices in participants undergoing percutaneous
EVAR but found no cases in either group (Analysis 13.4).
Groin haematoma
Nelson 2014 measured groin haematoma between the PerClose
ProGlide and ProStar XL devices in participants undergoing per-
cutaneous EVAR but found no cases in either group (Analysis
13.5).
Retroperitoneal haemorrhage
Nelson 2014 did not measure retroperitoneal haemorrhage as an
outcome.
Pseudoaneurysm
Nelson 2014 did not measure pseudoaneurysm as an outcome.
Arterial dissection
Arterial dissection was not reported in the Nelson 2014 study.
Arteriovenous ﬁstula
Nelson 2014 measured arteriovenous ﬁstula between the PerClose
ProGlide and ProStar XL devices in participants undergoing per-
cutaneous EVAR but found no cases in either group (Analysis
13.6).
Embolisation resulting in loss of distal pulse
Nelson 2014 did not report on embolisation resulting in loss of
distal pulse.
Deep vein thrombosis
Nelson 2014 measured deep vein thrombosis between the Per-
Close ProGlide and ProStar XL devices in participants undergoing
percutaneous EVAR and found no differences between the two
devices (OR 2.08, 95%CI 0.18 to 23.73; P value = 0.55) (Analysis
13.7).
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Limb ischaemia
Nelson 2014 measured limb ischaemia as an outcome but found
no differences between the PerClose ProGlide and ProStar XL
devices (OR 2.08, 95%CI 0.18 to 23.73; P value = 0.55) (Analysis
13.8).
Femoral artery thrombosis
Nelson 2014 did not measure femoral artery thrombosis as an
outcome.
Technical failure of VCDs
Nelson 2014 measured technical failure between the PerClose
ProGlide and ProStar XL devices in participants undergoing per-
cutaneous EVAR but found no cases in either group (Analysis
13.9).
Time spent in angiography suite
Nelson 2014 did not measure time spent in angiography suite as
an outcome.
Length of hospital stay
Nelson 2014 measured length of hospital stay between the Per-
Close ProGlide and ProStar XL devices in participants undergoing
percutaneous EVAR but found no differences (MD -0.10 hours,
95% CI -0.41 to 0.21; P value = 0.53) (Analysis 13.10).
Patient satisfaction
Patient satisfaction was not reported as an outcome of the Nelson
2014 study.
Cost of VCD and extrinsic compression
Device cost was not assessed in the included study (Nelson 2014).
Haemostasis after EVAR with open exposure of CFA
(sheath size ≥ 10 Fr)
One study compared the PerClose ProGlide and ProStar XL de-
vices with surgical suture-based closure in participants undergoing
open femoral exposure of the CFA (Nelson 2014).
Time to haemostasis
Nelson 2014 measured time to haemostasis between suture-based
devices and surgically mediated closure in participants undergoing
EVAR. The suture-based device was associated with shorter time
to haemostasis than surgical closure (MD -11.58 minutes, 95%
CI -18.85 to -4.31; 101 participants; P value = 0.002) (Analysis
14.1).
Time to mobilisation
Nelson 2014 measured time tomobilisation between suture-based
devices and surgically mediated closure in participants undergoing
EVAR but found no differences between the two groups (MD: -
2.50 hours, 95% CI -7.21 to 2.21) (Analysis 14.2).
Major adverse event
Nelson 2014measuredmajor adverse events between suture-based
devices and surgically mediated closure in participants undergoing
EVAR and found no differences between the suture-based device
and surgical closure in preventing death (OR 1.51, 95% CI 0.66
to 37.67; P value = 0.80) nor in vascular injury requiring repair
(OR 2.02, 95% CI 0.22 to 18.57; P value = 0.53) (Analysis 14.3).
Adverse events
Infection
Nelson2014measured infectionbetween suture-based devices and
surgically mediated closure in participants undergoing EVAR but
found no cases in either group (Analysis 14.4).
Groin haematoma
Nelson 2014 measured groin haematoma between suture-based
devices and surgically mediated closure in participants undergoing
EVAR but found no cases in either group (Analysis 14.5).
Retroperitoneal haemorrhage
Nelson 2014 did not measure retroperitoneal haemorrhage as an
outcome.
Pseudoaneurysm
Nelson 2014 did not measure pseudoaneurysm as an outcome.
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Arterial dissection
Arterial dissection was not reported in the Nelson 2014 study.
Arteriovenous ﬁstula
Nelson 2014 measured arteriovenous ﬁstula between suture-based
devices and surgically mediated closure in participants undergoing
EVAR but found no cases in either group (Analysis 14.6).
Embolisation resulting in loss of distal pulse
Nelson 2014 did not report on embolisation resulting in loss of
distal pulse.
Deep vein thrombosis
Nelson 2014 measured deep vein thrombosis between suture-
based devices and surgically mediated closure in participants un-
dergoing EVAR and found no differences between the two devices
(OR 0.48, 95% CI 0.09 to 2.47; P value = 0.38) (Analysis 14.7).
Limb ischaemia
Nelson 2014 measured limb ischaemia between suture-based de-
vices and surgically mediated closure in participants undergoing
EVARbut found no differences between the two groups (OR0.73,
95% CI 0.12 to 4.54; P value = 0.74) (Analysis 14.8).
Femoral artery thrombosis
Nelson 2014 did not measure femoral artery thrombosis as an
outcome.
Time spent in angiography suite
Nelson 2014 did not measure time spent in angiography suite as
an outcome.
Length of hospital stay
Length of hospital stay was measured in the Nelson 2014 study,
which reported no differences between participants treated with
a suture-based device and those who underwent surgical closure
following EVAR (MD -10.80 hours, 95% CI -27.20 to 5.60; P
value = 0.20).
Patient satisfaction
Patient satisfaction was not an outcome of the Nelson 2014 study.
Cost of VCD and extrinsic compression
Device cost was not assessed in the included study (Nelson 2014).
Subgroup analysis
The ﬁrst planned subgroup analysis included looking at studies
using smaller sheath sizes (5 to 6 Fr) compared with those with
larger sheath sizes in participants undergoing EVAR procedures.
However, all studies included in this review used sheath size 9 Fr
or smaller. As only one study compared the effectiveness of VCDs
in participants undergoing EVAR procedures, it was not possible
to complete this subgroup analysis.
A second planned subgroup analysis was conducted to compare
studies according to whether they used antegrade or retrograde
puncture. However, very few studies reported on the direction of
puncture used in the procedure; therefore, it was not feasible to
conduct this subgroup analysis.
D I S C U S S I O N
Summary of main results
Time to haemostasis
Meta-analysis indicated that collagen-based or plug-based, metal
clip-based and suture-based vascular closure devices (VCDs) were
all associated with reduced time to haemostasis when compared
with manual or mechanical compression. However, consider-
able heterogeneity could not be explained; therefore, results of
the meta-analysis may not be meaningful. Every included study
used a strict deﬁnition of time to haemostasis, deﬁned as the
time from sheath removal to complete cessation of bleeding
and absence of palpable haematoma in minutes. Most studies
(Ansel 2006; Brachmann 1998; Castañeda 2003; Gerckens 1998;
Gwechenberger 1997;Hermiller2005;Hermiller 2006;Kussmaul
1995;Magosaki 1999;Martin 2008; Perlowski 2011;Reddy 2004;
Rickli 2002; Sanborn 1993; SEAL Trial Study Team; Seidelin
1997; Silber 1998; Sun 2009; Tron 2003; Ward 1998; Wetter
2000; Wong 2009; Yadav 2003) measured time to haemostasis in
minutes. One study (Juergens 2004) measured time to haemosta-
sis in hours, and another study (Diaz 2001) measured time to
haemostasis in seconds. For the purposes of the review, data from
Diaz 2001 and Juergens 2004 were converted to minutes. Seven
studies (Gerckens 1998; Kussmaul 1995; Sanborn 1993; SEAL
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Trial Study Team; Sun 2009; Wong 2009; Yadav 2003) presented
time to haemostasis for the entire study population and also sepa-
rately for the subgroup of participants who underwent diagnostic
and interventional procedures. Seven studies could not be used in
the meta-analysis because standard deviations were not reported
(Doneaux 2001; Martin 2008; Ward 1998; Yadav 2003) or be-
cause median and interquartile range were presented (Holm 2014;
Schulz-Schüpke 2014; SEAL Trial Study Team).
Evidence on the effectiveness of one VCD compared with another
VCD is lacking. No study compared time to haemostasis between
collagen-based and metal clip-based VCDs. Only one study (Sun
2009) compared one metal clip-based VCD (StarClose) with a
suture-based VCD (PerClose) and found that StarClose was asso-
ciated with shorter time to haemostasis. However, this study was
based on 469 participants, and the quality of the study could not
be assessed because reporting of methods was insufﬁcient. Two
studies (Michalis 2002; Shammas 2002) compared the effective-
ness of two collagen devices: AngioSeal and VasoSeal. In Michalis
2002, VasoSeal was associated with shorter time to haemostasis
for both diagnostic and interventional procedures.However, when
Shammas 2002 was added to the meta-analysis, no difference in
time to haemostasis was noted overall between the two devices.
Michalis 2002 also provided a third treatment arm with the Duett
device. In this study, VasoSeal was associated with shorter time to
haemostasis than AngioSeal for both diagnostic and interventional
procedures. Similarly the Duett device was associated with shorter
time to haemostasis when compared with AngioSeal in both diag-
nostic and interventional procedures. However, no difference was
found in either type of procedure when VasoSeal was compared
with the Duett device. Martin 2008 reported that AngioSeal was
associated with signiﬁcantly reduced time to haemostasis com-
paredwith PerClose.Nelson 2014 comparedProStar andProGlide
devices in participants undergoing percutaneous EVAR but found
no differences in time to haemostasis between the two devices. The
same study (Nelson 2014) compared the ProStar and ProGlide
devices with surgical suture-based closure following EVAR and
found reduced time to haemostasis for the VCDs.
Time to mobilisation
Meta-analysis showed that collagen-based, metal clip-based and
suture-based VCDs were all associated with reduced time to
mobilisation when compared with manual/mechanical compres-
sion. However, considerable heterogeneity could not be explained;
therefore, results of the meta-analysis may not be meaningful.
Some studies (Ansel 2006; Brachmann 1998; Carere 2000;
Castañeda 2003; Gerckens 1998; Jensen 2008; Martin 2008;
Rickli 2002; SEAL Trial Study Team; Seidelin 1997; Ward 1998;
Wetter 2000; Wong 2009) encouraged VCD participants to am-
bulate sooner than manual compression participants. Other stud-
ies (Hermiller 2005; Hermiller 2006; Juergens 2004; Legrand
2005; Machnik 2012; Sanborn 1993; Yadav 2003) measuring
time to mobilisation did so at the same time intervals regard-
less of the treatment. Some studies speciﬁed a particular distance
for time to ambulation (Ansel 2006; Castañeda 2003; Gerckens
1998; Hermiller 2005; Hermiller 2006; Michalis 2002; SEAL
Trial StudyTeam;Wong 2009; Yadav 2003), including3 to5 steps,
3 metres, 10 feet, 20 feet and 110 feet; other studies (Brachmann
1998; Carere 2000; Juergens 2004; Legrand 2005;Machnik 2012;
Martin 2008; Rickli 2002; Sanborn 1993; Seidelin 1997; Ward
1998; Wetter 2000) simply speciﬁed out-of-bed moving or did
not deﬁne time to mobilisation.
Although it was featured in the study protocol, time to ambulation
is usually a clinician-deﬁned occurrence that varies according to
local protocols and depends on the procedure undertaken as well
as on themethod of haemostasis. The authors of this review believe
that it is not suitable for use as an outcome measure unless it is
used in combinationwith the occurrence of vascular complications
associated with different ambulation times.
Evidence on the effectiveness of one VCD compared with another
VCD is lacking. Only one study (Sun 2009) compared time to
ambulation between one metal clip-based VCD (StarClose) and
a suture-based VCD (PerClose). This study found that StarClose
was associated with shorter time to ambulation (0.30 hour) when
compared with PerClose. However, the mean difference was very
small and the conﬁdence interval was close to zero, suggesting no
differences between the two devices. Two studies (Michalis 2002;
Shammas 2002) compared the effectiveness of two collagen de-
vices: AngioSeal and VasoSeal. In the study by Michalis 2002,
AngioSeal was associated with shorter time to mobilisation for
both diagnostic and interventional procedures. However, when
Shammas 2002 was added to the meta-analysis, no differences in
time tomobilisation were noted between the two devices.Michalis
2002 also included a third treatment arm using the Duett device.
AngioSeal was associated with shorter time to mobilisation when
compared with the Duett device in diagnostic but not in inter-
ventional procedures. Finally, no difference in time to haemostasis
was noted for VasoSeal and Duett devices regardless of procedure
type. No study compared time to ambulation between collagen-
based and metal clip-based VCDs. Martin 2008 reported that An-
gioSeal was associated with less time to mobilisation when com-
paredwith PerClose.Nelson 2014 comparedProStar andProGlide
devices in participants undergoing percutaneous endovascular aor-
tic aneurysm repair (EVAR) but found no differences in time to
mobilisation between the two devices. The same study (Nelson
2014) also compared the VCDs with surgical closure following
EVARbut reported no differences in time tomobilisation between
the two treatment groups.
Major adverse events and adverse events
Very few studies eligible for inclusion in this review recorded the
incidence of major adverse events including mortality and vascu-
lar injury requiring repair. When incidence of death was reported
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in the included studies,no cases of death were described, except
when PerClose ProGlide was compared with ProStar XL for per-
cutaneous EVAR (Nelson 2014). For vascular injury repair, meta-
analyses demonstrated that neither collagen-based nor clip-based
VCDs were more effective than manual compression. Data on
the effectiveness of one VCD versus another were lacking. Re-
sults showed no differences in effectiveness between ProGlide and
ProStar after percutaneous EVAR nor when the same two devices
were compared with surgical closure after EVAR.
Infection
Meta-analyses of nine studies showed no difference in the inci-
dence of this outcome between participants treated with a colla-
gen-based VCD and those treated with manual compression. In
addition, four studies reported no cases of infection. No differ-
ences in the incidence of infection were noted between metal clip-
based VCDs nor suture-based VCDs and manual compression.
Furthermore, no difference was identiﬁed between different types
of VCDs. Suture-based devices were compared with each other
following percutaneous EVAR, and also with surgical closure fol-
lowing EVAR, but no differences between treatment groups were
reported.
Groin haematoma
Collagen VCDs were associated with a lower incidence of groin
haematoma when compared with manual compression, but no
differences were noted between metal clip-based and suture-based
devices and manual compression. The clinical signiﬁcance of the
haematoma was not recorded in these studies, thus it was not pos-
sible to distinguish between the incidence of self-limiting and clin-
ically relevant haematoma. Furthermore, no differences between
different types of VCDs were identiﬁed. Suture-based devices were
compared with each other following percutaneous EVAR and also
with surgical closure following EVAR, but no differences in the in-
cidence of groin haematomawere noted between treatment groups
The incidence of pseudoaneurysm was lower with collagen-based
devices than with manual or mechanical compression. The inci-
dence of all other adverse events including retroperitoneal haemor-
rhage, arteriovenous ﬁstula, deep vein thrombosis, limb ischaemia
and femoral artery thrombosis did not differ by type of VCD nor
when VCD was compared with manual or mechanical compres-
sion. Suture-based devices were compared with one other follow-
ing percutaneous EVAR and also with surgical closure following
EVAR, but no differences in these outcomes were reported be-
tween treatment groups. No study measured arterial dissection
nor time spent in angiography suite, and one study reported only
distal embolisation and femoral artery thrombosis.
Length of hospital stay
Meta-analysis showed that participants treated with a VCD were
discharged from hospital earlier than those undergoing manual
compression. Signiﬁcant heterogeneity demonstrated in the re-
ported data could not be controlled by the use of standard tech-
niques of meta-analysis. Owing to the short duration of stay of-
ten expected in patients undergoing percutaneous arterial proce-
dures, the duration of stay could have been inﬂuenced mainly by
procedural factors, not by the method of haemostasis. Further-
more, time to discharge after the procedure is often locally deﬁned
and controlled and may not be suitable as an outcome measure.
Length of hospital stay did not differ signiﬁcantly between suture-
based devices following percutaneous EVAR or between suture-
based devices and surgical closure following EVAR.
Patient satisfaction
Some studies have shown increased patient satisfaction when a
closure device was used over extrinsic compression, but owing to
differences in the tools used to assess this, we could not make
a formal comparison between different mechanisms of action of
VCD.
Cost of VCD and extrinsic compression
Only three studies reported on the cost of VCDs; all found that
treatment with a suture-based VCD cost less than manual com-
pression. Study authors’ calculations show that this was due to an
associated time saving. These costs and calculations vary widely
between different centres, and the review authors therefore believe
that evidence is insufﬁcient to allow ﬁrm conclusions.
Overall completeness and applicability of
evidence
As detailed above, we observed heterogeneity in the studies iden-
tiﬁed including a wide variety of deﬁnitions for different outcome
measures. The study protocol required that the closure device use
must be assessed in diagnostic and interventional procedures. Prac-
tice varies between specialities, between centres and between coun-
tries, and possible differences between interventional and diagnos-
tic procedures that could inﬂuence outcomes (e.g. anticoagulant
use, time between procedure end and sheath removal) were not
clearly deﬁned in the included studies. Outcome measures such
as local arterial damage could be caused by the arteriotomy or by
the closure device used, and most of the included studies did not
consider this. Arteriovenous ﬁstula formation is a complication of
arterial puncture, not of closure device use per se. Some studies did
not speciﬁcally report whether the device was used in a manner
consistent with the manufacturer’s instructions for use or did not
comment on operator training and experience with the device.
No study measured the pre-deﬁned outcomes of arterial dissec-
tion and time spent in the angiography suite, and only one study
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reported on distal embolisation and femoral artery thrombosis.
Furthermore, some studies did not report data in useable format;
therefore, we could not include those particular studies in the
meta-analysis. In such instances, we attempted to contact the study
authors, but we did not receive the requested data.
Quality of the evidence
Very few studies reported on the method of randomisation used
or the way in which treatment allocation was concealed. No study
reported that participants were blinded. However, we judged that,
as most reported outcomes required physical measurements, lack
of blinding was unlikely to bias outcome measures. Only eight
studies blinded outcome assessors. This is important to note as
measures at the puncture site could be inﬂuenced by the assessor’s
knowledge of allocated treatment. We judged most studies as hav-
ing low risk of attrition, reporting and other bias. Overall, we de-
termined that the methodological quality of the studies included
in this review was moderate to low.
The quality of evidence, deﬁned according to GRADE (Grades
of Recommendation, Assessment, Development and Evaluation)
(GRADE 2004), was deemed to be low for the primary outcomes
of this review: time to haemostasis, time tomobilisation andmajor
adverse events. We downgraded the quality of the outcomes time
to haemostasis and time to mobilisation for serious imprecision
on the basis of substantial and unexplained heterogeneity between
studies.Wedowngraded the outcomemajor adverse event to low in
the domain of precision because we observed in the meta-analysis
a small sample size in relation to the expected effect size and wide
conﬁdence intervals. For secondary outcomes including adverse
events, technical failure of the device and length of hospital stay,
we judged the quality of the evidence as moderate for precision,
consistency and directness.
A major limitation of this review is the inclusion of data from the
past 20 years. Device and delivery systemdevelopment throughout
this period may have inﬂuenced success and complication rates,
potentially allowing masking of signiﬁcant differences. Further-
more, the remit of the review was to evaluate VCDs bymechanism
of action (clip-, collagen- or suture-based) rather than by speciﬁc
device, resulting in limited transferability to clinical practice. Dif-
ferences between speciﬁc devices and their delivery systems may
account, at least in part, for the substantial heterogeneity evident
within the data set, and this could mask associated beneﬁts or
detrimental effects.
Many studies did not state the direction of puncture (as ante-
grade or retrograde), and many differentiated between diagnostic
and interventional procedures without deﬁning the relevant dif-
ferences in procedure technique (e.g. sheath size, anticoagulant
administration, differences in time between end of the procedure
and sheath removal). Many studies showed wide variability in the
stratiﬁcation of complications into groups, meaning that a large
quantity of the data was unﬁt for meta-analysis.
It is important to note that other known techniques for closure of
the puncture site have not been covered by this review but will be
considered for inclusion in future versions of the review.
Potential biases in the review process
None of the authors of this review were involved in any of the
included or excluded studies. Furthermore, none of the review au-
thors have commercial or other conﬂicts of interest. The search
was as comprehensive as possible, and two review authors inde-
pendently assessed all studies for inclusion in the review. We are
conﬁdent that we have included all relevant studies, and we have
attempted to reduce bias in the review process by performing data
extraction and assessing study quality independently. However,
the possibility remains that studies may have been overlooked by
the search methods.
For one study included in this review (Sun 2009), data on time
to haemostasis and time to ambulation were presented separately
by type of procedure. So these data could be included in a meta-
analysis, we combined the mean and standard deviations for the
outcomes of time to haemostasis and time to ambulation ac-
cording to the formula given in Table 7.7.a in Chapter 7 of the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011). For a second study (Nelson 2014), which compared two
suture-based devices with surgical closure in participants undergo-
ing EVAR, data on time to haemostasis, time to ambulation and
length of hospital stay were presented separately for each device.
So these data could be included in a meta-analysis, we combined
the mean and standard deviations for these outcomes according
to the formula given in Table 7.7.a in Chapter 7 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Agreements and disagreements with other
studies or reviews
To date, four (Biancari 2010; Jiang 2015; Koreny 2004; Nikolsky
2004) systematic reviews and meta-analyses have been conducted
to investigate the efﬁcacy and safety of VCDs.
Koreny 2004 included 30 randomised controlled trials (RCTs)
of VCDs versus manual compression and found that participants
treated with a VCD had shorter time to haemostasis (mean dif-
ference (MD) 17 minutes, range 14 to 19 minutes), shorter du-
ration of bedrest (MD 10.8 hours, range 8.5 to 13.1 hours) and
shorter duration of hospital stay (MD 0.6 days, range 0.1 to 1.1
days) than those treated with manual compression. However, con-
siderable statistical heterogeneity was observed for these efﬁcacy
endpoints. With regard to safety outcomes, Koreny 2004 found
no differences between VCDs and manual compression for groin
haematoma (risk ratio (RR) 1.14, 95% conﬁdence interval (CI)
0.86 to 1.51), bleeding (RR 1.48, 95%CI 0.88 to 2.48) and pseu-
doaneurysm (RR 1.19, 95% CI 0.75 to 1.88). The authors of the
34Vascular closure devices for femoral arterial puncture site haemostasis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
review raised concerns about the quality of the included studies,
which they judged as poor to moderate.
Nikolsky 2004 included 30 studies on VCDs versus manual com-
pression. However, only 18 of these were RCTs. Nikolsky 2004
performed device-speciﬁc meta-analysis and found no differences
in complication rates between AngioSeal and mechanical com-
pression (odds ratio (OR) 0.73, 95%CI 0.38 to 1.39) nor between
PerClose ProGlide and mechanical compression (OR 1.00, 95%
CI 0.53 to 1.88). The authors of the review did report that Va-
soSeal was associated with an increase in complications (OR 2.78,
95% CI 1.51 to 5.13); this consistent ﬁnding has led to removal
of the device from clinical use.
Biancari 2010 included 31 RCTs with a total of 7528 participants
randomised to VCD or manual/mechanical compression after di-
agnostic angiography or interventional procedures. Meta-analysis
showed no differences in the incidence of haematoma, bleeding
and pseudoaneurysm between the two treatment groups. How-
ever, lower limb ischaemia (0.3% vs 0% P value = 0.02), the need
for surgery for vascular complications (0.7% vs 0.4%; P value =
0.10) and groin infection (0.6% vs 0.2%; P value = 0.02) were
more frequent in the VCD group. Meta-analysis also showed that
VCDs were associated with shorter time to haemostasis for par-
ticipants undergoing both diagnostic (MD 16.64 minutes, range
-21.96 to -11.32 minutes) and interventional procedures (MD -
37.67 minutes, range -47.94 to -27.40 minutes). However, the
authors of the review reported substantial heterogeneity for time
to haemostasis outcomes.
Jiang 2015 included 40 RCTs with a total of 16,868 participants
and found no differences in the rate of adverse vascular events
between all VCDs combined and manual compression. How-
ever, subgroup analysis showed that both FemoSeal and AngioSeal
devices were associated with fewer adverse events, in particular,
haematoma.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review has included randomised controlled trials comparing
extrinsic compression and VCDs in the closure of femoral arterial
punctures and in surgical closure with percutaneous closure after
large-calibre arterial access. We have demonstrated no signiﬁcant
differences in the primary endpoints of time to haemostasis and
time to mobilisation when VCD use is compared with extrinsic
compression, owing to data heterogeneity in the included studies.
Furthermore, we found no signiﬁcant differences in the incidence
of vascular injury or mortality when use of VCDs is compared
with use of extrinsic compression. Collagen-based VCDs are asso-
ciated with a lesser incidence of groin haematoma when compared
with extrinsic compression but no difference when metal clip-
based VCDs or suture-based VCDs were compared with manual
or mechanical compression. The incidence of pseudoaneurysm
was lower among individuals treated with collagen-based devices
than in those treated with manual or mechanical compression,
but no difference was evident when metal clip-based VCDs or
suture-based VCDs were compared with manual or mechanical
compression. For other adverse events, we observed no differences
between collagen, clip-based or suture-based. and manual or me-
chanical compression. With larger-calibre arterial access, percuta-
neous closure has been shown to be associated with shorter time
to haemostasis without an increase in complication rates when
compared with surgical closure.
A major limitation of this review is the inclusion of data span-
ning the past 20 years. Device and delivery system development
throughout this period may have inﬂuenced success and com-
plication rates, potentially allowing masking of signiﬁcant differ-
ences.Differences between speciﬁc devices and their delivery sys-
temsmay account, at least in part, for the substantial heterogeneity
evident within the data set, and this couldmask associated beneﬁts
or detrimental effects.
Many studies did not state the direction of puncture (as antegrade
or retrograde), and many others differentiated between diagnos-
tic and interventional procedures without deﬁning the relevant
differences in procedure technique (e.g. sheath size, anticoagulant
administration, differences in time between end of the procedure
and sheath removal). Many studies showed wide variety in the
stratiﬁcation of complications into groups, meaning that a large
quantity of the data was unﬁt for analysis. This variability in study
and reporting methodology means that the ﬁndings of thi review
are of limited value in speciﬁc clinical situations.
Three studies describe cost-savings associated with decreased time
to haemostasis. Owing to wide variation in VCD cost and local
hospital costs, formal economic analysis should be performed at a
local level before VCDs are accepted on the basis of cost-savings
alone.
Implications for research
Overall, successful VCD deployment is associated with a reduced
incidence of groin hematoma and shorter length of hospital stay,
with no increase in local arterial complications or major adverse
events. Further work is necessary to evaluate the efﬁcacy of speciﬁc
devices currently used and to compare these with one other and
with extrinsic compression with respect to clearly deﬁned outcome
measures. Researchers should evaluate primary and secondary out-
comes of different devices in antegrade and retrograde puncture
and should evaluate VCD outcome measures with respect to their
on-label and off-label uses.
Some studies report increased patient satisfaction with successful
VCD deployment. A formal assessment of this could be under-
taken.
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VCDs are widely used and are convenient for both patients and
operators. Large longitudinal data demonstrate their safety and
efﬁcacy with low complication rates; thus investigators may resist
development of randomised controlled trials of sufﬁciently robust
methodology to truly evaluate their efﬁcacy.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Amin 2000
Methods Study design : randomised prospective study
Participants Country : UK
Setting : hospital
Number of centres : 1
Numbers : AngioSeal 75, FemoStop 75
Age (mean (SD)) : AngioSeal 58.0 (9.2) years, FemoStop 59.5 (9.6) years
Sex : AngioSeal 48 M/17 F, FemoStop 49 M/16 F
Inclusion criteria : patients undergoing intracoronary stent deployment
Exclusion criteria :
patients with a history of previous application of AngioSeal within 90 days, peripheral
vascular disease, recent acute myocardial infarction, anticoagulation therapy, pre-existing
haematoma, formation of haematoma during the procedure or a concomitant femoral
venous sheath. Patients in whom the puncture needle had penetrated the posterior wall
of the artery during the procedure were also considered for exclusion
Interventions Intervention 1 : AngioSeal
Intervention 2 : FemoStop groin compression device
Sheath size : 8 Fr
Outcomes Primary : composite of bleeding, haematoma formation, bruise, requirement for blood
transfusion, clinical indication for ultrasound examination and cross-over to either
method at 2 and 24 hours following the procedure; bleeding (deﬁned as signiﬁcant ex-
ternal blood loss after the application of either device, with signiﬁcant bleeding deﬁned
as blood loss (Hb < 10.0 g/dL) requiring blood transfusion); haematoma (deﬁned as
development of a palpable mass over the access site classiﬁed as mild (< 5 cm), moderate
(5 to 10 cm) or severe (> 10 cm))
Secondary : pseuodaneurysm (palpable expansible mass detected by clinical examination
and conﬁrmed by ultrasound imaging); groin discomfort (minimal, moderate or severe)
Time of measurement : 2 and 24 hours after the procedure
Notes All participants received a bolus dose of 10,000 units of heparin after diagnostic an-
giograms
Antithrombotic agents following the procedure: aspirin 150 mg once daily long term
and ticlopidine 250 mg twice daily for 3 weeks
Outcomes measured at 2 and 24 hours post procedure, but 9 participants crossed over
from AngioSeal to FemoStop because of persistent bleeding despite prolonged manual
pressure
Risk of bias
Bias Authors’ judgement Support for judgement
42Vascular closure devices for femoral arterial puncture site haemostasis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Amin 2000 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised”
Comment: insufﬁcient information to per-
mit judgement of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Low risk Study appears to be free from other sources
of bias
Amine 1999
Methods Study design : randomised study
Participants Country : France
Setting : hospital
Number of centres : 1
Numbers: Techstar 50, manual compression 50
Age (mean (SD)) : Techstar 61 (10) years, manual compression 60 (8) years
Sex : Techstar 72 M/28 F, manual compression 70 M/30 F
Inclusion criteria : patients undergoing diagnostic coronography
Exclusion criteria : patients in an acute phase of myocardial infarct, with or without
thrombolysis treatment, with known anomalies of coagulation or plaque counting, with
severe and uncontrollable arterial hypertension (systolic > 190 mmHg and diastolic >110
mmHg) and inﬂammation of arthritis of the inferior limbs
Interventions Intervention 1 : PerClose
Intervention 2 : manual compression
Sheath size : 6 Fr
Outcomes Primary : clinical and ultrasound complications during the ﬁrst 15 days after treatment
Secondary : time to haemostasis; time to ambulation (deﬁned as time between removal
of the closure device and the moment the participant could stand up and walk for 5
metres); success rate of the system
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Amine 1999 (Continued)
Clinical exams at 1 hour and 24 hours looked for signs of ischaemia, haematoma, re-
bleeding, pseudo-aneurysm and arteriovenous ﬁstula. Doppler echographic examination
at 24 hours looked for signs of haematoma, pseudo-aneurysm, arteriovenous ﬁstula,
intra-arterial thrombus or the presence of arterial narrowing at the puncture level
Notes Coronography with 6 Fr sheath for all participants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomised in blocks of 4
for the manual compression group and by envelope
opened at the end of the coronography procedure
for the suture device group”
Comment: Envelopes were used, so sequence gen-
eration was probably random. Study was judged to
be at low risk of selection bias
Allocation concealment (selection bias) Low risk Quote: “closed envelope system”
Comment: Envelopes were sealed, so the study was
judged to be at low risk of selection bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged that out-
comes and outcome measurements are not likely to
be inﬂuenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judgement of
high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Unclear risk Insufﬁcient information to permit judgement of
high or low risk
Other bias Unclear risk Insufﬁcient information to permit judgement of
high or low risk
Ansel 2006
Methods Study design : randomised multi-centre study
Participants Country : USA
Setting : hospital
Number of centres : 7
Numbers: Angiolink EVS 243, manual compression 119
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Ansel 2006 (Continued)
Age (mean (SD)) : Angiolink EVS 61.2 (11.3) years, manual compression 62.9 (10.2)
years
Sex : Angiolink EVS 137 M/106 F, manual compression 75 M/44 F
Inclusion criteria : patients 18 to 80 years of age undergoing percutaneous femoral
access for elective or urgent transfemoral cardiac or peripheral vascular diagnostic or
interventional procedures
Exclusion criteria :
• Pre-procedure exclusion procedure
◦ Patients already participating in another research protocol; history of a pre-
existing autoimmune disease/vasculitis; history of bleeding/platelet disorder;
thrombolytic therapy administered within 24 hours; absent pedal pulses of either
extremity; use of a closure device in ipsilateral CFA within 6 months; prior femoral
vascular surgery at the targeted site; prior stent placement in the vicinity of the arterial
puncture site; pre-existing pseudoaneurysm/arteriovenous ﬁstula/haematoma at
targeted site; pre-existing terminal illness that would preclude follow up; pre-existing
systemic or cutaneous infection or pre-procedure platelet count < 100,000 × 103/µL or
haematocrit > 28%
• Intraprocedural exclusion procedure
◦ Obesity precluding access with a standard needle; arterial access requiring
multiple punctures; failed single wall arterial puncture; bleeding around sheath before
sheath removal; use of a sheath < 6 Fr; tortuous vascular anatomy with bends > 90°;
chronic limb ischaemia identiﬁed by claudication and severe peripheral vascular disease
at or immediately adjacent to the access site arteriotomy as determined by femoral
angiography; arterial access obtained in or near a vascular graft; cardiogenic shock
experienced during or immediately post procedure; systolic blood pressure < 90 mmHg
after the start of the procedure; uncontrolled hypertension; unresponsive to
pharmaceutical treatment before closure; failure to remove the sheath within the
cardiac catheterisation laboratory
Type of procedure : 188 diagnostic (EVS n = 125, compression n = 63), 174 interven-
tional (EVS n = 118, compression n = 56)
Interventions Intervention 1 : Angiolink Vascular Closure System (EVS)
Intervention 2 : Manual compression
Sheath size : > 6 Fr
Outcomes Primary : time to haemostasis (deﬁned as time from sheath removal to complete cessation
of bleeding); time to ambulation (deﬁned as time from sheath removal to independent
ambulation ≥ 20 feet without complication); time to device deployment (deﬁned as the
interval from sheath removal to device deployment); combined rate of major complica-
tions at 30-day follow-up
Secondary :
• Major complications
◦ Requirement for ultrasound-guided compression for pseudoaneurysm;
vascular surgery; femoral occlusion; retroperitoneal bleeding; uncontrolled bleeding
requiring surgical intervention; groin-related infection requiring IV antibiotics or
extended hospitalisation; new neuropathy in the ipsilateral lower extremity or decline
≥ 1 Rutherford class
• Minor complications
◦ Bleeding not requiring transfusion; haematoma ≥ 6 cm; intraluminal staple
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Ansel 2006 (Continued)
delivery not requiring surgical intervention; access site wound dehiscence; localised
access site infection treated without intravenous antibiotics; pseudoaneurysm treated
with thrombin injection or spontaneous resolution; arteriovenous ﬁstula; ipsilateral
pedal pulse ≤ 2 grades
Time of measurement : after sheath removal, before hospital discharge and 30 ± 7 days
post procedure
Notes EVS participants who did not receive IIb/IIIa inhibitors were ambulated 1 hour and
those treated with IIb and IIIa were ambulated 2 hours post sheath removal. Manual
compression participants were ambulated 4 (no IIb/IIIa inhibitors) and 6 hours (IIb/
IIIa inhibitors) post sheath removal
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomised
weighted 2:1 toward the device”
Comment: insufﬁcient information to per-
mit judgement of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judge that
outcomes and outcome measurements are
not likely to be inﬂuenced by lack of blind-
ing
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Low risk Study appears to be free from other sources
of bias
Behan 2007
Methods Study design : prospective randomised controlled trial
Participants Country : United Kingdom
Setting : district general hospital
Number of centres : 1
46Vascular closure devices for femoral arterial puncture site haemostasis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Behan 2007 (Continued)
Numbers: AngioSeal 107, manual compression 99
Age (mean (SD)) : AngioSeal 66.3 (9.7) years, manual compression 65.4 (8.7) years
Sex : AngioSeal 61 M/46 F, manual compression 57 M/42 F
Inclusion criteria : patients undergoing day case cardiac catheterisation
Exclusion criteria : unstable angina or acutemyocardial infarction; signiﬁcant peripheral
vascular disease; previous peripheral vascular surgery or percutaneous intervention; in-
ability to fully consent; pregnancy; age < 18 years; known ASDor VSD; previous femoral
artery complication from angiography; patients whose vascular access site was obtained
through a vascular graft; patients with uncontrolled hypertension (> 180 mmHg sys-
tolic); puncture site in superﬁcial femoral artery, distal to or at the bifurcation of the
superﬁcial femoral and profunda femoris arteries, proximal to the inguinal ligament or
multiple punctures
Interventions Intervention 1 : AngioSeal
Intervention 2 : manual compression
Sheath size : 6 Fr
Outcomes Primary : bruising; bleeding (deﬁned as the requirement for transfusion); retroperitoneal
bleed; pseudoaneurysm; leg ischaemia; vasovagal reaction; access site infection
Secondary : participant satisfaction (comfort, experience, duration of hospital stay, im-
mobilisation time, pain during and after the procedure and post-procedure bruising)
Notes Participants randomised to AngioSeal were mobilised within 30 minutes; manual com-
pression participants were mobilised within 2 hours
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Angiogram lists were randomised”
Comment: insufﬁcient information to per-
mit judgement of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Bruise size measurements were
carried out for all the patients by the same
trained nurse, who was separate from the
group of operators. This person was not
blinded to themethodof haemostasis used”
Comment: no blinding or incomplete
blinding for bruising, but this was not an
outcome of the review; therefore, it does
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Behan 2007 (Continued)
not introduce detection bias
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Seventy-six of 107 (71%) patients
in the Angio-Seal group attended for the 1
week follow up as did 71 of the 99 (72%)
in themanual compression group. Further-
more the AngioSeal device was deployed in
only 74 out of 107 patients randomised to
the device. Reasons are stated for 23 pa-
tients but the reasons were not recorded in
10 cases”
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Low risk Study appears to be free from other sources
of bias
Brachmann 1998
Methods Study design : prospective multi-centre randomised trial
Participants Country : Germany
Setting : hospital
Number of centres : not stated
Numbers : VasoSeal 306, manual compression 204
Age (mean (SD)) : VasoSeal (angiography) 61 (12) years, VasoSeal (PTCA) 62 (11)
years, manual compression (angiography) 61 (10) years, manual compression (PTCA)
61 (10) years
Sex: VasoSeal 224 M/82 F, manual compression 153 M/51 F
Inclusion criteria : patients 18 to 80 years of age who were acceptable candidates for
diagnostic angiography and percutaneous transluminal coronary angioplasty (PTCA)
procedures and manual compression after intervention
Exclusion criteria: patients who were morbidly obese (body mass index > 40); with
bleeding disorders; with a clinically signiﬁcant haematoma (> 6 cm) present before sheath
removal; admitted for emergency angioplasty; with known allergies to beef or collagen
products; with elevated blood pressure (> 140/90 mmHg) that could not be controlled
by medical therapy; pregnant women
Interventions Intervention 1 : VasoSeal
Intervention 2 : manual compression
Sheath size : 6 to 8 Fr
Outcomes Primary : time to haemostasis; time to mobilisation (deﬁned as time from sheath pull
to getting out of bed and moving about as necessary)
Secondary : vascular repair; transfusion; infection prolonging hospital stay; haematoma
> 6 cm; bleeding requiring > 30 minutes to re-achieve haemostasis; pseudoaneurysm
requiring mechanical compression; deep vein thrombosis; arteriovenous ﬁstula; infection
not prolonging hospital stay; retroperitoneal bleed; thromboembolism; failure to deploy
collagen
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Brachmann 1998 (Continued)
Time of measurement : immediately after sheath pull, 24 hours and 30 days post
procedure
Notes PTCA participants were randomised to VasoSeal normal (2 hours after sheath pull) and
immediate (immediately after sheath pull)
21 participants removed from the analysis for time tomobilisation because of prior illness
Initial mobilisation was attempted at 1 hour after sheath pull in VasoSeal participants
and 6 hours post sheath pull in manual compression participants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised”
Comment: insufﬁcient information about
the sequence generation process to permit
judgement of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding, but review authors judge that
outcomes and outcome measurements are
not likely to be inﬂuenced by lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Selective reporting (reporting bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Other bias Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Camenzind 1994
Methods Study design : randomised study
Participants Country : The Netherlands
Setting : hospital
Number of centres : 1
Numbers : VasoSeal 62, manual compression 62
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Camenzind 1994 (Continued)
Age (mean (SD)) : VasoSeal 59 (12) years, manual compression 60 (11) years
Sex : VasoSeal 50 M/12 F, manual compression 53 M/9 F
Inclusion criteria : patients undergoing percutaneous transluminal coronary angioplasty
performed with a 6F guiding catheter and full-dose heparinisation for > 12 hours or
coronary angioplasty with 7F or 8F guiding catheters and optional subsequent herparin-
isation
Exclusion criteria : pre-existing local haematoma andknown allergy to collagenproducts
Interventions Intervention 1 : VasoSeal
Intervention 2 : manual compression
Sheath size : 8 Fr
Outcomes Primary : immediate haemostasis
Secondary : haematoma; pseudoaneurysm; arteriovenous ﬁstula; venous thrombosis;
arterial occlusion
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised”
Comment: insufﬁcient information about the se-
quence generation process to permit judgement of
high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judgement of
high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged that out-
comes and outcome measurements are not likely to
be inﬂuenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Two physicians interpreted the ultrasound
examinations without knowledge of treatment as-
signment”
Comment: Blinding of outcome assessors was done.
Study was judged to be at low risk of performance
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Study outcomes clearly reported
Other bias Unclear risk Insufﬁcient information to permit judgement of
high or low risk
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Carere 2000
Methods Study design : randomised controlled trial
Participants Country : Canada
Setting : hospital
Number of centres : 1
Numbers : ProStar-Plus 50, C-Clamp 50
Age (mean (SD)) : ProStar-Plus 62 (11) years, C-Clamp 59 (12) years
Sex : ProStar-Plus 44 M/6 F, C-Clamp: 39 M/11 F
Inclusion criteria : patients with elective or urgent coronary angioplasty with or without
stenting in whom same-day discharge was reasonable
Exclusion criteria : clinical evidence of peripheral arterial disease, pre-existing femoral
haematoma, serum creatinine > 150 mmol/L, blood pressure > 180/100 mmHg, partic-
ipating in another research project
Interventions Intervention 1 : ProStar-Plus
Intervention 2 : C-Clamp
Sheath size : 8 Fr
Outcomes Primary : time to mobilisation; time to discharge
Secondary : insertion failure; need for vascular surgery; external bleeding after initial
haemostasis; an ooze of blood; haematomas (small < 5 cm, medium 5 to 10 cm, large >
10 cm); blood transfusion; participant satisfaction; cost per participant
Notes Participants randomised to ProStar were mobilised after 4 hours; manual compression
participants were mobilised 6 hours after sheath removal
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly allocated”
Comment: insufﬁcient information to per-
mit judgement of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
51Vascular closure devices for femoral arterial puncture site haemostasis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Carere 2000 (Continued)
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Low risk Study appears to be free of other sources of
bias
Castañeda 2003
Methods Study design : randomised trial
Participants Country : United States of America
Setting : hospital
Number of centres : 1
Numbers : QuickSeal 85, manual compression 56
Age (mean (SD)) : QuickSeal 62 (11.4) years, manual compression mean 65 (10.8)
years
Sex : QuickSeal 54 M/31 F, manual compression 31 M/25 F
Inclusion criteria : patients 18 to 80 years of age undergoing percutaneous diagnostic
or interventional procedure via the common femoral artery
Exclusion criteria : pre-existing autoimmune disease; punctures through a vascular
graft; puncture depth < 3 cm or > 7.5 cm; haematoma present before sheath removal;
signiﬁcant bleeding or platelet disorders; uncontrolled hypertension; ipsilateral arterial
site closure with QuickSeal within 6 weeks; closure with manual compression within 6
weeks, or closure with another device within 180 days; pregnant or breastfeeding women.
Intraprocedural exclusion criteria included bleeding before sheath removal, suspected
contamination of access site, multiple or double wall punctures, ipsilateral venous sheath,
palpable haematomabefore sheath removal and intraprocedural therapeutic thrombolysis
Interventions Intervention 1 : QuickSeal
Intervention 2 : manual compression
Sheath size : ≤ 8 Fr
Outcomes Primary : time to haemostasis (time between sheath pull and haemostasis); time to
ambulation (deﬁned as time between end of the procedure and the participant walking
10 feet); rate of major complications (need for medical intervention beyond that of
standard procedure (haematoma requiring transfusion, severe vessel damage or infection)
and that required extended hospitalisation, transfusion or unanticipated surgery); rate
of minor complications (haematoma, ecchymosis, bleeding and minor pseudoaneurysm
requiring no intervention)
Secondary : time to hospital discharge
Notes Ambulation was attempted at 1 hour, followed by subsequent checks at hourly intervals,
in theQuickSeal group. The ﬁrst check for ambulation in themanual compression group
was attempted at 4 hours in participants undergoing diagnostic procedures and at 6
hours among participants undergoing interventional procedures
Risk of bias
Bias Authors’ judgement Support for judgement
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Castañeda 2003 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomised according to a 3:
2 ratio. Randomization was also stratiﬁed to type of
procedure”
Comment: random aspect of sequence generation.
Study judged to be at low risk of bias
Allocation concealment (selection bias) Low risk Quote: “Opaque envelopes containing the random
assignment that speciﬁed the method for achieving
haemostasis were used to randomise patients”
Comment: adequate concealment of allocation, so
study judged to be at low risk of selection bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged that out-
comes and outcome measurements are not likely to
be inﬂuenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judgement of high
or low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Low risk Study appears to be free from other sources of bias
Chen 2013
Methods Study design : randomised study
Participants Country : Taiwan
Setting : hospital
Number of centres : 1
Numbers : Boomerang 30, PerClose 30
Age (mean (SD)) : Boomerang 63.1 (9.9) years, PerClose mean 69.8 (10.6) years
Sex : QuickSeal 21 M/9 F, manual compression 20 M/10 F
Inclusion criteria : patients undergoing percutaneous interventional procedure via the
common femoral artery
Exclusion criteria : patients with “double wall” arterial punctures, intraluminal thrombi,
pseudoaneurysms, haematomas, arteriovenous (AV) ﬁstulas or infection in the target
artery lesion; history of protamine allergy; previous injections of neutral protamine
hagedorn (NPH). We also excluded patients who required a long sheath (> 23 cm)
Interventions Intervention 1 : Boomerang
Intervention 2 : PerClose
Sheath size : 7 Fr
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Chen 2013 (Continued)
Outcomes Primary : procedure success; device success; device deployment time; device dwell time;
manual compression time; time to ambulation; major complications
Secondary : pain score; minor complications
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised”
Comment: insufﬁcient information to permit
judgement of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judgement of
high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged that out-
comes and outcome measurements are not likely to
be inﬂuenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judgement of
high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Low risk Study appears to be free from other sources of bias
Deuling 2008
Methods Study design : prospective randomised trial
Participants Country: The Netherlands
Setting: hospital
Number of centres : 1
Numbers : AngioSeal 150, StarClose 150, manual compression 150
Age (mean (SD)) : AngioSeal 62.7 (11.8) years, StarClose 64.1 (10.8) years, manual
compression 62.9 (12.5) years
Sex : AngioSeal 102 M/48 F, StarClose 109 M/41 F, manual compression 110 M/40 F
Inclusion criteria : patients admitted for elective diagnostic or interventional cardiac
catheterisation procedures who were eligible for femoral access
Exclusion criteria : high or low arterial puncture
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Deuling 2008 (Continued)
Interventions Intervention 1 : AngioSeal
Intervention 2 : StarClose
Intervention 3 : manual compression
Sheath size : 6 Fr
Outcomes Primary: success of haemostasis; oozing; haemoglobin change duringhospital admission;
complications (haematoma, need for blood transfusion, surgical intervention at access
site, infection)
Secondary: participant comfort
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Patients received a device or man-
ual compression based on order of presen-
tation”
Comment: non-random sequence genera-
tion. Study judged to be at high risk of se-
lection bias
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Selective reporting (reporting bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Other bias Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
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Diaz 2001
Methods Study design : quasi-randomised controlled trial
Participants Country : Spain
Setting : hospital
Number of centres : 1
Numbers : AngioSeal 75, manual compression 75
Age (mean (SD)) : AngioSeal 59 (9.5) years, manual compression 60 (9) years
Sex : AngioSeal 65 M/10 F, manual compression 64 M/11 F
Inclusion criteria : patients aged over 18 years undergoing coronary angiography and/
or percutaneous transluminal coronary angioplasty (PTCA) via the femoral artery with
or without implantation of stent
Exclusion criteria : the drilling of the posterior wall of the artery during puncture,
presence of a femoral murmur, history of aortic vascular surgery or lower limb and the
presence of haematoma before randomisation
Interventions Intervention 1 : AngioSeal
Intervention 2 : manual compression
Sheath size : 6 Fr
Outcomes Primary : time to haemostasis; time to ambulation
Secondary : Hhaematoma
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Sequence generated by odd and even num-
bers
Allocation concealment (selection bias) High risk Allocation based on alternation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No missing data
Selective reporting (reporting bias) Unclear risk Data on pre-speciﬁed outcomes reported
Other bias Low risk Study appears to be free from other sources
of bias
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Doneaux 2001
Methods Study design : randomised comparison
Participants Country : Belgium
Setting : hospital
Number of centres : not stated
Numbers : AngioSeal 58, manual compression 63
Age : not stated
Sex : not stated
Inclusion criteria : patients undergoing percutaneous coronary intervention
Exclusion criteria : not stated
Interventions Intervention 1 : AngioSeal
Intervention 2 : manual compression
Sheath size : not stated
Outcomes Primary : device success; time to compression; duration of compression; time to ambu-
lation; participant satisfaction
Secondary : large haematoma (> 5 cm); pseudoaneurysm; groin discomfort; subcuta-
neous bleeding
Notes Study is published as an abstract only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomised”
Comment: insufﬁcient information about
the sequence generation process to permit
judgement of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judge that
outcomes and outcome measurements are
not likely to be inﬂuenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Selective reporting (reporting bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
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Doneaux 2001 (Continued)
Other bias Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Fargen 2011
Methods Study design : blinded randomised controlled trial
Participants Country : United States of America
Setting : hospital
Number of centres : 1
Numbers : AngioSeal 32, Mynx 32
Age (mean (SD)) : Mynx 55.0 (1.9) years, AngioSeal 58.5 (2.6) years
Sex : Mynx 11 M/21 F, AngioSeal 13 M/19 F
Inclusion criteria : adult patients undergoing diagnostic cerebral angiography via
femoral access
Exclusion criteria : patients undergoing angiography through any non-femoral artery
percutaneous access site; those with documented psychiatric disorders, altered mental
status or necessitating conscious sedation during their procedures; those reporting a
baseline chronic pain rating≥ 4 on the visual analogue scale (VAS) before closure device
deployment; patients in which the puncture was distal to the bifurcation of the superﬁcial
femora and profunda femoris arteries; puncture site proximal to the inguinal ligament;
puncture through a vascular graft; multiple punctures required to obtain arterial access;
patients with clinically signiﬁcant peripheral vascular disease; uncontrolled hypertension
(systolic blood pressure > 180 mmHg); femoral artery size < 5 mm
Interventions Intervention 1 : AngioSeal
Intervention 2 : Mynx M5
Sheath size : not stated
Outcomes Primary : change in pain from baseline (pre-closure) to post closure, assessed by VAS
Secondary : participant reporting of the most painful portion of the procedure from
a multiple choice selection. Major complications (access site-related surgical vascular
repair; amputation related to access closure complication; permanent access site-related
nerve injury; access site-related bleeding requiring transfusion; new ipsilateral lower ex-
tremity ischaemia by exam, Doppler or angiography requiring non-surgical interven-
tion; local access site-related infection, inﬂammation or generalised infection due to the
procedure requirement of intravenous antibiotics or prolonged hospitalisation); minor
complications (arteriovenous ﬁstula documented by ultrasound not requiring treatment;
pseudoaneurysm not requiring treatment or treated with thrombin injection; access site
haematoma≥ 6 cm; access site bleeding requiring ≥ 30 minutes to achieve haemostasis;
late (pre- or post-discharge) access site-related bleeding; ipsilateral deep vein thrombosis;
transient access site-related nerve injury; local access-site related infection or inﬂamma-
tion requiring oral antibiotics)
Notes
Risk of bias
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Fargen 2011 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomization was performed
utilizing pre study-created, randomly allot-
ted, sealed envelopes containing the name
of the VCD to be used”
Comment: insufﬁcient information re-
garding random sequence generation to
permit judgement of high or low risk
Allocation concealment (selection bias) Low risk Quote: “Randomization was performed
utilizing pre study-created, randomly allot-
ted, sealed envelopes containing the name
of the VCD to be used”
Comment: adequate concealment of allo-
cation. Study judged to be at low risk of
selection bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The patients, nurses administering
the questionnaire and study coordinators
were blinded to the VCD treatment used”
Comment: Blinding of participants and
personnel was done. Study was judged to
be at low risk of performance bias
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The patients, nurses administering
the questionnaire and study coordinators
were blinded to the VCD treatment used”
Comment: Blinding of outcome assessors
was done. Study was judged to be at low
risk of performance bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Low risk Study appears to be free from other sources
of bias
Gerckens 1998
Methods Study design : single-centre randomised trial
Participants Country : Germany
Setting : hospital
Number of centres : 1
Numbers : suturing device 298, manual compression 292
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Gerckens 1998 (Continued)
Age (mean (SD)) : suturing device 60 (9) years, manual compression 62 (8) years
Sex : suturing device 206 M/92 F, manual compression 207 M/85 F
Inclusion criteria : patients who were possible candidates for same-day ambulation and
who had undergone a catheterisation procedure via the common femoral artery through
a 5.5 Fr to 8 Fr introducer sheath
Exclusion criteria : patients with suspected signiﬁcant peripheral vascular disease; those
in whom contralateral or bilateral arterial access site was punctured; previous vascular
complication or repair; small common femoral artery; back wall of common femoral
artery was punctured; multiple puncture attempts were made; patient’s anatomy made
successful device deployment unlikely
Interventions Intervention 1 : Techstar or ProStar Plus
Intervention 2 : manual compression
Sheath size : 6 Fr or 8 Fr
Outcomes Primary : incidence of major vascular complications; time to haemostasis; time to ambu-
lation (elapsed time between randomisation and time the participant walked 3 meters)
Secondary : surgery; untreated pseudoaneurysm; infection requiring oral antibiotics;
arteriovenous ﬁstula; peripheral ischaemia; haematoma > 4 cm
Notes Guidelines for ambulation allowed the participant to walk within 1 hour after the suture-
mediated closure procedure in the diagnostic subset and within 4 hours in the interven-
tional subset. Ambulation for compression participants was based on hospital standards
(usually 4 hours after diagnotic procedures and 6 hours after achievement of haemostasis
after interventional procedures)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomisation process”
Comment: insufﬁcient information to per-
mit judgement of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
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Gerckens 1998 (Continued)
Selective reporting (reporting bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Other bias Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Gwechenberger 1997
Methods Study design : randomised study
Participants Country : Austria
Setting : hospital
Number of centres : 1
Numbers: VasoSeal 33, manual compression 33
Age (mean (SD)) : VasoSeal 59.8 (8.1) years, manual compression 56.9 (10.8) years
Sex : VasoSeal 31 M/2 F, manual compression 24 M/5 F
Inclusion criteria : patients undergoing diagnostic or therapeutic percutaneous trans-
luminal coronary angioplasty
Exclusion criteria : not stated
Interventions Intervention 1 : VasoSeal
Intervention 2 : manual compression
Sheath size : not stated
Outcomes Primary : time to haemostasis
Secondary : complications (arteriovenous ﬁstula, pseudoaneurysm, bleeding,
haematoma > 6 cm in diameter)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomised”
Comment: insufﬁcient information to permit
judgement of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judgement of
high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged that out-
comes and outcome measurements are not likely to
be inﬂuenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judgement of
high or low risk
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Gwechenberger 1997 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Unclear risk Study outcomes are not clearly reported
Other bias Unclear risk Insufﬁcient information to permit judgement of
high or low risk
Hattab 2012
Methods Study design : prospective randomised study
Participants Country : France
Setting : hospital
Number of centres : 1
Numbers: ExoSeal 50, ProGlide 50
Age : not stated
Sex : not stated
Inclusion criteria : patients undergoing PCI and endovascular peripheral procedures
via retrograde femoral artery access
Exclusion criteria : not stated
Interventions Intervention 1 : ExoSeal
Intervention 2 : PerClose ProGlide
Sheath size : 6 Fr
Outcomes Primary : immediate total haemostasis
Secondary : incidence of vascular complications (haematoma, blood transfusion)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly assigned”
Comment: insufﬁcient information to per-
mit judgement of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
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Hattab 2012 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Selective reporting (reporting bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Other bias Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Hermanides 2010
Methods Study design : single-centre retrospective randomised study
Participants Country : The Netherlands
Setting : hospital
Number of centres : 1
Numbers: AngioSeal 313, manual compression 314
Age (mean (SD)) : AngioSeal 64.5 (11.3) years, manual compression 64.0 (11.0) years
Sex : AngioSeal 238 M/75 F, manual compression 239 M/75 F
Inclusion criteria : patients undergoing PCI via femoral artery access
Exclusion criteria : age < 18 years; serious co-morbidity such as cancer; advanced cere-
brovascular disease; unwilling or unable to sign the consent form for participation; fe-
males of childbearing age not using medically prescribed contraceptives; unsuitable ac-
cess site (severe peripheral vascular disease, poor location)
Interventions Intervention 1 : AngioSeal
Intervention 2 : manual compression
Sheath size : 6 Fr
Outcomes Primary : combined incidence of (1) severe haematoma > 5 cm at the puncture site or
groin bleeding resulting in prolonged hospital stay, transfusion and/or surgical interven-
tion at the puncture site; (2) arteriovenous ﬁstula formation at the puncture site and/or
surgical intervention at the puncture site
Secondary : decrease in haemoglobin 1 day after inclusion; hospital admission duration
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed by
means of a computer program in blocks
(randomly changing block size)”
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Hermanides 2010 (Continued)
Comment: random sequence generation.
Study was judged to be at low risk of selec-
tion bias
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “A blinded independent clinical
endpoint committee adjudicated all clini-
cal endpoints”
Comment: Blinding of outcome assessors
was done. Study was judged to be at low
risk of performance bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Low risk Study appears to be free from other sources
of bias
Hermiller 2005
Methods Study design : prospective randomised multi-centre trial (CLIP trial). Substudy of di-
agnostic arm
Participants Country : United States of America
Setting : hospital
Number of centres : 17
Numbers : StarClose 136, manual compression 72
Age (mean (SD)) : StarClose 62.07 (12.12) years, manual compression 60.85 (11.11)
years
Sex : StarClose 93 M/43 F, manual compression 46 M/26 F
Inclusion criteria : patients undergoing diagnostic angiography; arterial puncture site
in an appropriate vessel; suitable as a candidate for vascular surgery; ability to complete
required clinical follow-up
Exclusion criteria : patients with uncontrolled hypertension, clinically severe peripheral
vascular disease (including calciﬁcation at the arteriotomy), obesity (BMI > 35) or a
history of bleeding diathesis
Interventions Intervention 1 : StarClose
Intervention 2 : manual compression
Sheath size : 6 Fr
64Vascular closure devices for femoral arterial puncture site haemostasis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hermiller 2005 (Continued)
Outcomes Primary : major vascular complications (composite of vascular injury requiring repair,
new ipsilateral distal ischaemia requiring revascularisation, access site nerve injury re-
quiring intervention, access site bleeding requiring transfusion and access site infection
requiring intravenous antibiotics or prolonged hospital stay); time to haemostasis (de-
ﬁned as time between sheath removal and ﬁrst observed clinical haemostasis)
Secondary : device success; procedure success; time to ambulation (deﬁned as time from
sheath pull to participant walking 20 feet without bleeding); time to discharge
Follow-up : 30 days post procedure
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised”
Comment: insufﬁcient information to per-
mit judgement of low or high risk
Allocation concealment (selection bias) Unclear risk Comment: insufﬁcient information to per-
mit judgement of low or high risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: insufﬁcient information to per-
mit judgement of low or high risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Low risk Study appears to be free from other sources
of bias
Hermiller 2006
Methods Study design : prospective randomised multi-centre trial (CLIP trial). Substudy of in-
terventional arm
Participants Country : United States of America
Setting : hospital
Number of centres : 17
Numbers: StarClose 184, manual compression 91
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Hermiller 2006 (Continued)
Age : 62.8 (9.9) years
Sex : 221 M/54 F
Inclusion criteria : patients undergoing interventional catheterisation procedures; arte-
rial puncture site in an appropriate vessel; suitability as a candidate for vascular surgery
with ability to complete required clinical follow-up
Exclusion criteria : patients with uncontrolled hypertension; clinically severe peripheral
vascular disease (including calciﬁcation at the arteriotomy); obesity (BMI > 35);history
of bleeding diathesis
Interventions Intervention 1 : StarClose
Intervention 2 : manual compression
Sheath size : 6 Fr
Outcomes Primary : major vascular complications (composite of vascular injury requiring repair,
new ipsilateral distal ischaemia requiring revascularisation, access site nerve injury re-
quiring intervention, access site bleeding requiring transfusion and access site infection
requiring intravenous antibiotics or prolonged hospital stay); time to haemostasis (de-
ﬁned as time between sheath removal and ﬁrst observed clinical haemostasis)
Secondary : device success; procedure success; time to ambulation (deﬁned as time from
sheath pull to participant walking 20 feet without bleeding); time to discharge
Notes All participants received anticoagulation medication (heparin, aspirin, clopidogrel, gly-
coprotein IIb/IIIa inhibitors)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Subjects were randomised”
Comment: insufﬁcient information to per-
mit judgement of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
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Hermiller 2006 (Continued)
Other bias Low risk Study appears to be free from other sources
of bias
Holm 2014
Methods Study design : prospective randomised non-blinded single-centre trial (CLOSE-UP
trial)
Participants Country : Denmark
Setting : hospital
Number of centres : 1
Numbers: FemoSeal 500, manual compression 501
Age (mean (SD)) : FemoSeal 64.3 (11) years, manual compression 65.2 (11) years
Sex : FemoSeal 310 M/190 F, manual compression 311 M/190 F
Inclusion criteria : patients > 18 years of age eligible for femoral access and scheduled
for elective diagnostic coronary angiography
Exclusion criteria
• Patients with expected life span < 1 year
• Coronary angiography within the past month or subsequent coronary
angiography within 14 days
• Presence of groin haematoma before closure procedure
• Known pseudoaneurysm at the femoral artery
• Sheath size other than 6 Fr
• Known stenosis of > 50% in the femoral or iliac artery
• INR above 3.0
• Platelet count < 120 × 199/L
• Thrombolysis within 24 hours
• Femoral disease
• Pregnancy
• Systolic blood pressure > 200 mmHg and/or diastolic pressure > 110 mmHg
• Patients with femoral vein access during the same procedure
Interventions Intervention 1 : FemoSeal
Intervention 2 : manual compression
Sheath size : 6 Fr
Outcomes Primary
• In-hospital incidence of access site haematoma > 5 cm
Secondary
• 14-Day major bleeding
• Retroperitoneal bleeding
• Pseudoaneurysm
• Arteriovenous ﬁstula
• Infection
• Other complications necessitating surgery
• Time to haemostasis
• Time to ambulation
• Device deployment failure
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Holm 2014 (Continued)
• Need for repeat manual compression after haemostasis was obtained
• Vasovagal response
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation was performed 1:
1 by telephone call to a voice prompt stand-
alone computer-based system”
Comment: random sequence generation.
Study was judged to be at low risk of selec-
tion bias
Allocation concealment (selection bias) Low risk Quote: “Randomisation was performed 1:
1 by telephone call to a voice prompt stand-
alone computer-based system”
Comment: adequate concealment of allo-
cation. Study was judged to be at low risk
of selection bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Low risk Study appears to be free from other sources
of bias
Jensen 2008
Methods Study design : prospective randomised single-centre study
Participants Country : Sweden
Setting : hospital
Number of centres : 1
Numbers : AngioSeal 22, PerClose 22, FemoStop 24
Age (mean (SD)) : AngioSeal 63 (11) years, PerClose 62 (9) years, FemoStop 61 (9)
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years,
Sex : AngioSeal 15 M/7 F, PerClose 16 M/6 F, FemoStop 21 M/3 F
Inclusion criteria : Patients undergoing planned coronary angiography because of sta-
ble angina pectoris were able to complete the required clinical follow-up and provide
informed consent
Exclusion criteria : patients with unstable angina pectoris, ongoing infection, known
inﬂammatory disease, previous PCI or coronary bypass grafting or other major surgery
within 12 months and during follow-up, and ongoing treatment with warfarin, steroids
or non-steroid anti-inﬂammatory drugs
Interventions Intervention 1 : AngioSeal
Intervention 2 : PerClose
Intervention 3 : FemoStop
Sheath size : 6 Fr
Outcomes Primary : inﬂammatory markers
Secondary : immediate haemostasis; vascular injury; bleeding; haematoma
Notes FemoStop participants were ambulated after 2 hours; those who received AngioSeal or
PerClose were ambulated after 1 hour
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised to one
of the following devices”
Comment: insufﬁcient information to per-
mit judgement of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Unclear risk Number of side effects not reported
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Other bias Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Juergens 2004
Methods Study design : randomised trial
Participants Country : Australia
Setting : hospital
Number of centres : 1
Numbers : 58 AngioSeal, 57 FemoStop
Age (mean (SD)) : AngioSeal 59 (11) years, FemoStop 59 (10) years
Sex : AngioSeal 44 M/14 F, FemoStop 46 M/11 F
Inclusion criteria : patients undergoing percutaneous coronary intervention, clean (sin-
gle puncture through the anterior wall only) arterial access with a 7 Fr sheath and guiding
system, no development of haematoma during the procedure
Exclusion criteria : patients in whom repeat femoral access through the same side was
likely within the ensuing 90 days
Interventions Intervention 1 : AngioSeal
Intervention 2 : FemoStop
Sheath size : 7 Fr
Outcomes Primary : patient tolerance and resource utilisation (cost of disposals, amount of medical
and nursing time spent attending to the femoral access site)
Secondary : time to removal of participant from angiography suite; time to haemostasis;
time to ambulation; time to hospital discharge; incidence of vascular complications
Notes First outcome assessments were made at 4 hours, at 8 hours and on the morning after
the procedure
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised at the end of the
procedure”
Comment: insufﬁcient information to permit judge-
ment of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judgement of high
or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged that out-
comes and outcome measurements are not likely to
be inﬂuenced by lack of blinding
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Patients underwent a duplex ultrasound re-
ported by a vascular surgeon who was blinded to
treatment assignment”
Comment: outcome assessors blinded to treatment.
Study was judged to be at low risk of detection bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Low risk Study appears to be free from other sources of bias
Kalsch 2008
Methods Study design : prospective single-centre randomised study
Participants Country : Germany
Setting : hospital
Number of centres : 1
Numbers : AngioSeal 214, PerClose 152
Age (mean (SD)) : AngioSeal 64 (11) years, PerClose 65 (10) years
Sex : AngioSeal 151 M/61 F, PerClose 111 M/43 F
Inclusion criteria : patients undergoing diagnostic cardiac catheterisation (n = 224) or
interventional coronary procedures (n = 144)
Exclusion criteria : patients < 18 years, pre-existing large haematoma, known allergy to
bovine products or reabsorbable suture material
Interventions Intervention 1 : AngioSeal
Intervention 2 : PerClose
Sheath size : 6 Fr or 8 Fr
Outcomes Primary : ankle-brachial index; incidence of major complications during the in-hospital
period
Secondary : successful technical deployment of the device; successful +haemostasis with-
out additional treatment
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised to...”
Comment: insufﬁcient information to per-
mit judgement of high or low risk
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Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Other bias Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Kussmaul 1995
Methods Study design : randomised multi-centre trial
Participants Country : United States of America
Setting : hospital
Number of centres : 8
Numbers : AngioSeal 218, manual compression 217
Age (mean (SD)) : AngioSeal 61 (11) years, manual compression 62 (11) years
Sex : AngioSeal 159 M/59 F, manual compression 156 M/61 F
Inclusion criteria : patients undergoing cardiac catheterisation or angioplasty
Exclusion criteria : patients < 18 or > 80 years; bleeding diathesis; warfarin therapy;
thrombolytic therapy within 24 hours of or during catheterisation; acute myocardial
infarction; marked obesity; uncontrolled hypertension and known allergy to bovine
collagen or reabsorbable suture material; clinical or ultrasound evidence of signiﬁcant
peripheral vascular disease; history of claudication or vascular surgery; absent pedal
pulses; femoral artery bruit; ankle/brachial systolic blood pressure index < 0.9; signiﬁcant
(> 20% occlusive) anterior atherosclerosis seen on ultrasound of the common femoral
artery
Interventions Intervention 1 : AngioSeal
Intervention 2 : manual compression
Sheath size : 8 Fr
Outcomes Primary : time to haemostasis (deﬁned as time between sheath removal and no bleeding)
Secondary : complications (bleeding (any external blood loss after device deployment,
≥ 30 minutes of manual pressure required or any late bleeding, whether or not a mea-
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surable decrease in hematocrit occurred or transfusion was necessary); haematoma (any
palpable mass); pseudoaneurysm (periarterial mass detected by physical examination or
ultrasound-containing Doppler-detected ﬂow); loss of pulse; infection; clinical evidence
of leg ischaemia)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomisation procedure en-
sured that equal numbers of patients would
be randomised to groups I and II by using
a block scheme with six patients per block”
Comment: random sequence generation.
Study was judged to be at low risk of selec-
tion bias
Allocation concealment (selection bias) Low risk Quote: “The results of randomisation were
place in sealed, sequential envelopes to be
opened at each site as needed”
Comment: adequate concealment of allo-
cation. Study was judged to be at low risk
of selection bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Of the 435 participants randomised,
115 underwent interventional procedures.
However, data on only 109 interventional
participants are reported. Therefore, 6 par-
ticipants are missing from this analysis, and
it is not stated why
Selective reporting (reporting bias) Unclear risk Study outcomes not clearly pre-speciﬁed
Other bias Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
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Legrand 2005
Methods Study design : randomised trial
Participants Country : Belgium
Setting : hospital
Number of centres : 1
Numbers : AngioSeal 100, manual compression 102
Age (mean (SD)) : AngioSeal 62.6 (10.3) years, manual compression 62.1 (13.0) years
Sex : AngioSeal 79 M/21 F, manual compression 77 M/25 F
Inclusion criteria : patients undergoing coronary intervention through a femoral 6 Fr
access sheath
Exclusion criteria : uncontrolled hypertension (> 200 mmHg); platelet count < 75,000;
septicaemia; acute myocardial infarction; cardiogenic shock; severe acute non-cardiac
systemic disease or terminal illness; sheath in place longer than 24 hours;multiple femoral
punctures; signiﬁcant femoral disease and/or vascular tortuosity in the region of the
puncture; vessel diameter < 5 mm; arterial puncture performed in the profunda femoris
or close to the bifurcation; access through a femoral prosthesis; access sheath in the
femoral vein; presence of a palpable haematoma at the end of the procedure
Interventions Intervention 1 : AngioSeal
Intervention 2 : manual compression
Sheath size : 6 Fr
Outcomes Primary : freedom from puncture site-related complications (vasovagal response requir-
ing atropine and ﬂuid administration; large haematoma deﬁned as any palpable mass > 5
cm diameter; pseudoaneurysm detected by Doppler ultrasound with signiﬁcant bleeding
after an initial period of haemostasis; loss of pulse; vessel occlusion; deep vein thrombosis;
retroperitoneal haemorrhage; infection; arteriovenous ﬁstula; crural nerve compression)
Secondary : time to haemostasis; time to ambulation (deﬁned as time between the end
of PCI and cessation of bedrest); nursing time; participant satisfaction
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The computer assisted randomisationproce-
dure ensured that approximately 100 patients would
be included in each group”
Comment: random sequence generation. Study was
judged to be at low risk of selection bias
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judgement of high
or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged that out-
comes and outcome measurements are not likely to
be inﬂuenced by lack of blinding
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judgement of high
or low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Low risk Study appears to be free from other sources of bias
Machnik 2012
Methods Study design : randomised study
Participants Country : Poland
Setting : hospital
Number of centres : 1
Numbers : AngioSeal 91, manual compression 110
Age (mean (SD)) : AngioSeal 66.9 (8) years, manual compression 66.7 (8) years
Sex : AngioSeal 53 M/38 F, manual compression 66 M/44 F
Inclusion criteria : patients undergoing percutaneous interventions on carotid, vertebral
or peripheral arteries
Exclusion criteria : not stated
Interventions Intervention 1 : AngioSeal
Intervention 2 : manual compression
Sheath size : 6 Fr and 8 Fr
Outcomes Primary : complications (large haematomas (> 10 cm), acute lower limb ischaemia
requiring surgical intervention, pseudoaneurysm, arteriovenous ﬁstula)
Secondary : time to mobilisation; duration of post-procedural hospitalisation
Notes All participants were receiving dual antiplatelet therapy (aspirin 75 mg + clopidogrel
75 mg). Unfractionated heparin was used during the procedure to achieve activated
coagulation time > 250 seconds. Oral anticoagulant therapy was stopped before the
procedure in all participants receiving long-term treatmentwith acenocoumarol/warfarin
to obtain INR < 1.4, allowing an elective percutaneous intervention. Subcutaneous
injections of low molecular weight heparin were stopped for ≥ 12 hours before the
procedure and after the procedure for all participants receiving this type of therapy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised”
Comment: insufﬁcient information to permit
judgement of high or low risk
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Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judgement of
high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged that out-
comes and outcome measurements are not likely to
be inﬂuenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judgement of
high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Unclear risk Study outcomes are not clearly pre-speciﬁed
Other bias Low risk Study appears to be free from other sources of bias
Magosaki 1999
Methods Study design : propsective randomised trial
Participants Country : Japan
Setting : hospital
Number of centres : 4
Numbers : AngioSeal 120, manual compression 120
Age (mean (SD)) : AngioSeal 61.1 (10.9) years, manual compression 60.9 (9.9) years
Sex : AngioSeal 93 M/27 F, manual compression 90 M/30 F
Inclusion criteria : patients undergoing diagnostic angiography or coronary angioplasty
Exclusion criteria : not stated
Interventions Intervention 1 : AngioSeal
Intervention 2 : manual compression
Sheath size : 5 to 8 Fr
Outcomes Primary : time to haemostasis; time to ambulation; complications
Secondary : activated clotting time; successful placement of device
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised”
Comment: insufﬁcient information to per-
mit judgement of high or low risk
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Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Selective reporting (reporting bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Other bias Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Martin 2008
Methods Study design : prospective randomised trial
Participants Country : United States of America
Setting : hospital
Number of centres : 1
Numbers : AngioSeal 70, PerClose ProGlide 63, manual compression 67
Age (mean (SD)) : AngioSeal 63 (12) years, PerClose 66 (12) years, manual compression
68 (11) years
Sex : AngioSeal 50 M/20 F, PerClose 40 M/23 F, manual compression 50 M/17 F
Inclusion criteria : patients undergoing PCI using a 6 Fr femoral sheath
Exclusion criteria : arterial insertion site not in the common femoral artery; more than
minimal arterial calciﬁcation or common femoral artery < 6 mm in diameter; patients
with INR > 1.4 or who had prior arterial access at the same femoral site within 30 days
Interventions Intervention 1 : AngioSeal
Intervention 2 : PerClose
Intervention 3 : manual compression
Sheath size : not stated
Outcomes Primary : major and minor bleeding; time to haemostasis (deﬁned as time at which no
compression was required to control bleeding at the arteriotomy site)
Secondary : time to ambulation; vascular complications (retroperitoneal haemorrhage,
pseudoaneurysm, thrombosis, arteriovenous ﬁstula); participant satisfaction
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Notes Ambulation was allowed 3 hours after PerClose or AngioSeal and 6 hours after compres-
sion
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised”
Comment: insufﬁcient information to per-
mit judgement of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “A patient questionnaire was ad-
ministered at hospital discharge by study
personnel blinded to treatment assign-
ment”
Comment: Study personnel assessing par-
ticipant satisfaction were blinded to treat-
ment allocation. However, it is not clear
whether assessors measuring other study
outcomes such as time to haemostasis, time
to mobilisation and complications were
blinded to treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Low risk Study appears to be free from other sources
of bias
Michalis 2002
Methods Study design : prospective randomised single-centre trial
Participants Country : Greece
Setting : hospital
Number of centres : 1
Numbers : AngioSeal 290, VasoSeal 280, Duett 281
Age (mean (SD)) : AngioSeal 62.7 (14.3) years, VasoSeal 64.1 (10.2) years, Duett 62.4
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(12.6) years
Sex : AngioSeal 200 M/90 F, VasoSeal 196 M/84 F, Duett 205 M/76 F
Inclusion criteria : patients undergoing coronary angiography and/or angioplasty who
were deemed appropriate for immediate sheath removal
Exclusion criteria : patients in whom the sheath was retained for prolonged access
Interventions Intervention 1 : AngioSeal
Intervention 2 : VasoSeal
Intervention 3 : Duett
Sheath size : 6 Fr
Outcomes Primary : successful deployment of the device; time of device deployment; time to
haemostasis (deﬁned as time between completion of the device insertion procedure to
achievement of haemostasis by compression); time to ambulation (measured from end
of the catheterisation procedure until participant was able to stand and walk 3 to 5 steps
unaided)
Secondary : major complications (haematoma > 5 cm in diameter; haematoma or bleed-
ing requiring transfusion; pseudoaneurysm; arteriovenous ﬁstula; retroperitoneal haem-
orrhage; plug embolism; groin infection; death); minor complications (bleeding from
the puncture site that did not require transfusion and/or vascular surgery; haematoma <
5 cm in diameter; pain at the puncture site; skin allergic reaction related to the device)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were prospectively ran-
domised”
Comment: insufﬁcient information to per-
mit judgement of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
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Other bias Low risk Study appears to be free from other sources
of bias
Nelson 2014
Methods Study design : prospective multi-centre randomised controlled trial
Participants Country : America
Setting : hospital
Number of centres : 20
Numbers : ProGlide 50, ProStar XL 51
Age (mean (SD)) : ProGlide (70 (6.6)) years, ProStar XL (74 (11)) years
Sex (M/F) : ProGlide 47 M/3 F, ProStar XL 44 M/7 F
Inclusion criteria : patients ≥ 18 years old with an abdominal aortic aneurysm (AAA)
of maximum diameter≥ 5 cm, or in the range of 4 to 5 cm, which has increased by≥ 0.
5 cm in the past 6 months; suitable ipsilateral common femoral artery for percutaneous
access using a ’PreClose’ technique as detailed in the protocol
Exclusion criteria
• Life expectancy < 1 year as judged by the investigator
• Psychiatric or other condition that may interfere with the study
• Participation in the enrolment or 30-day follow-up phase of another clinical study
• Known allergy to any device component
• Coagulopathy or uncontrolled bleeding disorder
• Ruptured, leaking or mycotic aneurysm
• Serum creatinine (S-Cr) level > 1.7 mg/dL
• Traumatic vascular injury
• Active systemic or localised groin infection
• Connective tissue disease (e.g. Marfan’s syndrome)
• Renal transplant patient
• Recent (within prior 3 months) cerebrovascular accident or myocardial infarction
• Planned major intervention or surgery within 30 days following the EVAR
procedure
• Requirement for an arterial conduit at the access site
• Morbid obesity (BMI ≥ 40)
• Calciﬁcation throughout the CFA target area anterior wall or circumferentially, or
over > 50% of the posterior wall
• Femoral artery aneurysm, arteriovenous ﬁstula or pseudoaneurysm
• Evidence of prior common femoral artery surgery (e.g. groin incision)
• Prior clip-based vascular closure device placement in either arterial access site
• Collagen-based vascular closure device placement in either arterial access site
within the prior 90 days
• Femoral artery needle puncture in either arterial access site within the prior 30
days
• Haematoma at the ipsilateral arterial access site
• Signiﬁcant scarring at the ipsilateral arterial access site
Interventions Intervention 1 : ProGlide
Intervention 2 : ProStar XL
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Sheath size : ProGlide 8 Fr, ProStar XL 10 Fr
Outcomes Primary : treatment success deﬁned as the composite of procedural technical success,
absence of vascular complications and absence of major adverse events
Secondary : all serious and non-serious adverse events; stent graft patency and integrity;
health-related quality of life survey; clinical utility measures
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was conducted by
study site, using two block sizes (3 or 6)
with random choice of block size order”
Comment: random sequence generation.
Study was judged to be at low risk of selec-
tion bias
Allocation concealment (selection bias) Low risk Quote: “One set of sealed randomization
envelopes was provided to each site after
completion of roll-in cases and on spon-
sor approval to initiate the randomized
trial. On screening eligibility conﬁrmation,
the next sequential randomization enve-
lope was opened and the assignment was
immediately allocated”
Comment: adequate concealment of allo-
cation. Study was judged to be at low risk
of selection bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Low risk Study appears to be free from other sources
of bias
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Noguchi 2000
Methods Study design : prospective randomised controlled trial
Participants Country : Japan
Setting : hospital
Number of centres : 1
Numbers : ProStar 30, manual compression 30
Age (mean (SD)) : ProStar 63 (10) years, manual compression 61 (12) years
Sex : ProStar 27 M/3 F, manual compression 25 M/5 F
Inclusion criteria : patients undergoing angioplasty or stenting
Exclusion criteria : arterial access at a site other than the right or left femoral artery;
emergency procedure; continued use of warfarin before the procedure; haematoma for-
mation during the procedure; history of claudication due to arteriosclerosis obliterans
or vascular surgery that involved the groin area such as aortofemoral bypass surgery;
unwillingness or inability to provide written informed consent
Interventions Intervention 1 : ProStar
Intervention 2 : manual compression
Sheath size : 8 Fr
Outcomes Primary : time to haemostasis; time to ambulation; time to discharge
Secondary : surgical repair; infection; arteriovenous ﬁstula; pseudoaneurysm; distal em-
bolisation; haematoma; participant comfort; hospital costs
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised”
Comment: insufﬁcient information about
the sequence generation process to permit
judgement of high or low risk
Allocation concealment (selection bias) Low risk Quote: “Randomisationwas carried out us-
ing consecutive sealed envelopes”
Comment: Envelopes were sealed, so the
study was judged to be at low risk of selec-
tion bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
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Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Study outcomes are clearly reported
Other bias Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Park 2005
Methods Study design : prospective randomised study
Participants Country : Korea
Setting : hospital
Number of centres : 1
Numbers : AngioSeal 961, Closure S 715
Age (mean) : AngioSeal 56.8 years, Closure S 51.1 years
Sex : AngioSeal 727 M/234 F, Closure S 435 M/280 F
Inclusion criteria : patients undergoing diagnostic angiography or endovascular inter-
ventional treatment
Exclusion criteria : difﬁculty in puncturing the artery; severe peripheral vascular disease;
marked obesity; age < 15 years; arterial sheath size < 4 Fr or > 8 Fr; patient’s refusal to
provide written informed consent
Interventions Intervention 1 : AngioSeal
Intervention 2 : Closure S
Sheath size : 6 Fr or 8 Fr
Outcomes Primary : immediate haemostasis; successful vascular device closure (deﬁned as imme-
diate haemostasis without complications)
Secondary : major complications (need for vascular surgery; haemorrhage requiring
transfusion; pseudoaneurysm; arteriovenous ﬁstula; arterial occlusion or distal arterial
embolism; infection necessitating treatment with intravenous antibiotics or surgical de-
bridement); minor complications (haemorrhage from the puncture site that was con-
trolled via conservative management without transfusion (i.e. additional manual com-
pression, sandbag placement or prolonged bedrest); infection that could be treated with
oral antibiotics). All complications were categorised as early (< 24 hours of the procedure)
and late (≥ 24 hours after the procedure)
Notes This study included participants with several femoral artery punctures. Outcomes are
based on the number of punctures rather than on the number of individual participants.
After personal communication with the study author, it was decided that although this
study was relevant and met the inclusion criteria, we would not include data in the
analyses, as they were not comparable with data based on individuals from the other
included studies
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised”
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Selective reporting (reporting bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Other bias Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Perlowski 2011
Methods Study design : single-centre prospective randomised trial
Participants Country : United States of America
Setting : hospital
Number of centres : 1
Numbers : StarClose 39, manual compression 42
Age : not stated
Sex : not stated
Inclusion criteria : patients with conﬁrmed peripheral arterial disease undergoing per-
cutaneous endovascular and coronary procedures
Exclusion criteria : not stated
Interventions Intervention 1 : StarClose
Intervention 2 : manual compression
Sheath size : not stated
Outcomes Primary : vascular complications (pseudoaneurysm, arteriovenous ﬁstula)
Secondary : time to haemostasis; procedural success; device success; death
Notes
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Perlowski 2011 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised to”
Comment: insufﬁcient information to per-
mit judgement of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Selective reporting (reporting bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Other bias Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Rastan 2008
Methods Study design : prospective single-centre randomised controlled trial
Participants Country : Switzerland
Setting : hospital
Number of centres : 1
Numbers : AngioSeal 285, StarClose 286
Age (mean (SD)) : AngioSeal 67.6 (9.3) years, StarClose 66.1 (10.3) years
Sex : AngioSeal 201 M/84 F, StarClose 204 M/82 F
Inclusion criteria : patients undergoing a percutaneous transluminal procedure through
a 5 Fr or 6 Fr femoral sheath
Exclusion criteria : patients with a history of vascular surgery at the intended access
site; treatment with glycoprotein IIb/IIIa inhibitors or ﬁbrinolytic therapy; history of
bleeding diathesis or documented puncture of the superﬁcial or deep femoral artery near
the femoral artery bifurcation
85Vascular closure devices for femoral arterial puncture site haemostasis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rastan 2008 (Continued)
Interventions Intervention 1 : AngioSeal
Intervention 2 : StarClose
Sheath size : 5 Fr or 6 Fr
Outcomes Primary : composite incidence of access site pseudoaneurysm, major bleeding requiring
transfusion, in-hospital access site vascular surgery or catheter intervention or in-hospital
death from all causes
Secondary : incidence of arteriovenous ﬁstula; device failure (deﬁned as access site bleed-
ing requiring adjunctive therapy such as prolonged manual compression and/or pressure
bandage); groin haematoma ≥ 5 cm in diameter
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomization was by envelope”
Comment: insufﬁcient information re-
garding random sequence generation to
permit judgement of high or low risk
Allocation concealment (selection bias) Low risk Quote: “Randomization was by sealed en-
velope”
Comment: adequate concealment of allo-
cation. Study was judged to be at low risk
of selection bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Low risk Study appears to be free from other sources
of bias
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Reddy 2004
Methods Study design : prospective randomised study
Participants Country : United States of America
Setting : hospital
Number of centres : 1
Numbers : AngioSeal 25, manual compression 25
Age (mean (SD)) : AngioSeal 64 (3) years, manual compression 61 (3) years
Sex : AngioSeal 15 M/10 F, manual compression 14 M/11 F
Inclusion criteria : patients undergoing diagnostic cardiac catheterisation; ≥ 18 years
of age; easily palpable femoral and radial pulses; a normal Allen’s test
Exclusion criteria : vascular disease of the upper or lower extremities precluding access
at the femoral or radial artery; prior femoral artery graft surgery; unstable coronary
syndromes; unstable patients with myocardial infarction who require an intervention
within 7 days; patients for whom additional procedures were planned at the same setting
or during the same hospital stay; those who were unable or unwilling to provide informed
consent
Interventions Intervention 1 : AngioSeal
Intervention 2 : manual compression
Sheath size : 6 Fr
Outcomes Primary : quality of life
Secondary : cardiovascular and major vascular complications
Notes All participants were ambulated within 1 hour
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were prospectively ran-
domised”
Comment: insufﬁcient information to per-
mit judgement of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
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Reddy 2004 (Continued)
Selective reporting (reporting bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Other bias Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Rickli 2002
Methods Study design : single-centre multiple-operator prospective study
Participants Country : Switzerland
Setting : hospital
Number of centres : 1
Numbers : PerClose 96, manual compression 97
Age (mean (SD)) : PerClose 62 (11) years, manual compression 59 (10) years
Sex : PerClose 71 M/25 F, manual compression 81 M/16 F
Inclusion criteria : patients undergoing percutaneous coronary intervention by 6 Fr or
7 Fr femoral access
Exclusion criteria : not stated
Interventions Intervention 1 : PerClose
Intervention 2 : manual compression
Sheath size : 6 Fr and 7 Fr
Outcomes Primary : major (need for surgical intervention; local infection; need for blood trans-
fusion); minor complications (pseudoaneurysm; local haematoma > 1 mL assessed by
ultrasound); time to haemostasis; time to ambulation; time to discharge
Secondary : participant discomfort; costs
Notes Participants treated with PerClose were allowed to ambulate 4 hours after the procedure,
but manual compression participants were ambulated the morning after the procedure
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised”
Insufﬁcient information to permit judge-
ment of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
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Rickli 2002 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Low risk Study appears to be free from other sources
of bias
Sanborn 1993
Methods Study design : prospective multi-centre randomised trial
Participants Country : United States of America
Setting : hospital
Number of centres : not stated
Numbers : VasoSeal 246 (90 diagnostic catheterisation, 156 coronary angioplasty), man-
ual compression 209 (75 diagnostic catheterisation, 134 coronary angioplasty)
Age (mean (SD)) : VasoSeal diagnostic catheterisation 62.4 (10.8) years, VasoSeal coro-
nary angioplasty without heparin 58.6 (9.8) years, VasoSeal coronary angioplasty with
heparin 60.8 (9.8) years, manual compression diagnostic catheterisation 62.8 (10.7)
years, manual compression coronary angioplasty 61.3 (11.0) years
Sex : VasoSeal 181 M/65 F, manual compression 141 M/68 F
Inclusion criteria : patients undergoing diagnostic cardiac catheterisation or balloon
angioplasty; > 20 years of age; ability to give written consent and understand the obli-
gation for a follow-up study
Exclusion criteria : patients who were markedly obese; known platelet dysfunction;
uncontrolled hypertension; haematoma during catheterisation or angioplasty procedure.
Patients undergoing atherectomy or intracoronary stent placement were not enrolled
because the interventions required larger sheaths or greater anticoagulant regimens
Interventions Intervention 1 : VasoSeal
Intervention 2 : manual compression
Sheath size : 6 to 9 Fr
Outcomes Primary : time to haemostasis (deﬁned as time elapsed from initial compression and
removal of pre-existing sheath until completion of compression); time to ambulation
(calculated as total time from start of the procedure until ambulation)
Secondary : peripheral vascular complications requiring vascular surgical repair for bleed-
ing; large pseudoaneurysm; arteriovenous ﬁstula; thrombosis or loss of distal pulse; trans-
fusion due to bleeding at puncture site; deep vein thrombosis; infection at the puncture
site requiring intravenous antibiotics; bleeding from the puncture site; small pseudoa-
neurysm treated medically; haematomas 2 to 6 cm and > 6 cm
Follow-up : in hospital, 3 days and 30 days after sheath removal
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Sanborn 1993 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised”
Comment: insufﬁcient information to pro-
vide judgement on low or high risk of bias
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to provide judge-
ment on low or high risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to provide judge-
ment on low or high risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Low risk Study appears to be free from other sources
of bias
Schräder 1992
Methods Study design : randomised single-centre study
Participants Country : Germany
Setting : hospital
Number of centres : 1
Numbers: VasoSeal 50, manual compression 50
Age (mean (SD)) : VasoSeal 58.5 (10.2) years, manual compression 58.5 (9.2) years
Sex : VasoSeal 43 M/7 F, manual compression 45 M/5 F
Inclusion criteria : patients undergoing femoral artery catheterisation for coronary
angiography or coronary artery dilation
Exclusion criteria : patients taking vitamin K antagonists; thrombyte disorders; allergy
to collagen products
Interventions Intervention 1 : VasoSeal
Intervention 2 : pressure dressing
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Schräder 1992 (Continued)
Outcomes Primary : compression time; time to ambulation
Secondary : bleeding; haematoma
Follow-up : not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised”
Comment: insufﬁcient information to pro-
vide judgement on low or high risk of bias
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to provide judge-
ment on low or high risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to provide judge-
ment on low or high risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufﬁcient information to provide judge-
ment on low or high risk of bias
Selective reporting (reporting bias) Unclear risk Insufﬁcient information to provide judge-
ment on low or high risk of bias
Other bias Unclear risk Insufﬁcient information to provide judge-
ment on low or high risk of bias
Schulz-Schüpke 2014
Methods Study design : randomised large-scale multi-centre open-label clinical trial
Participants Country : Germany
Setting : hospital
Number of centres : 4
Numbers: FemoSeal 1509, ExoSeal 1506, manual compression 1509
Age (mean (range)) : FemoSeal 66.6 (57.8 to 74.3) years, ExoSeal 68.1 (59.3 to 74.9)
years, manual compression 68.4 (59.5 to 74.8 years)
Sex : FemoSeal 1040 M/469 F, ExoSeal 1058 M/448 F, manual compression 1031 M/
478 F
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Schulz-Schüpke 2014 (Continued)
Inclusion criteria : Patientswere eligible for enrolment if they providedwritten informed
consent and were undergoing diagnostic coronary angiography (without subsequent
percutaneous coronary intervention) with a 6 Fr sheath through the common femoral
artery, which had to have a diameter > 5 mm (proven by angiography)
Exclusion criteria : Major exclusion criteria were implantation of a VCD within the
last 30 days, symptomatic leg ischaemia, prior thromboendarteriectomy (TEA) or patch
plastic of the common femoral artery, planned invasive diagnostic or interventional
procedure in the following 90 days, a heavily calciﬁed vessel, active bleeding or bleeding
diathesis, severe arterial hypertension (> 220/110 mmHg), local infection, autoimmune
disease, allergy to resorbable suture and pregnancy
Interventions Intervention 1 : FemoSeal
Intervention 2 : ExoSeal
Intervention 3 : manual compression
Sheath size : 6 Fr
Outcomes Primary : incidence of vascular access site complications (i.e. the composite of
haematoma measuring ≥ 5 cm, pseudoaneurysm, arteriovenous ﬁstula, access site-re-
lated major bleeding, acute ipsilateral leg ischaemia, need for vascular surgical or inter-
ventional treatment or local infection at 30 days after randomisation
Secondary : time to haemostasis; repeat manual compression; VCD failure
Follow-up : 30 days
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Sealed opaque envelopes contain-
ing a computer-generated sequence were
used”
Comment: random sequence generation.
Study was judged to be at low risk of selec-
tion bias
Allocation concealment (selection bias) Low risk Quote: “Sealed opaque envelopes contain-
ing a computer-generated sequence were
used”
Comment: adequate concealment of allo-
cation. Study was judged to be at low risk
of selection bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
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Schulz-Schüpke 2014 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All events were adjudicated and
classiﬁed by an event adjudication commit-
tee in which members were unaware of the
assigned treatment”
Comment: Outcome assessors were
blinded to treatment allocation. Study was
judged to be at low risk of detection bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Low risk Study appears to be free from other sources
of bias
SEAL Trial Study Team
Methods Study design : multi-centre randomised study
Participants Country : United States of America
Setting : hospital
Number of centres : 16
Numbers : Duett 392, manual compression 238
Age (mean (SD)) : Duett 62 (11) years, manual compression 63 (12) years
Sex : Duett 309 M/83 F, manual compression 165 M/73 F
Inclusion criteria : patients >18 years undergoing a diagnostic (n = 209) or interventional
(n = 421) cardiac procedure with femoral arterial access who could provide written
informed consent
Exclusion criteria : arterial sheath < 5 Fr or > 9 Fr or longer than 10 cm; presence
of a ≥ 6 cm diameter haematoma before initial sheath removal; presence of clinically
severe peripheral vascular disease manifested by claudication at < 100 feet; weak or
absent pulses in the affected limb; ankle brachial index < 0.5 at rest; known stenosis ≥
50% in the iliac or femoral artery on the affected side; prior vascular bypass surgery or
stent placement involving the affected femoral artery; suspected posterior femoral artery
puncture or puncture distal to the common femoral artery bifurcation; known bleeding
disorder including platelet count < 100,000 or receipt of thrombolytic therapy within
the previous 24 hours; haemoglobin < 10 g/dL; international normalised ratio > 1.5;
activated clotting time > 400 seconds at the conclusion of the catheterisation procedure;
suspected pregnancy; life expectancy < 1 year; Q wave myocardial infarction within
72 hours; uncontrolled severe hypertension (systolic blood pressure > 180 mmHg or
diastolic blood pressure > 110 mmHg); medical indication for continued intravenous
heparin therapy after the procedure; known allergy to bovine-derived products; estimated
femoral artery diameter < 6 mm on the basis of femoral angiography results
Interventions Intervention 1 : Duett
Intervention 2 : manual compression + FemoStop or C-Clamp
Sheath size : 5 to 9 Fr
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SEAL Trial Study Team (Continued)
Outcomes Primary : time tohaemostasis; time to ambulation (deﬁned as time from the endof sheath
removal to time when the participant had gotten out of bed and walked 110 feet without
loss of haemostasis); incidence ofmajor complications (vascular surgery; ultrasound scan-
guided compression to treat a pseudoaneurysm; bleeding requiring transfusion; infection
of the puncture site requiring extended hospitalisation; antibiotic administration within
30 days)
Secondary : device success rate; time to discharge; composite of the primary endpoints
divided by diagnostic and interventional procedures
Follow-up : 30 days
Notes Participants randomised to the Duett device were ambulated 2 to 4 hours after the
procedure according to manufacturer guidelines. Participants randomised to standard
compression were ambulated according to the institution’s practice
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomly allocated
to 1 of the 2 treatment groups with a closed
envelope system and permuted block de-
sign supplied by the coordinating centre”
Comment: random sequence generation.
Study was judged to be at low risk of selec-
tion bias
Allocation concealment (selection bias) Low risk Quote: “Closed envelope system”
Comment: adequate concealment of allo-
cation. Study was judged to be at low risk
of selection bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Treatment masked analysis of ul-
trasound examination tape”
Comment: Outcome assessors were
blinded to treatment allocation. Study was
judged to be at low risk of detection bias
Incomplete outcome data (attrition bias)
All outcomes
High risk Only 227 of 392 Duett participants com-
pleted 7-day and 30-day follow-up exami-
nations in the quality of life substudy. No
explanation for incomplete data was pro-
vided by the study authors
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SEAL Trial Study Team (Continued)
Selective reporting (reporting bias) High risk Under Results, study authors reported 7-
day and 30-day follow-up examinations
in the quality of life substudy participant
group to measure participant discomfort,
but this is not speciﬁed as an outcome of
the study
Other bias Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Seidelin 1997
Methods Study design : randomised pilot trial
Participants Country : Canada
Setting : hospital
Number of centres : 1
Numbers: AngioSeal 24, manual compression 26
Age (mean (SD)) : AngioSeal 55 (10) years, manual compression 56 (9) years
Sex : AngioSeal 18 M/6 F, manual compression 19 M/7 F
Inclusion criteria : patients < 75 years of age referred for elective coronary angiography
Exclusion criteria : patients with a femoral bruit; reduced femoral pulses; previous vas-
cular surgery of the aorta or lower limb arteries; history or evidence of peripheral vascu-
lar disease; history of puncture site complications from prior percutaneous procedures;
known allergy to materials in the device; current anticoagulant therapy; known hyperco-
agulation or hypocoagulation conditions; presence of severe acute non-cardiac systemic
disease or terminal illness; female of child-bearing potential; evidence of systemic bacte-
rial or cutaneous infection
Interventions Intervention 1 : AngioSeal
Intervention 2 : manual compression
Sheath size : 7 Fr
Outcomes Primary : time to haemostasis (deﬁned as time elapsed from sheath removal to time
haemostasis was ﬁrst conﬁrmed); time to mobilisation (deﬁned as time elapsed from
sheath removal to time the participant was mobilised)
Secondary : groin complications (re-bleeding after initial haemostasis (3 categories):
insigniﬁcant oozing requiring further compression or requiring transfusion); swelling;
haematoma (minor≤ 3 cm,moderate 3 to 6 cm, large > 6 cm); pseudoaneurysm; need for
blood transfusion; need for vascular surgery; other groin complications not pre-speciﬁed
Follow-up : at 30 minutes, at 2 hours, at 4 hours, at discharge, at 7 days after the
procedure
Notes Participants treatedwith the AngioSeal device weremobilisedwithin 5minutes of tamper
removal, but manual compression participants were placed on bedrest for 4 to 6 hours
before mobilisation
Risk of bias
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Seidelin 1997 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly allocated”
Comment: insufﬁcient information to permit
judgement of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judgement
of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged that
outcomes and outcome measurements are not
likely to be inﬂuenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judgement
of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Low risk Study appears to be free from other sources of
bias
Shammas 2002
Methods Study design : single-centre randomised study
Participants Country : United States of America
Setting : hospital
Number of centres : 1
Numbers : AngioSeal 79, VasoSeal 78
Age (mean (SD)) : AngioSeal 60 (11.4) years, VasoSeal 60 (10.9) years
Sex : AngioSeal 37 M/42 F, VasoSeal 42 M/36 F
Inclusion criteria : patients undergoing cardiac catheterisation or percutaneous inter-
ventional procedures
Exclusion criteria : arteriotomy larger than 8 Fr; any suspicion that the introducer has
been placed through the superﬁcial femoral artery and the profunda femoris, or at the
bifurcation of these 2 vessels; the presence of signiﬁcant vascular disease as judged by the
cardiologist; uncontrolled hypertension at the time of deployment of the device; allergy
to beef product, collagen or polyglycolic or polylactic acid polymers; emergency cases;
therapeutic thrombolysis; vascular graft puncture; bleeding disorder; pregnant or lactat-
ing females; previous device placed within 6 weeks in the same common femoral artery;
pre-existing autoimmune disease; morbid obesity; hematoma before the procedure; < 18
or > 80 years of age
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Shammas 2002 (Continued)
Interventions Intervention 1 : AngioSeal
Intervention 2 : VasoSeal
Sheath size : 8 Fr
Outcomes Primary : time to haemostasis; time to ambulation
Secondary : major complications (pseudoaneurysm; arteriovenous ﬁstula; thrombosis
of common femoral artery;retroperitoneal bleed; infection; bleeding from the puncture
site requiring transfusion; death)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised”
Comment: insufﬁcient information to per-
mit judgement of high or low risk
Allocation concealment (selection bias) Unclear risk Comment: insufﬁcient information to per-
mit judgement of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Silber 1998
Methods Study design : prospective randomised study
Participants Country : Germany
Setting : hospital
Number of centres : 1
Numbers : VasoSeal 74, manual compression 76
Age (mean (SD)) : VasoSeal 59.8 (9.0) years, manual compression 58.0 (9.2) years
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Silber 1998 (Continued)
Sex : VasoSeal 58 M/16 F, manual compression 58 M/18 F
Inclusion criteria : patients undergoing PTCA
Exclusion criteria : prolonged duration PTCA patients requiring an additional bolus
of heparin; patients with need for overnight heparin infusion or coumadin; inadvertent
penetration of the dorsal arterial wall within the puncture needle; previous application
of collagen sealing of the femoral access site; known allergy to collagen; peripheral artery
disease; patients with acute myocardial infarction; status post thrombolytic therapy;
known coagulation defects or known platelet dysfunction; severe uncontrolled arterial
hypertension (systolic > 220 mmHg or diastolic > 120mmHg); pre-existing haematoma;
haematoma developed during the procedure; patients with a venous femoral sheath
Interventions Intervention 1 : VasoSeal
Intervention 2 : manual compression
Sheath size : 8 Fr
Outcomes Primary : time to haemostasis; groin discomfort; haematoma (small < 7 cm, medium 7
to 15 cm, large > 15 cm)
Secondary : major complications (thrombosis; loss of distal pulses; large pseudoa-
neurysm; arteriovenous ﬁstula; bleedingwith need for transfusionor any vascular surgery)
; minor complications (bleeding from the puncture site not requiring transfusion; vas-
cular surgery and small pseudoaneurysm treated medically)
Follow-up : 24 hours after sheath pull
Notes As time to ambulation was not an endpoint of the study, participants had to stay in bed
until the morning after the procedure
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly assigned”
Comment: insufﬁcient information to per-
mit judgement of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
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Silber 1998 (Continued)
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Low risk Study appears to be free from other sources
of bias
Sun 2009
Methods Study design : randomised comparative study
Participants Country : China
Setting : hospital
Number of centres : 1
Numbers : StarClose 286, PerClose 183, manual compression 271
Age (mean (SD)) : StarClose CAG 62.0 (10.5) years, StarClose PCI 63.9 (12.1) years,
PerClose CAG 61.9 (11.1) years, StarClose PCI 64.0 (10.1) years, manual compression
CAG 61.7 (10.5) years, manual compression PCI 64.1 (12.3) years
Sex : StarClose 179 M/107 F, PerClose 115 M/68 F, manual compression 158 M/113 F
Inclusion criteria : patients undergoing coronary angiography (CAG) and percutaneous
coronary intervention (PCI)
Exclusion criteria : not reported
Interventions Intervention 1 : StarClose
Intervention 2 : PerClose
Intervention 3 : Boomerang
Sheath size : not reported
Outcomes Primary : haemostasis operation time; immobilisation time; incidence of vascular com-
plications
Secondary : device failures
Follow-up : not stated
Notes Data presented by diagnosis/intervention
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomized”
Insufﬁcient information to permit judge-
ment of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
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blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Selective reporting (reporting bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Other bias Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Tron 2003
Methods Study design : randomised study
Participants Country : France
Setting : hospital
Number of centres : 1
Numbers : PerClose 91, manual compression 76
Age (mean (SD)) : PerClose 59 (10) years, manual compression 59 (11) years
Sex : PerClose 85 M/6 F, manual compression 76 M/0 F
Inclusion criteria : patients undergoing successful PTCA through the femoral artery
with a 6 Fr or 8 Fr sheath
Exclusion criteria : difﬁculty in puncturing the artery; peripheral vascular disease;
marked obesity; age > 80 years; acute myocardial infarction; ilio-femoral tortuosities;
presence of a venous sheath; arterial sheath already inserted the day before PTCA; > 3
previous punctures in the same artery; refusal to give written informed consent
Interventions Intervention 1 : PerClose
Intervention 2 : manual compression
Sheath size : 6 Fr or 8 Fr
Outcomes Primary : success rate; time to haemostasis; haematoma (deﬁned as a palpable mass at
the puncture site); blood oozing; length of hospital stay
Secondary : participant pain
Follow-up : 2 days post procedure
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Tron 2003 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised”
Comment: insufﬁcient information to permit
judgement of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judgement of
high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged that out-
comes and outcome measurements are not likely to
be inﬂuenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judgement of
high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Low risk Study appears to be free from other sources of bias
Upponi 2007
Methods Study design : prospective randomised study
Participants Country : United Kingdom
Setting : hospital
Number of centres : 1
Numbers: AngioSeal 50, manual compression 50
Age (mean (SD)) : AngioSeal 68.9 years, manual compression 70.1 years
Sex : AngioSeal 33 M/17 F, manual compression 35 M/15 F
Inclusion criteria : patients undergoing retrograde femoral arterial puncture
Exclusion criteria : not stated
Interventions Intervention 1 : AngioSeal
Intervention 2 : manual compression
Sheath size : 5 Fr to 7 Fr
Outcomes Primary : minor complications (haematoma < 6 cm); major complications (false
aneurysm; arterio-venous ﬁstula; vessel occlusion; those requiring further percutaneous
or surgical intervention)
Secondary : none
Follow-up : up to 6 weeks post procedure
Notes
Risk of bias
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Upponi 2007 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “50 patients were randomised to
each group”
Comment: insufﬁcient information to per-
mit judgement of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Unclear risk Outcomes are not clearly stated
Other bias Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Veasey 2008
Methods Study design : randomised single-blind prospective trial
Participants Country : United Kingdom
Setting : district general hospital
Number of centres : 1
Numbers: AngioSeal 208, StarClose 193
Age (mean (SD)) : AngioSeal 65.3 (10.6) years, StarClose 66.5 (10.8) years
Sex : AngioSeal 115 M/93 F, StarClose 107 M/86 F
Inclusion criteria : patients undergoing elective day-case diagnostic coronary angiogra-
phy with immediate post-procedure mobilisation
Exclusion criteria : patients with a diagnosis of unstable angina or acute myocardial
infarction; signiﬁcant peripheral vascular disease; previous peripheral vascular surgery;
pregnant; unable to give written informed consent; younger than 18 years; previous
femoral artery complication from coronary angiography
Interventions Intervention 1 : AngioSeal
Intervention 2 : StarClose
Sheath size : 5 Fr
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Veasey 2008 (Continued)
Outcomes Primary : complications (induration; haematoma; bleeding; retroperitoneal bleed; pseu-
doaneurysm; leg ischaemia; access site infection)
Secondary : participant satisfaction; pain scores
Follow-up : 1 week post procedure
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised to”
Comment: insufﬁcient information to per-
mit judgement of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Outcomes are not clearly stated
Selective reporting (reporting bias) Unclear risk Outcomes are not clearly stated
Other bias Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
von Hoch 1995
Methods Study design : prospective randomised study
Participants Country : Germany
Setting : hospital
Number of centres : 1
Numbers: VasoSeal 154, manual compression 155
Age (median (IQR)) : VasoSeal 63 (54 to 70) years, manual compression 60 (53 to 70)
years
Sex : VasoSeal 125 M/29 F, 118 M/37 F
Inclusion criteria : patients requiring emergency coronary stenting or elective percuta-
neous coronary angioplasty
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Exclusion criteria : patients with known allergies to collagen or other animal products;
any haemostatic disorder; previous catheterisation from the right femoral artery within
1 week before the qualifying procedure; acute myocardial infarction
Interventions Intervention 1 : VasoSeal
Intervention 2 : manual compression
Sheath size : not stated
Outcomes Primary : complications at the vascular access site (pseudoaneurysm; arteriovenous ﬁs-
tula; local bleeding requiring blood transfusion or surgical treatment; groin infection;
occlusion of the femoral artery)
Secondary : time to haemostasis
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly assigned
to”
Insufﬁcient information to permit judge-
ment of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Low risk Study appears to be free from other sources
of bias
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Ward 1998
Methods Study design : randomised multi-centre study
Participants Country : United States of America
Setting : hospital
Number of centres : 8
Numbers: AngioSeal 202, manual compression 102
Age (mean (SD)) : AngioSeal 61.7 (12) years, manual compression 64.7 (10) years
Sex : AngioSeal 140 M/62 F, manual compression 72 M/30 F
Inclusion criteria : patients undergoing diagnostic catheterisation via the femoral ap-
proach with an 8 Fr sheath or smaller
Exclusion criteria : patients with severe systemic or terminal illness, systemic or cuta-
neous infection, platelet count < 75,000 cells/µL, use of an intra-aortic balloon pump,
thrombolytic therapy within previous 24 hours, ﬁbrinogen count < 100 mg/dL, sheath
in place > 36 hours, presence of haematoma before sheath removal, suspected profunda
femoris puncture, younger than 18 years or unable to give informed consent
Interventions Intervention 1 : AngioSeal
Intervention 2 : manual compression
Sheath size : 5 Fr to 8 Fr
Outcomes Primary : time to haemostasis (deﬁned as elapsed time between sheath removal and ﬁrst
observed haemostasis); time to ambulation; time to discharge
Secondary : vascular injury (need for vascular repair or pseudoaneurysm); bleeding
complications (bleeding requiring transfusion; haematoma < 6 cm; haematoma≥ 6 cm;
late bleeding)
Follow-up : 14 days and 30 days after hospital discharge
Notes Participants randomised to AngioSeal were ambulated at 1 hour; manual compression
participants were ambulated 4 to 6 hours after sheath removal
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised”
Comment: insufﬁcient information to per-
mit judgement of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
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Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Wetter 2000
Methods Study design : prospective randomised study
Participants Country : Switzerland
Setting : hospital
Number of centres : 1
Numbers: PerClose 50, manual compression 50
Age (mean (SD)) : PerClose 58.5 (10.5) years, manual compression 59.9 (9.7) years
Sex : not stated
Inclusion criteria : patients who had undergone elective percutaneous transluminal
coronary angioplasty
Exclusion criteria : patients not ambulatory on the day of the intervention
Interventions Intervention 1 : PerClose
Intervention 2 : manual compression
Sheath size : 6 Fr or 7 Fr
Outcomes Primary : time to haemostasis (measured from insertion of device until application of
bandage); time to mobilisation
Secondary : haematoma; pseudoaneurysm; arteriovenous ﬁstula
Follow-up : 4 hours post procedure
Notes PerClose participants had 4 hours of bedrest; manual compression participants were kept
in bed until the morning after the procedure
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised”
Comment: insufﬁcient information to per-
mit judgement of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
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are not likely to be inﬂuenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Wong 2009
Methods Study design : randomised non-blinded trial
Participants Country : United States of America
Setting : hospital
Number of centres : 17
Numbers: ExoSeal 267, manual compression 134
Age (mean (SD)) : ExoSeal 63.3 (11.1) years, manual compression 61.4 (10.5) years
Sex : ExoSeal 182 M/85 F, manual compression 83 M/51 F
Inclusion criteria : patients 18 to 84 years of age scheduled to undergo a diagnostic or
interventional coronary or peripheral procedure via arterial puncture of a > 5 mm lumen
diameter common femoral artery
Exclusion criteria : patients who had sustained amyocardial infarction with ST-segment
elevation < 48 hours before the catheterisation procedure; uncontrolled hypertension at
time of closure; symptomatic leg ischaemia in the target vessel limb or prior femoral
vascular surgery or placement of a vascular graft at the target site; history of bleeding
or platelet disorder or previous treatment with a thrombin-speciﬁc anticoagulant or
low molecular wegiht heparin < 24 hours before the catheterisation procedure; required
puncture of both femoral arteries; prior closure of the target artery with any vascular
closure device; pre-existing systemic or cutaneous infection
Interventions Intervention 1 : ExoSeal
Intervention 2 : manual compression
Sheath size : 6 Fr
Outcomes Primary : time to haemostasis (deﬁned as time from sheath removal to time haemostasis
was achieved); time to ambulation (deﬁned as time from sheath removal to time the
participant was able to walk > 20 feet without recurrence of bleeding)
Secondary : time to eligibility for hospital discharge; time to hospital discharge; proce-
dure success; major adverse event (need for vascular repair by surgical or non-surgical
techniques; bleeding requiring a blood transfusion; infection requiring antibiotics; new-
onset ischaemia of the ipsilateral lower extremity; permanent access site-related nerve
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injury); device success; post-procedural complications (recurrent local bleeding requir-
ing a haemostatic intervention or a > 6 cm haematoma or ecchymosis; pseudoaneurysm;
arterio-venous ﬁstula; vascular laceration or retroperitoneal bleeding; ipsilateral mani-
festations of vascular insufﬁciency or embolisation including loss of distal pulse, total
arterial occlusion or deep vein thrombosis, infection and nerve injury)
Follow-up : 30 days post procedure
Notes ExoSeal participants were ambulated at 1 hour (received no glycoprotein IIb/IIIa in-
hibitors), 2 hours (received glycoprotein IIb inhibitor) and 6 hours (received glycopro-
tein IIIa inhibitors); manual compression participants were ambulated no later than 4
hours post haemostasis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Assignment was based on a com-
puter-generated treatment list, which bal-
anced the randomisationby centre and type
of procedure performed”
Comment: random sequence generation.
Study was judged to be at low risk of selec-
tion bias
Allocation concealment (selection bias) Low risk Quote: “Patients were randomly assigned
using sealed envelopes”
Comment: allocation of treatment was
concealed. Study was judged to be at low
risk of selection bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Nonblinded”
Comment: no blinding, but review authors
judged that outcomes and outcome mea-
surements are not likely to be inﬂuenced by
lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Low risk Study appears to be free from other sources
of bias
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Yadav 2003
Methods Study design : randomised multi-centre controlled clinical investigation
Participants Country : United States of America
Setting : hospital
Number of centres : 9
Numbers: QuickSeal 240, manual compression 158
Age (mean (SD)) : QuickSeal 62 (10.4) years, manual compression 61 (11.2) years
Sex : QuickSeal 156 M/84 F, manual compression 102 M/56 F
Inclusion criteria : patients 18 to 80 years of age who provided written informed consent
and underwent a percutaneous diagnostic or interventional procedure by way of the
common femoral artery
Exclusion criteria : patients with pre-existing autoimmune disease; ipsilateral arterial
site closure with the QuickSeal device or manual compression within previous 6 weeks;
closure utilising another device within 180 days; pregnant or lactating women; signiﬁcant
bleeding or platelet disorders; platelet count < 100,000; haemoglobin < 10 mg/dL;
hematocrit < 30%; blood pressure > 170/100 mmHg
Interventions Intervention 1 : QuickSeal
Intervention 2 : manual compression
Sheath size : 5 to 8 Fr
Outcomes Primary : time to haemostasis (deﬁned as time between end of the procedure and
haemostasis); time to ambulation (deﬁned as time between end of the procedure and
participant ambulation > 10 feet); incidence of major complications (vascular repair;
bleeding requiring transfusion and/or intervention; infection requiring intravenous an-
tibiotics and/or extended hospitalisation)
Secondary : time to discharge; minor complications (haematoma; ecchymosis; bleeding
and pseudoaneurysm)
Follow-up : 30 days after discharge
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised”
Comment: insufﬁcient information to per-
mit judgement of high or low risk
Allocation concealment (selection bias) Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding, but review authors judged
that outcomes and outcome measurements
are not likely to be inﬂuenced by lack of
blinding
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Yadav 2003 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufﬁcient information to permit judge-
ment of high or low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Data on pre-speciﬁed outcomes reported
Other bias Low risk Study appears to be free from other sources
of bias
ASD: atrial septal defect
BMI: body mass index
CAG: coronary angiography
CFA: common femoral artery
INR: international normalised ratio
PCI: percutaneous coronary intervention
PTCA: percutaneous transluminal coronary angioplasty
SD: standard deviation
VAS: visual analogue scale
VCD: vascular closure device
VSD: ventricular septal defect
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Baim 2000 ProStar-Plus device was used with an 8 Fr or 10 Fr sheath size, but data are not presented separately. We
contacted study authors twice but received no response
Beyer-Enke 1996 Could not conﬁrm with study authors that access for the procedure was attained through the femoral artery
Chalmers 2007 EVICEL is not a vascular closure device
Chevalier 2000 Data on review outcomes were not presented in the study report (abstract)
Jean-Baptiste 2008 Not a randomised controlled trial
Kuraklio lu 2008 Cannot conﬁrm that this is a randomised controlled trial and that access was attained via the femoral artery
Larzon 2015 Did not use a vascular closure device
Leinbudgut 2013 Participants were randomised by drug received to prevent bleeding rather than by vascular closure device (VCD)
110Vascular closure devices for femoral arterial puncture site haemostasis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Lupi 2012 Not a randomised controlled trial
Neudecker 2003 Not a randomised controlled trial
Ratnam 2007 Not a randomised controlled trial
Slaughter 1995 Cost-effectiveness analysis. No relevant data
Smilowitz 2012 Not a randomised controlled trial
Starnes 2003 Arteriography participants who were treated with 7 Fr to 10 Fr sheaths. Data are not presented according to
sheath size. Attempts to contact the study author for speciﬁc data were unsuccessful
Characteristics of studies awaiting assessment [ordered by study ID]
NCT01297322
Methods Study design : randomised open-label trial
Country : United States of America
Setting : hospital
Number of centres : 21
Participants Inclusion criteria
• Patients 18 to 80 years of age
• Undergoing an elective, non-emergent diagnostic or interventional endovascular procedure via the common
femoral artery with a 6 Fr or 7 Fr introducer sheath
Exclusion criteria
• Advanced refusal of blood transfusion, if necessary
• Active systemic or cutaneous infection or inﬂammation
• Pre-existing immunodeﬁciency disorder and/or long-term use of systemic steroids
• Known, signiﬁcant history of bleeding diathesis, coagulopathy, von Willebrand’s disease or current platelet
count < 100,000 cells/mm3
• Baseline international normalised ratio (INR) ≥ 1.8, or ﬁbrinogen level < 150 mg/dL (if received a ﬁbrinolytic
agent within previous 24 hours)
• Severe co-existing morbidities
• Life expectancy < 30 days
• Ipsilateral femoral arteriotomy within previous 30 days
• Previous ipsilateral femoral artery closure with a permanent implant-based closure device
• Previous vascular grafts or surgery at the target vessel access site
• History of symptomatic peripheral arterial disease
• Revascularisation or deep vein thrombosis in the ipsilateral limb
• Unilateral or bilateral lower extremity amputation
• Renal insufﬁciency
• Females who are pregnant, planning to become pregnant within 3 months of the procedure or lactating
• Extreme morbid obesity (body mass index (BMI) > 45 kg/m2) or underweight (BMI < 20 kg/m2)
• Known allergy/adverse reaction to bovine derivatives, sodium hyaluronate or hyaluronan preparations
• Administration of low molecular weight heparin within 8 hours of the procedure
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Interventions Intervention 1 : VASCADE Vascular Closure System
Intervention 2 : manual compression
Outcomes Primary
• Time to haemostasis and rate of access site-relayed major complications including access site-related bleeding
requiring transfusion, vascular injury requiring repair (via surgery, ultrasound-guided compression, transcatheter
embolisation or stent graft)
• New ipsilateral lower extremity ischaemia causing a threat to the viability of the limb and requiring surgical or
additional percutaneous intervention. This compromised blood ﬂow is documented by participant symptoms,
physical exam and/or decreased or absent blood ﬂow on lower extremity angiogram
• Access site-related infection requiring intravenous antibiotics and/or extended hospitalisation
• New-onset access site-related neuropathy in the ipsilateral lower extremity requiring surgical repair
• Permanent access site-related nerve injury
Secondary
• Time to ambulation
• Time to discharge eligibility
• Time to hospital discharge
• Device success
• Procedure success
• Rate of minor access site-related complications including access site-related bleeding requiring > 30 minutes to
achieve haemostasis
• Access site-related hematoma > 6 cm
• Late access site-related bleeding (after hospital discharge)
• Ipsilateral lower extremity arterial emboli
• Ipsilateral deep vein thrombosis
• Access site-related vessel laceration
• Access site wound dehiscence
• Localised access site infection treated with intramuscular or oral antibiotics
• Arteriovenous ﬁstula not requiring treatment
• Pseudoaneurysm requiring thrombin injection or ﬁbrin adhesive injection
• Pseudoaneurysm not requiring treatment
• New-onset access site-related neuropathy in the ipsilateral lower extremity not requiring surgical repair
• Ipsilateral pedal pulse diminished by 2 grades or transiently lost
Notes This study was published just after the searches were run and will be included in a future update
Characteristics of ongoing studies [ordered by study ID]
ACTRN12611001248954
Trial name or title ACTRN12611001248954
Methods Study design : open-label randomised multi-centre controlled trial
Country : United States of America
Setting : hospital
Number of centres : multi-centre
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ACTRN12611001248954 (Continued)
Participants Inclusion criteria
• Patients 18 to 80 years of age
• Clinically indicated for an elective, non-emergent diagnostic or interventional endovascular procedure
via the common femoral artery with a 6 Fr or 7 Fr introducer sheath.
Exclusion criteria
• Active systemic or cutaneous infection
• Pre-existing immunodeﬁciency disorder and/or long-term use of systemic steroids
• Ipsilateral femoral arteriotomy within previous 30 days
• Planned endovascular procedure within next 30 days
• Unilateral or bilateral lower extremity amputation(s)
• Extreme morbid obesity (BMI > 45 kg/m2) or underweight (BMI < 22 kg/m2)
• Difﬁcult insertion of procedural sheath or needle stick problems at onset of the procedure (e.g.
multiple stick attempts, ”back-wall stick”)
• Fluoroscopically visible calcium
• Atherosclerotic disease
• Stent within 1 cm of the puncture site
Interventions Intervention 1 : VASCADE Vascular Closure System
Intervention 2 : manual compression
Outcomes Primary
• 30-Day rate of combined access site-related major complications (major complications include access
site-related bleeding requiring transfusion; assessment of site-related bleeding was performed via direct
observation; excessive blood loss would be determined via Institutional guidelines)
• Vascular injury requiring repair: Prolonged bleeding would require further assessment for vascular
injury by techniques such as ultrasound imaging
• New ipsilateral lower extremity ischaemia causing a threat to the viability of the limb and requiring
surgical or additional percutaneous intervention: Compromised blood ﬂow is documented by participant
symptoms, physical exam and/or decreased or absent blood ﬂow on lower extremity angiogram
• Access site-related infection: assessment based on participant symptoms and physical exam
• New-onset access site-related neuropathy in the ipsilateral lower extremity requiring surgical repair:
assessment based on participant symptoms and physical exam
• Permanent access site-related nerve injury (> 30 days): based on participant symptoms and physical
exam
Secondary
• Time to ambulation: deﬁned as elapsed time between device removal for Cardiva VASCADE VCS and
sheath removal for manual compression and when participant stands and walks 20 feet without evidence of
arterial re-bleeding from the access site
• Time to discharge eligibility: deﬁned as elapsed time between device removal for Cardiva VASCADE
VCS and sheath removal for manual compression and when participant is medically able to be discharged
based solely on access site assessment
• Time to hospital discharge: deﬁned as elapsed time between device removal for Cardiva VASCADE
VCS and sheath removal for manual compression and when participant actually is discharged from the
hospital, as recorded on the discharge
Starting date December 2011
Contact information charles maroney@cardivamedical.com
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Notes
CTRI/2014/09/004946
Trial name or title Closure of puncture site in the groin after coronary stenting
Methods Study design randomised parallel-group active controlled trial
Country : India
Setting : hospital
Number of centres : 1
Participants Inclusion criteria
• Patients 18 to 85 years of age
• Acceptable candidates for elective PCI through common femoral artery (CFA) with 6 Fr to 8 Fr
procedural sheath
• Voluntary participation as per signed, informed consent by the participant
Exclusion criteria
• Patient requiring emergency or primary PCI
• Anaemia with pre-procedure haemoglobin < 10 g
• History of bleeding diathesis
• Pregnancy, suspected pregnant or lactating mothers
• Previous deployment of VCD in ipsilateral femoral artery at any time
• Peripheral vascular disease of ipsilateral limb deﬁned as history of claudication, weak or absent pulse or
lower extremity vascular graft
• Active systemic infection
• Local access site cutaneous infection or inﬂammation
• Patient known or determined to require treatment that will extend his/her hospitalisation (requiring
CABG, staged PCI, etc)
• Presence of clinically signiﬁcant hematoma > 5 cm, pseudoaneurysm or arterio-venous ﬁstula in
ipsilateral access site as detected clinically and conﬁrmed by Doppler ultrasound
• Placement of arterial access sheath with < 6 Fr or > 8 Fr
• Placement of both arterial and venous sheaths during PCI
• Difﬁculty inserting the introducer sheath at the start of the PCI due to vessel scarring, tortuosity,
stenosis, etc, as judged by the operator
• Intraprocedural bleeding and/or haematoma at the access site
• Sheath angiography reveals anatomical unsuitability for device closure, which is deﬁned as
◦ the site of arterial puncture distal or at common femoral artery bifurcation
◦ the site of arterial puncture above the inguinal ligament, which is typically deﬁned by the inferior
border of the inferior epigastric artery or the upper third of the femoral head by plain ﬂuoroscopy
◦ the arterial lumen diameter at the access site < 5 mm by visual estimate
◦ angiographic evidence of calciﬁed lesions at the access site
Interventions Intervention 1 : PerClose ProGlide
Intervention 2 : manual compression
Outcomes Primary
• Haematoma at access site < 5 cm
• Access site-related re-bleeding
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CTRI/2014/09/004946 (Continued)
• Localised access site-related infection requiring oral antibiotics
• Haematoma at access site > 5 cm
• Pseudoaneurysm
• Arterio-venous ﬁstula
• Retroperitoneal haematoma
• Any access site-related major bleeding
• Ipsilateral lower extremity ischaemia
• Access site-related infection requiring intravenous antibiotics
• Access site-related nerve injury
Secondary
• Time to haemostasis: average time to stop arterial bleeding
• Flat time: average time participant has to lie ﬂat on bed with movement restriction
• Time to ambulate: average time between arterial sheath pull and ﬁrst observed ambulation of 10 feet in
the ward without occurrence of bleeding at the access site
• Patient satisfaction questionnaire: recorded at 24 hours post PCI or at discharge (if sooner)
Starting date 01/09/2014
Contact information drssandeep@hotmail.com
Notes
DRKS00000802
Trial name or title VCD trial
Methods Study design : prospective, randomised clinical trial
Country : Germany
Setting : hospital
Number of centres : multi-centre
Participants Inclusion criteria
• Patients 18 years of age or older
• Undergoing diagnostic angiography or coronary intervention with a 5 Fr or 6 Fr introducer sheath via
femoral artery puncture
Exclusion criteria
• Uncontrolled blood pressure > 180/110 mmHg
• Previous vascular surgery or femoral bypass surgery
• Previous femoral or iliac vascular intervention
• Former femoral vascular closure with internal closure system (e.g. AngioSeal, CoStar)
• Heavily calciﬁed or atheromatous modiﬁed femoral artery
Interventions Intervention 1 : ExoSeal
Intervention 2 : Safeguard
Intervention 3: manual compression
Outcomes Primary
• Combined endpoint of complications after puncture of the femoral artery (haematoma ≥ 5 cm,
aneurysm spurium, bleeding with haemoglobin decrease ≥ 2 mg/dL, transfusion requirement,
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DRKS00000802 (Continued)
retroperitoneal haemorrhage, pressure ulcer ≥ grade 2, ischaemia of the ipsilateral lower extremity, nerve
injury within 48 hours, after 7 days and 31 days
Secondary
• Haematoma < 5 cm
• Bleeding with haemoglobin drop < 2 mg/dL
• Abrasion of the skin
• Pressure ulcer grade 1
• Prolonged tourniquet time
• Prolonged hospitalisation
• Fever within 24 hours after surgery
• Local infection of the puncture
• Pain
• User satisfaction
Starting date May 2011
Contact information stefan.kberich at uniklinik-freiburg.de
marc.kollum at hbh-kliniken.de
Notes
NCT00264264
Trial name or title ACDC trial
Methods Study design : randomised parallel-assignment double-blind trial
Country : Canada
Setting : hospital
Number of centres : 1
Participants Inclusion criteria
• Patients older than 20 years of age
• Undergoing elective PCI procedures in whom femoral anatomy is favourable for placement of a closure
device
Exclusion criteria
• Patients undergoing emergency PCI
• End-stage renal disease
• Haemoglobin level < 100 g/L
• Fish allergy
• Known allergy to protamine
• Use of low molecular weight heparin within previous 12 hours
• Prior closure device use within 90 days
• Symptomatic peripheral vascular disease
• Femoral artery calciﬁcation on ﬂuoroscopy
• Arterial puncture of the superﬁcial femoral artery
• Double wall puncture (puncture of anterior and posterior wall of femoral artery)
• Placement of intra-aortic balloon pump
• Placement of a femoral venous sheath
• Coronary dissection
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NCT00264264 (Continued)
• Thrombus or perforation not resolved by the end of the case
Interventions Intervention 1 : vascular closure device
Intervention 2 : direct compression
Outcomes Primary
• Composite of major vascular complications (device failure, bleeding, haematoma, infection,
pseudoaneurysm, arterio-venous ﬁstula and vascular repair)
Secondary
• Time to haemostasis
• Ambulation time
• Quality of life
• Composite of minor vascular complications (bleeding, repeat compression, failure to ambulate per
protocol)
• Post-procedural infarction
• Death
• MI
Starting date July 2006
Contact information Asim Cheema, St Michael’s Hospital, Toronto
Notes
NCT00428155
Trial name or title ACDC trial II
Methods Study design : randomised single-group assignment single-blind trial
Country : Canada
Setting : hospital
Number of centres : 1
Participants Inclusion criteria
• Patients older than 25 years of age
• Undergoing non-emergent PCI procedures with a 6 Fr arterial sheath, with femoral artery favourable
for placement of an arterial closure device
Exclusion criteria
• Patients undergoing emergency PCI
• End-stage renal disease
• Prior arterial closure device use within 90 days
• Symptomatic peripheral vascular disease
• Arterial puncture of the superﬁcial femoral artery
• Suspected double wall puncture (puncture of anterior and posterior wall of femoral artery)
• Placement of intra-aortic balloon pump
• Placement of femoral venous sheath
Interventions Intervention 1 : AngioSeal
Intervention 2 : StarClose
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Outcomes Primary
• Composite of major vascular complications (device failure, bleeding, haematoma, infection)
Secondary
• Time to haemostasis
• Lack of ambulation per protocol
• Need for additional measures to achieve haemostasis (manual pressure, FemoStop use, etc)
• Minor vascular complication (minor bleeding, analgesic use)
• Post-procedural myocardial infarction
• 30-Day incidence of death
• MI
• Participant discomfort
• Quality of life measurements at discharge and at 4 weeks
• Nurse resource utilisation at discharge
Starting date January 2007
Contact information Asim Cheema, St Michael’s Hospital, Toronto; cheemaa@smh.toronto.on.ca
Notes
NCT01389375
Trial name or title Instrumental sealing of arterial puncture site closure device versus manual compression trial
Methods Study design : prospective randomised open-label trial
Country : Germany
Setting : hospital
Number of centres : not stated
Participants Inclusion criteria
• Patients between 18 and 85 years of age
• Undergoing femoral access coronary angiography
Exclusion criteria
• Peripheral arterial occlusive disease
• Prior peripheral artery surgery
• Percutaneous coronary intervention
• Femoral access device closure in previous 30 days
• Scheduled coronary angiography/intervention within 90 days
• Critical limb ischaemia
• Uncontrolled hypertension > 220/110 mmHg
• Coagulopathy (bleeding disorder)
• Local infection
• Common femoral artery lumen diameter < 5 mm
• Allergy to absorbable suture
• Autoimmune disease
• Pregnancy
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NCT01389375 (Continued)
Interventions Intervention 1 : ExoSeal
Intervention 2 : FemoSeal
Intervention 3 : manual compression
Outcomes Primary
• Composite of arterial access-related complications, deﬁned as the composite of rate of ipsilateral groin
haematomas with largest diameter exceeding 5 cm, pseudoaneurysm, arteriovenous ﬁstula, major bleeding,
critical limb ischaemia, local infection, surgical repair and revascularisation
Secondary
• Time to haemostasis (from sheath removal to complete haemostasis)
• Device deployment failure
• Need for repeated manual compression after end of closure procedure
• Cost/beneﬁt analysis
Starting date July 2011
Contact information Maryam Linhardt, Deutsches Herzzentrum München, Klinik für Herz-und Kreislauferkrankungen
Notes
NCT01600482
Trial name or title Clinical investigation for safety and efﬁcacy study of CELT ACD arterial closure device
Methods Study design : randomised multi-centre open-label study
Countries : United States of America, Germany and Ireland
Setting : hospital
Number of centres : multi-centre
Participants Inclusion criteria
• Patients older than 18 years
• Willingness to give informed consent
• Clinical indication for an intra-arterial procedure involving access through the common femoral artery
and conducted through an access sheath size between 6 Fr and 7 Fr inclusive
Exclusion criteria
• Patients with known allergy to any materials used in the device
• Severe acute non-cardiac systemic disease or terminal illness with life expectancy < 1 year
• Evidence of systemic bacterial or cutaneous infection, including groin infection, deﬁnitive or potential
coagulopathy or platelet count < 100,000/µL
• Use of systemic thrombolytic agents within 24 hours before or during the catheterisation procedure
that cause the concentration of ﬁbrinogen to be < 100 mg/dL, or when post-thrombolytic ﬁbrinogen (in
case of thrombolysis within 24 hours or intraprocedural) cannot be measured
• Patients in whom an introducer sheath smaller than 6 Fr or greater than 7 Fr has been used
• Currently participating in another investigational device or drug study
• Severe claudication
• Iliac or femoral artery diameter stenosis > 50%
• Previous bypass surgery or stent placement in the vicinity of the access site
• Indication that puncture has been made in the profunda femoris artery or the superﬁcial femoral
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NCT01600482 (Continued)
artery, or adjacent to the bifurcation
• Common femoral artery lumen diameter <an 5 mm
• Any amputation from an access site limb
• Patients who have undergone a percutaneous procedure performed with a vascular closure device for
haemostasis within the previous 30 days or those treated with manual/mechanical pressure for haemostasis
within the previous 30 days in the same leg
• Systolic blood pressure < 90 mmHg
• Active haematoma, arteriovenous ﬁstula or pseudoaneurysm
• A very superﬁcial artery in which the depth from skin to the artery surface at the access site is less than
4 mm
• Morbidly obese patients (BMI > 35 kg/m2)
• A stent ≤ 1 cm of the puncture site that would interfere with placement of the device implant
• Patients known or suspected to be pregnant or lactating
• Patients with an antegrade puncture
• Difﬁculty in obtaining vascular access resulting in multiple arterial punctures and/or posterior arterial
wall puncture
• Patients who have undergone prior or recent use of an intra-aortic balloon pump through the arterial
access site
• Uncontrolled hypertension (BP ≥ 180/110 mmHg) at time of vascular closure
• Acute ST-elevation myocardial infarction ≤ 48 hours before catheterisation procedure
• Cardiogenic shock (haemodynamic instability requiring intravenous medication or mechanical
support) experienced during or immediately post catheterisation
• Inability to ambulate at baseline
• Patients known to require an extended hospitalisation (e.g. patient undergoing cardiac surgery)
• Patient who has already participated in the trial or is unavailable for follow-up
Interventions Intervention 1 : CELT ACD
Intervention 2 : manual compression
Outcomes Primary
• Combined rate of major complications and time to haemostasis, both within 30 ± 7 days following the
PCI procedure
Secondary
• Combined rate of minor complications
• Time to ambulation
• Time to dischargeability
• Procedure success
• Device successes, all within 30 ± 7 days following the procedure
Starting date May 2012
Contact information Turi-Zoltan@CooperHealth.edu
scwong@med.cornell.edu
michael.laule@charite.de
Notes
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NCT01669382
Trial name or title ACCESS
Methods Study design : randomised multi-centre single-blinded trial
Country : Germany
Setting : hospital
Number of centres : multi-centre
Participants Inclusion criteria
• Patients 18 years of age and older
• Receive coronary angiography/intervention with a 6 Fr sheath
Exclusion criteria
• Severe calciﬁcation of the access vessel
• Severe peripheral artery disease
• Puncture in the origin of the profound femoral artery
• Non-femoral sheath insertion
• Marked tortuosity of the femoral or iliac artery
• Marked obesity or cachexia (BMI > 40 kg/m2 or < 20 kg/m2)
• Patients on continuous medication with oral anticoagulants
Interventions Intervention 1 : ExoSeal
Intervention 2 : AngioSeal
Outcomes Primary
• Bleeding
• Need for vascular surgery
• Device failure
Secondary
• Occurrence of false aneurysms
• Severe pain (Borg scale ≥ 5)
• Haematoma ≥ 5 cm
Starting date January 2012
Contact information johannes.brachmann@klinikum-coburg.de
harald.rittger@uk-erlangen.de
holger.nef@innere.med.uni-giessen.de
Notes
NCT02061696
Trial name or title A randomised controlled trial to assess safety and efﬁcacy of AXERA (device name) 2 Access System compared
with manual compression
Methods Study design : randomised parallel-assignment open-label
Country : United States of America
Setting : hospital
Number of centres : multi-centre
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Participants Inclusion criteria
• Between 18 and 85 years of age
• Cardiac catheterisation procedure indicated involving access through a 5 Fr or 6 Fr introducer in the
femoral artery
• Ability to ambulate without assistance before the procedure and expected to ambulate (20 feet) post
procedure
• Participant or legally authorised representative has signed informed consent
Exclusion criteria
• Inability to routinely ambulate 20 feet without assistance (e.g. requires a walker or wheelchair to
mobilise, has paralysis)
• Active systemic or cutaneous infection or inﬂammation (e.g. septicaemia) at the time of the procedure
• Emergent or urgent cardiac catheterisation for acute myocardial infarction
• Extensive calciﬁcation of the femoral artery as seen on ﬂuoroscopy
• Systemic hypertension unresponsive to treatment (> 180 mmHg systolic and > 110 mmHg diastolic)
• Thrombolytic therapy within the 72 hours before catheterisation
• Known bleeding disorder, such as Factor 5 deﬁciency, idiopathic thrombocytopenic purpura (ITP),
thrombasthaenia, von Willebrand’s disease
• Taking warfarin with an international normalised ratio (INR) of 1.5
• Platelet count < 100,000
• Anaemia (haemoglobin < 10 g/dL or haematocrit < 30%)
• Compromised femoral artery access site
• Procedure requires an introducer sheath size > 6 Fr
• Prior vascular surgery or vascular grafts at the femoral artery access site
• Presentation with haemodynamic instability or in need of emergent surgery
• Femoral artery closure on the target access vessel with a collagen/PEG closure device within 90 days
• Pre-existing severe non-cardiac systemic disease or illness that results in life expectancy < 1 year
• Participation in an investigational drug or another device research study that interferes with current
research study endpoints
• Pregnant or lactating women
Interventions Intervention 1 : AXERA 2 Access System
Intervention 2 : manual compression
Outcomes Primary
• Observation of any site-related major adverse events
• Observation of any major access site-related complications
Secondary
• AXERA 2 Access System success
• Time to haemostasis .
• Time to discharge eligibility
• Time to actual discharge
• Time to ambulation
• Ability to sit up at a 45-degree angle
• Minor access site-related complications
• Participant satisfaction
• Pain score
Starting date 30 January 2014
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Contact information frank.saltiel@borgess.com
vishal.gupta@borgess.com
Notes
NCT02234830
Trial name or title CLOSE-UP II trial
Methods Study design : randomised parallel-assignment open-label
Country : Denmark
Setting : hospital
Number of centres : multi-centre
Participants Inclusion criteria
• Ability to provide valid informed signed consent
• PCI procedure including treatment by balloon and/or stent
• PCI indicated by silent ischaemia, stable angina pectoris, non-ST elevation myocardial infarction
(NSTEMI) or ST elevation myocardial infarction (STEMI)
Exclusion criteria
• Only coronary angiography
• Multiple punctures
• Active infection
• Groin haematoma before the closure procedure
• Sheath size > 7 Fr
• Known pseudoaneurysm or arterio-venous (AV) ﬁstula in the ipsilateral groin
• Prior arterial surgery in abdomen and/or lower extremities
• Cardiogenic shock
• Life expectancy < 1 year
• Female of childbearing potential with possible pregnancy or positive pregnancy test within 7 days
before index procedure, or lactating
• Simultaneous or planned subsequent femoral vein access
• Allergy to any of the components in the closure material left in the groin
• Puncture of same site < 30 days
• Peripheral artery disease patients can be included at operator’s discretion except if heavy calciﬁcation is
present at the access site, which at the operator’s discretion precludes insertion of the VCD
Interventions Intervention 1 : AngioSeal
Intervention 2 : ExoSeal
Outcomes Primary
• Incidence at 30 days of the composite endpoint of access site-related major adverse vascular events.
This includes major bleeding and/or bleeding necessitating blood transfusion, pseudoaneurysm with
indication for treatment, arteriovenous ﬁstula, groin surgery and/or possible related vascular surgery and
infection needing antibiotic
Secondary
• Time to haemostasis from removal of the sheath (AngioSeal) or insertion of the device (ExoSeal) until
haemostasis
123Vascular closure devices for femoral arterial puncture site haemostasis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT02234830 (Continued)
• Device failure
• Vasovagal reaction until 5 minutes after end of closure procedure
• Need for new onset of manual compression
• Pain and discomfort related to the closure procedure
• Time to mobilisation
• In-hospital large groin haematoma
• Bleeding according to BARC deﬁnitions
• Major bleeding and/or bleeding necessitating blood transfusion
• Pseudoaneurysm with indication for treatment
• Arteriovenous ﬁstula
• Groin surgery and/or possible related vascular surgery
• Infection needing antibiotics
• Need for medical evaluation of possible closure procedure-related symptom(s)
Starting date December 2012
Contact information hellbarg@rm.dk
niels.holm@clin.au.dk
Notes
NCT02237430
Trial name or title CLOSE-UP III trial
Methods Study design : randomised parallel-assignment open-label
Country : Denmark
Setting : hospital
Number of centres : multi-centre
Participants Inclusion criteria
• > 18 years of age
• Ability to provide valid informed signed consent
• CAG, possibly including intracoronary measurement (FFR) or intracoronary imaging (IVUS, optical
coherence tomography (OCT), NIRS)
Exclusion criteria
• Percutaneous coronary intervention (PCI) procedure and/or implantation of stents
• ST-elevation myocardial infarction (STEMI)
• Multiple punctures
• Active infection
• Groin haematoma before the closure procedure
• Known pseudoaneurysm or arterio-venous (AV) ﬁstula in the ipsilateral groin
• Cardiogenic shock
• Prior peripheral arterial surgery in abdomen or lower extremities
• Sheat size > 7 Fr
• Life expectancy < 1 year
• Possible pregnancy or positive pregnancy test or breastfeeding women
• Simultaneous or planned subsequent femoral vein access
• Allergy to any of the components in the closure material left in the groin
124Vascular closure devices for femoral arterial puncture site haemostasis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT02237430 (Continued)
• Puncture or closure with closure device at same site < 30 days
• Puncture or closure with manual compression at same site < 5 days
• Patients with peripheral artery disease can be included at operator’s discretion, except if heavy
calciﬁcation is present at the access site, which at the operator’s discretion precludes insertion of the closure
device
Interventions Intervention 1 : Mynx
Intervention 2 : manual compression
Outcomes Primary
• Incidence at 30 days of the composite endpoint of access site-related major adverse vascular events,
including major bleeding and/or bleeding necessitating blood transfusion, pseudoaneurysm with indication
for treatment, arteriovenous ﬁstula, groin surgery and/or possible related vascular surgery, infection needing
antibiotic
Secondary
• Time to haemostasis from removal of the sheath (AngioSeal) or insertion of the device (ExoSeal) until
haemostasis
• Device failure
• Vasovagal reaction until 5 minutes after end of closure procedure
• Need for new onset of manual compression
• Pain and discomfort related to the closure procedure
• Time to mobilisation
• In-hospital large groin haematoma
• Bleeding according to BARC deﬁnitions
• Major bleeding and/or bleeding necessitating blood transfusion
• Pseudoaneurysm with indication for treatment
• Arteriovenous ﬁstula
• Groin surgery and/or possible related vascular surgery
• Infection needing antibiotics
• Need for medical evaluation of possible closure procedure-related symptom(s)
Starting date June 2014
Contact information niels.holm@clin.au.dk
evald.christiansen@dadlnet.dk
Notes
AV: arterio-venous
BARC: Bleeding Academic Research Consortium
BMI: body mass index
BP: blood pressure
CABG: coronary artery bypass graft
CAG: coronary angiography
CFA: common femoral artery
cm: centimetres
FFR: fractional ﬂow reserve
Hct: haematocrit
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Hgb: haemoglobin
INR: International normalised ratio
ITP: idiopathic thrombocytopenic purpura
IV: intravenous
IVUS: intravascular ultrasound
MI: myocardial infarction
mm: millimetres
NIRS: near infrared spectroscopy
NSTEMI: non-ST elevation myocardial infarction
OCT: optical coherence tomography
PCI: percutaneous coronary intervention
PEG: polyethylene glycol
STEMI: ST elevation myocardial infarction
VCD: vascular closure device
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D A T A A N D A N A L Y S E S
Comparison 1. Collagen-based VCD versus manual or mechanical compression (sheath size ≤ 9 Fr)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to haemostasis (minutes) 12 Mean Difference (IV, Random, 95% CI) Totals not selected
2 Time to mobilisation (hours) 13 Mean Difference (IV, Random, 95% CI) Totals not selected
3 Major adverse event (any time) 6 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Mortality 1 141 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Vascular injury requiring
vascular repair by surgical or
non-surgical techniques
5 5731 Odds Ratio (M-H, Fixed, 95% CI) 2.81 [0.47, 16.79]
4 Infection 9 7616 Odds Ratio (M-H, Fixed, 95% CI) 2.14 [0.88, 5.22]
5 Groin haematoma 25 10247 Odds Ratio (M-H, Fixed, 95% CI) 0.46 [0.40, 0.54]
6 Retroperitoneal haemorrhage 3 744 Odds Ratio (M-H, Fixed, 95% CI) 1.58 [0.22, 11.42]
7 Pseudoaneurysm 21 9342 Odds Ratio (M-H, Fixed, 95% CI) 0.74 [0.55, 0.99]
8 Arterio-venous ﬁstula 8 6153 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.43, 2.21]
9 Deep vein thrombosis 3 629 Odds Ratio (M-H, Fixed, 95% CI) 2.41 [0.46, 12.50]
10 Limb ischaemia 3 4970 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Femoral artery thrombosis 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
12 Length of hospital stay (hours) 6 Mean Difference (IV, Random, 95% CI) Totals not selected
Comparison 2. Metal clip-based VCD versus manual or mechanical compression (sheath size ≤ 9 Fr)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to haemostasis (minutes) 5 1665 Mean Difference (IV, Random, 95% CI) -14.81 [-16.98, -12.
63]
2 Time to mobilisation (hours) 3 Mean Difference (IV, Random, 95% CI) Totals not selected
3 Major adverse event (any time) 4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Mortality 3 564 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Vascular injury requiring
vascular repair by surgical or
non-surgical techniques
3 783 Odds Ratio (M-H, Fixed, 95% CI) 0.49 [0.03, 7.95]
4 Infection 3 783 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Groin haematoma 4 1523 Odds Ratio (M-H, Fixed, 95% CI) 0.79 [0.46, 1.34]
6 Pseudoaneurysm 6 1966 Odds Ratio (M-H, Fixed, 95% CI) 0.76 [0.20, 2.89]
7 Arterio-venous ﬁstula 3 564 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Deep vein thrombosis 2 483 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Limb ischaemia 2 483 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 3. Suture-based VCD versus manual or mechanical compression (sheath size ≤ 9 Fr)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to haemostasis (minutes) 7 1664 Mean Difference (IV, Random, 95% CI) -14.58 [-16.85, -12.
32]
2 Time to mobilisation (hours) 7 Mean Difference (IV, Random, 95% CI) Totals not selected
3 Major adverse event (any time) 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Mortality 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Vascular injury requiring
vascular repair
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Infection 3 750 Odds Ratio (M-H, Fixed, 95% CI) 1.66 [0.22, 12.71]
5 Groin haematoma 6 1350 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.41, 1.02]
6 Retroperitoneal haemorrhage 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Pseudoaneurysm 6 1527 Odds Ratio (M-H, Fixed, 95% CI) 0.79 [0.25, 2.53]
8 Arterio-venous ﬁstula 4 880 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.02]
9 Embolisation 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
10 Limb ischaemia 2 720 Odds Ratio (M-H, Fixed, 95% CI) 1.02 [0.14, 7.22]
11 Length of hospital stay (hours) 3 327 Mean Difference (IV, Random, 95% CI) -11.66 [-20.46, -2.
85]
Comparison 4. Collagen-based VCD versus metal clip-based VCD: AngioSeal versus StarClose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Major adverse event (any time) 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Mortality 1 571 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Vascular injury requiring
vascular repair by surgical or
non-surgical techniques
2 871 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.22]
2 Infection 2 701 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Groin haematoma 2 871 Odds Ratio (M-H, Fixed, 95% CI) 0.84 [0.43, 1.65]
4 Retroperitoneal haemorrhage 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Pseudoaneurysm 3 1272 Odds Ratio (M-H, Fixed, 95% CI) 0.50 [0.15, 1.66]
6 Arterio-venous ﬁstula 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Limb ischaemia 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
8 Technical failure of VCD 3 1272 Odds Ratio (M-H, Fixed, 95% CI) 0.38 [0.23, 0.64]
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Comparison 5. Collagen-based VCD versus suture-based VCD (sheath size ≤ 9 Fr)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Infection 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Groin haematoma 3 510 Odds Ratio (M-H, Fixed, 95% CI) 1.26 [0.71, 2.22]
3 Retroperitoneal haemorrhage 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Pseudoaneurysm 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Arterio-venous ﬁstula 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Technical failure of VCD 3 510 Odds Ratio (M-H, Fixed, 95% CI) 0.24 [0.08, 0.69]
Comparison 6. Metal clip-based VCD versus suture-based VCD: StarClose versus PerClose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to haemostasis 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Time to mobilisation 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Groin haematoma 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Pseudoaneurysm 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Technical failure of VCD 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 7. Disc-based VCD versus suture-based VCD: Boomerang versus PerClose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to haemostasis (minutes) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Time to mobilisation (hours) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Groin haematoma 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Technical failure of VCD 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 8. Collagen-based VCD versus collagen-based VCD: AngioSeal versus VasoSeal
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to haemostasis (minutes) 2 Mean Difference (IV, Random, 95% CI) Totals not selected
2 Time to mobilisation (hours) 2 720 Mean Difference (IV, Random, 95% CI) -0.13 [-0.63, 0.37]
3 Major adverse event (any time) 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Mortality 1 150 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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3.2 Vascular injury requiring
vascular repair by surgical or
non-surgical techniques
1 150 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Infection 1 150 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Groin haematoma 2 720 Odds Ratio (M-H, Fixed, 95% CI) 0.49 [0.16, 1.47]
6 Retroperitoneal haemorrhage 2 720 Odds Ratio (M-H, Fixed, 95% CI) 0.36 [0.01, 9.09]
7 Pseudoaneurysm 1 150 Odds Ratio (M-H, Fixed, 95% CI) 0.31 [0.01, 7.71]
8 Arterio-venous ﬁstula 1 150 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Technical failure of VCD 1 570 Odds Ratio (M-H, Fixed, 95% CI) 0.68 [0.37, 1.26]
Comparison 9. Collagen-based VCD versus collagen-based VCD: AngioSeal versus Mynx
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Major adverse event (any time) 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Vascular injury requiring
vascular repair by surgical or
non-surgical techniques
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Infection 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Groin haematoma 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 10. Collagen-based VCD versus collagen-based VCD: AngioSeal versus Duett
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to haemostasis (minutes) 1 571 Mean Difference (IV, Fixed, 95% CI) 10.75 [9.95, 11.56]
2 Time to mobilisation (hours) 1 571 Mean Difference (IV, Fixed, 95% CI) -0.39 [-0.50, -0.29]
3 Groin haematoma 1 571 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.28, 3.40]
4 Retroperitoneal haemorrhage 1 571 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Technical failure of VCD 1 571 Odds Ratio (M-H, Fixed, 95% CI) 0.54 [0.30, 0.99]
Comparison 11. Collagen-based VCD versus collagen-based VCD: VasoSeal versus Duett
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to haemostasis (minutes) 1 561 Mean Difference (IV, Fixed, 95% CI) -0.54 [-1.13, 0.05]
2 Time to mobilisation (hours) 1 561 Mean Difference (IV, Fixed, 95% CI) 0.09 [-0.03, 0.21]
3 Groin haematoma 1 561 Odds Ratio (M-H, Fixed, 95% CI) 2.00 [0.67, 5.95]
4 Retroperitoneal haemorrhage 1 561 Odds Ratio (M-H, Fixed, 95% CI) 2.77 [0.11, 69.59]
5 Technical failure of VCD 1 561 Odds Ratio (M-H, Fixed, 95% CI) 0.80 [0.46, 1.38]
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Comparison 12. Collagen-based VCD versus collagen-based VCD: FemoSeal versus ExoSeal
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Major adverse event (any time) 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Vascular injury requiring
vascular repair by surgical or
non-surgical techniques
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Infection 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Groin haematoma 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Pseudoaneurysm 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Arteriovenous ﬁstula 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Limb ischaemia 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Technical failure of VCD 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 13. PerClose ProGlide versus ProStar XL after percutaneous EVAR
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to haemostasis (minutes) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Time to mobilisation (hours) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Major adverse event (any time) 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Mortality 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Vascular injury requiring
vascular repair by surgical or
non-surgical techniques
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Infection 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Groin haematoma 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Arterio-venous ﬁstula 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Deep vein thrombosis 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
8 Limb ischaemia 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
9 Technical failure of VCD 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
10 Length of hospital stay (hours) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 14. PerClose ProGlide ProStar XL versus suture-based closure after EVAR with open exposure of
CFA
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to haemostasis (minutes) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Time to mobilisation (hours) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Major adverse event (any time) 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Mortality 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
131Vascular closure devices for femoral arterial puncture site haemostasis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
3.2 Vascular injury requiring
vascular repair by surgical or
non-surgical techniques
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Infection 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Groin haematoma 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Arterio-venous ﬁstula 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Deep vein thrombosis 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
8 Limb ischaemia 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
9 Length of hospital stay (hours) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Collagen-based VCD versus manual or mechanical compression (sheath size ≤
9 Fr), Outcome 1 Time to haemostasis (minutes).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 1 Collagen-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 1 Time to haemostasis (minutes)
Study or subgroup VCD Compression
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Brachmann 1998 (1) 89 7.6 (4.1) 99 19.1 (5.9) -11.50 [ -12.94, -10.06 ]
Brachmann 1998 (2) 100 6.4 (4.2) 99 13.2 (5.1) -6.80 [ -8.10, -5.50 ]
Casta eda 2003 85 8.2 (4.1) 56 14.1 (5.4) -5.90 [ -7.56, -4.24 ]
Diaz 2001 75 2 (3.5) 75 22.5 (6.2) -20.50 [ -22.11, -18.89 ]
Gwechenberger 1997 33 9.6 (2) 29 23.6 (16.4) -14.00 [ -20.01, -7.99 ]
Juergens 2004 58 24 (66) 57 384 (102) -360.00 [ -391.46, -328.54 ]
Kussmaul 1995 218 2.5 (15.2) 217 15.3 (11.7) -12.80 [ -15.35, -10.25 ]
Magosaki 1999 120 0.8 (3.2) 120 12.2 (5.3) -11.40 [ -12.51, -10.29 ]
Reddy 2004 25 8.2 (16.7) 25 16.1 (11.6) -7.90 [ -15.87, 0.07 ]
Sanborn 1993 (3) 90 4.1 (2.8) 75 17.6 (9.2) -13.50 [ -15.66, -11.34 ]
Sanborn 1993 (4) 71 4.3 (3.7) 134 33.6 (24.2) -29.30 [ -33.49, -25.11 ]
Seidelin 1997 24 0.5 (1.4) 26 43 (21) -42.50 [ -50.59, -34.41 ]
Silber 1998 74 3 (3) 76 17.4 (7) -14.40 [ -16.12, -12.68 ]
Wong 2009 267 4.4 (11.6) 131 20.1 (22.5) -15.70 [ -19.80, -11.60 ]
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(1) Interventional procedure
(2) Diagnostic procedure
(3) Diagnostic procedure
(4) Interventional procedure
Analysis 1.2. Comparison 1 Collagen-based VCD versus manual or mechanical compression (sheath size ≤
9 Fr), Outcome 2 Time to mobilisation (hours).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 1 Collagen-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 2 Time to mobilisation (hours)
Study or subgroup VCD Compression
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Behan 2007 107 1.46 (0.72) 99 2.4 (0.27) -0.94 [ -1.09, -0.79 ]
Brachmann 1998 (1) 88 8.1 (4.2) 101 13.4 (5.3) -5.30 [ -6.66, -3.94 ]
Brachmann 1998 (2) 99 3.3 (8.8) 99 6.3 (5) -3.00 [ -4.99, -1.01 ]
Casta eda 2003 85 2.75 (2.5) 56 7.19 (3.37) -4.44 [ -5.47, -3.41 ]
Diaz 2001 75 3.1 (0.4) 75 12.3 (3.1) -9.20 [ -9.91, -8.49 ]
Holm 2014 501 1.48 (0.63) 500 1.4 (0.93) 0.08 [ -0.02, 0.18 ]
Juergens 2004 58 17 (8) 57 22 (13) -5.00 [ -8.95, -1.05 ]
Legrand 2005 100 4.5 (2) 102 12.2 (1.5) -7.70 [ -8.19, -7.21 ]
Machnik 2012 91 2.9 (2.4) 110 14.2 (2.3) -11.30 [ -11.95, -10.65 ]
Magosaki 1999 120 5.3 (3.7) 120 10.9 (5.1) -5.60 [ -6.73, -4.47 ]
Sanborn 1993 (3) 90 13.3 (12.1) 75 19.1 (17.8) -5.80 [ -10.54, -1.06 ]
Sanborn 1993 (4) 71 23 (11.1) 134 32.7 (18.8) -9.70 [ -13.80, -5.60 ]
Schra¨der 1992 50 6.4 (2.2) 50 21.6 (5.4) -15.20 [ -16.82, -13.58 ]
Seidelin 1997 24 0.53 (0.12) 26 5.38 (0.7) -4.85 [ -5.12, -4.58 ]
Wong 2009 264 2.5 (5) 129 6.2 (13.3) -3.70 [ -6.07, -1.33 ]
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(1) Interventional procedure
(2) Diagnostic procedure
(3) Diagnostic procedure
(4) Interventional procedure
Analysis 1.3. Comparison 1 Collagen-based VCD versus manual or mechanical compression (sheath size ≤
9 Fr), Outcome 3 Major adverse event (any time).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 1 Collagen-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 3 Major adverse event (any time)
Study or subgroup VCD Compression Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mortality
Casta eda 2003 0/85 0/56 Not estimable
Subtotal (95% CI) 85 56 Not estimable
Total events: 0 (VCD), 0 (Compression)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Vascular injury requiring vascular repair by surgical or non-surgical techniques
Sanborn 1993 1/246 0/209 30.0 % 2.56 [ 0.10, 63.18 ]
Schulz-Schu¨pke 2014 (1) 0/1506 0/754 Not estimable
Schulz-Schu¨pke 2014 (2) 0/1509 0/755 Not estimable
Seidelin 1997 0/24 0/26 Not estimable
Ward 1998 2/202 0/102 36.6 % 2.56 [ 0.12, 53.74 ]
Yadav 2003 2/240 0/158 33.3 % 3.32 [ 0.16, 69.67 ]
Subtotal (95% CI) 3727 2004 100.0 % 2.81 [ 0.47, 16.79 ]
Total events: 5 (VCD), 0 (Compression)
Heterogeneity: Chi2 = 0.02, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
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(1) ExoSeal
(2) FemoSeal
Analysis 1.4. Comparison 1 Collagen-based VCD versus manual or mechanical compression (sheath size ≤
9 Fr), Outcome 4 Infection.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 1 Collagen-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 4 Infection
Study or subgroup VCD Compression Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Behan 2007 0/107 0/99 Not estimable
Casta eda 2003 0/85 0/56 Not estimable
Deuling 2008 0/150 0/150 Not estimable
Holm 2014 1/501 2/500 28.0 % 0.50 [ 0.05, 5.51 ]
Sanborn 1993 2/246 2/209 30.1 % 0.85 [ 0.12, 6.08 ]
Schulz-Schu¨pke 2014 (1) 0/1506 0/754 Not estimable
Schulz-Schu¨pke 2014 (2) 1/1509 0/755 9.3 % 1.50 [ 0.06, 36.93 ]
SEAL Trial Study Team 0/392 0/238 Not estimable
Seidelin 1997 1/24 0/26 6.3 % 3.38 [ 0.13, 87.11 ]
von Hoch 1995 10/154 2/155 26.2 % 5.31 [ 1.14, 24.66 ]
Total (95% CI) 4674 2942 100.0 % 2.14 [ 0.88, 5.22 ]
Total events: 15 (VCD), 6 (Compression)
Heterogeneity: Chi2 = 3.73, df = 4 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.67 (P = 0.094)
Test for subgroup differences: Not applicable
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135Vascular closure devices for femoral arterial puncture site haemostasis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.5. Comparison 1 Collagen-based VCD versus manual or mechanical compression (sheath size ≤
9 Fr), Outcome 5 Groin haematoma.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 1 Collagen-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 5 Groin haematoma
Study or subgroup VCD Compression Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Amin 2000 3/75 6/75 1.3 % 0.48 [ 0.12, 1.99 ]
Camenzind 1994 7/62 6/62 1.2 % 1.19 [ 0.38, 3.76 ]
Casta eda 2003 1/85 0/56 0.1 % 2.01 [ 0.08, 50.12 ]
Deuling 2008 15/150 14/150 2.7 % 1.08 [ 0.50, 2.32 ]
Diaz 2001 1/75 0/75 0.1 % 3.04 [ 0.12, 75.83 ]
Doneaux 2001 0/58 6/63 1.3 % 0.08 [ 0.00, 1.37 ]
Gwechenberger 1997 1/33 2/29 0.4 % 0.42 [ 0.04, 4.91 ]
Hermanides 2010 5/313 11/314 2.4 % 0.45 [ 0.15, 1.30 ]
Holm 2014 11/501 31/500 6.6 % 0.34 [ 0.17, 0.68 ]
Jensen 2008 4/22 3/24 0.5 % 1.56 [ 0.31, 7.89 ]
Juergens 2004 8/58 9/57 1.7 % 0.85 [ 0.30, 2.39 ]
Kussmaul 1995 5/168 5/152 1.1 % 0.90 [ 0.26, 3.18 ]
Legrand 2005 2/100 5/102 1.1 % 0.40 [ 0.08, 2.09 ]
Machnik 2012 10/120 19/120 3.8 % 0.48 [ 0.21, 1.09 ]
Magosaki 1999 6/91 13/110 2.4 % 0.53 [ 0.19, 1.45 ]
Reddy 2004 9/25 9/25 1.3 % 1.00 [ 0.32, 3.17 ]
Sanborn 1993 10/161 17/209 3.0 % 0.75 [ 0.33, 1.68 ]
Schra¨der 1992 27/50 45/50 4.5 % 0.13 [ 0.04, 0.38 ]
Schulz-Schu¨pke 2014 (1) 65/1509 102/755 28.3 % 0.29 [ 0.21, 0.40 ]
Schulz-Schu¨pke 2014 (2) 80/1506 102/754 28.0 % 0.36 [ 0.26, 0.49 ]
Seidelin 1997 12/24 12/26 1.3 % 1.17 [ 0.38, 3.54 ]
Silber 1998 21/74 27/76 4.1 % 0.72 [ 0.36, 1.43 ]
Upponi 2007 6/50 7/50 1.3 % 0.84 [ 0.26, 2.70 ]
Ward 1998 8/202 4/102 1.1 % 1.01 [ 0.30, 3.44 ]
Wong 2009 6/267 1/134 0.3 % 3.06 [ 0.36, 25.66 ]
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(. . . Continued)
Study or subgroup VCD Compression Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Yadav 2003 4/240 0/158 0.1 % 6.03 [ 0.32, 112.81 ]
Total (95% CI) 6019 4228 100.0 % 0.46 [ 0.40, 0.54 ]
Total events: 327 (VCD), 456 (Compression)
Heterogeneity: Chi2 = 48.29, df = 25 (P = 0.003); I2 =48%
Test for overall effect: Z = 9.61 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Collagen-based VCD versus manual or mechanical compression (sheath size ≤
9 Fr), Outcome 6 Retroperitoneal haemorrhage.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 1 Collagen-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 6 Retroperitoneal haemorrhage
Study or subgroup VCD Compression Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Behan 2007 0/107 0/99 Not estimable
Martin 2008 1/70 1/67 60.5 % 0.96 [ 0.06, 15.61 ]
Wong 2009 2/267 0/134 39.5 % 2.53 [ 0.12, 53.13 ]
Total (95% CI) 444 300 100.0 % 1.58 [ 0.22, 11.42 ]
Total events: 3 (VCD), 1 (Compression)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Collagen-based VCD versus manual or mechanical compression (sheath size ≤
9 Fr), Outcome 7 Pseudoaneurysm.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 1 Collagen-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 7 Pseudoaneurysm
Study or subgroup VCD Compression Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Amin 2000 1/75 0/75 0.5 % 3.04 [ 0.12, 75.83 ]
Behan 2007 0/107 0/99 Not estimable
Camenzind 1994 4/62 4/62 3.7 % 1.00 [ 0.24, 4.19 ]
Deuling 2008 1/150 1/150 1.0 % 1.00 [ 0.06, 16.14 ]
Doneaux 2001 0/58 2/63 2.4 % 0.21 [ 0.01, 4.47 ]
Gwechenberger 1997 1/33 1/29 1.0 % 0.88 [ 0.05, 14.65 ]
Holm 2014 2/501 1/500 1.0 % 2.00 [ 0.18, 22.13 ]
Juergens 2004 0/58 1/57 1.5 % 0.32 [ 0.01, 8.07 ]
Legrand 2005 1/100 2/102 2.0 % 0.51 [ 0.05, 5.66 ]
Machnik 2012 0/91 5/110 4.9 % 0.10 [ 0.01, 1.92 ]
Magosaki 1999 0/120 1/120 1.5 % 0.33 [ 0.01, 8.20 ]
Martin 2008 0/70 2/67 2.5 % 0.19 [ 0.01, 3.94 ]
Reddy 2004 1/25 0/25 0.5 % 3.12 [ 0.12, 80.39 ]
Sanborn 1993 4/246 0/209 0.5 % 7.78 [ 0.42, 145.26 ]
Schulz-Schu¨pke 2014 (1) 22/1509 23/755 30.1 % 0.47 [ 0.26, 0.85 ]
Schulz-Schu¨pke 2014 (2) 31/1506 23/754 29.9 % 0.67 [ 0.39, 1.15 ]
SEAL Trial Study Team 2/142 0/51 0.7 % 1.83 [ 0.09, 38.82 ]
Silber 1998 1/74 0/76 0.5 % 3.12 [ 0.13, 77.88 ]
Upponi 2007 0/50 0/50 Not estimable
von Hoch 1995 18/154 16/155 14.0 % 1.15 [ 0.56, 2.35 ]
Ward 1998 2/202 1/102 1.3 % 1.01 [ 0.09, 11.27 ]
Yadav 2003 1/240 0/158 0.6 % 1.99 [ 0.08, 49.04 ]
Total (95% CI) 5573 3769 100.0 % 0.74 [ 0.55, 0.99 ]
Total events: 92 (VCD), 83 (Compression)
Heterogeneity: Chi2 = 14.00, df = 19 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 2.03 (P = 0.042)
Test for subgroup differences: Not applicable
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(1) Femoseal
(2) Exoseal
Analysis 1.8. Comparison 1 Collagen-based VCD versus manual or mechanical compression (sheath size ≤
9 Fr), Outcome 8 Arterio-venous fistula.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 1 Collagen-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 8 Arterio-venous ﬁstula
Study or subgroup VCD Compression Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gwechenberger 1997 0/33 1/29 13.4 % 0.28 [ 0.01, 7.24 ]
Hermanides 2010 0/313 1/314 12.8 % 0.33 [ 0.01, 8.21 ]
Machnik 2012 0/91 1/110 11.6 % 0.40 [ 0.02, 9.91 ]
Martin 2008 0/70 0/67 Not estimable
Schulz-Schu¨pke 2014 (1) 4/1509 2/755 22.7 % 1.00 [ 0.18, 5.48 ]
Schulz-Schu¨pke 2014 (2) 8/1506 2/754 22.7 % 2.01 [ 0.43, 9.48 ]
SEAL Trial Study Team 0/142 0/51 Not estimable
Upponi 2007 0/50 0/50 Not estimable
von Hoch 1995 2/154 2/155 16.8 % 1.01 [ 0.14, 7.24 ]
Total (95% CI) 3868 2285 100.0 % 0.98 [ 0.43, 2.21 ]
Total events: 14 (VCD), 9 (Compression)
Heterogeneity: Chi2 = 2.12, df = 5 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours VCD Favours compression
(1) Femoseal
(2) Exoseal
139Vascular closure devices for femoral arterial puncture site haemostasis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.9. Comparison 1 Collagen-based VCD versus manual or mechanical compression (sheath size ≤
9 Fr), Outcome 9 Deep vein thrombosis.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 1 Collagen-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 9 Deep vein thrombosis
Study or subgroup VCD Compression Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Camenzind 1994 1/62 0/62 24.3 % 3.05 [ 0.12, 76.30 ]
Sanborn 1993 2/246 1/209 53.3 % 1.70 [ 0.15, 18.94 ]
Seidelin 1997 1/24 0/26 22.5 % 3.38 [ 0.13, 87.11 ]
Total (95% CI) 332 297 100.0 % 2.41 [ 0.46, 12.50 ]
Total events: 4 (VCD), 1 (Compression)
Heterogeneity: Chi2 = 0.14, df = 2 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Collagen-based VCD versus manual or mechanical compression (sheath size ≤
9 Fr), Outcome 10 Limb ischaemia.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 1 Collagen-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 10 Limb ischaemia
Study or subgroup VCD Compression Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Behan 2007 0/107 0/99 Not estimable
Machnik 2012 0/120 0/120 Not estimable
Schulz-Schu¨pke 2014 (1) 0/1506 0/754 Not estimable
Schulz-Schu¨pke 2014 (2) 0/1509 0/755 Not estimable
Total (95% CI) 3242 1728 Not estimable
Total events: 0 (VCD), 0 (Compression)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Collagen-based VCD versus manual or mechanical compression (sheath size ≤
9 Fr), Outcome 11 Femoral artery thrombosis.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 1 Collagen-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 11 Femoral artery thrombosis
Study or subgroup VCD Compression Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Upponi 2007 0/50 0/50 Not estimable
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Analysis 1.12. Comparison 1 Collagen-based VCD versus manual or mechanical compression (sheath size ≤
9 Fr), Outcome 12 Length of hospital stay (hours).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 1 Collagen-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 12 Length of hospital stay (hours)
Study or subgroup VCD Compression
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Casta eda 2003 85 23.88 (53.43) 56 43.61 (127.13) -19.73 [ -54.91, 15.45 ]
Juergens 2004 58 32 (20) 57 40 (30) -8.00 [ -17.34, 1.34 ]
Machnik 2012 91 33.6 (14.2) 110 68.1 (34.1) -34.50 [ -41.51, -27.49 ]
Magosaki 1999 120 105.6 (129.6) 120 110.4 (124.8) -4.80 [ -36.99, 27.39 ]
Silber 1998 74 98.4 (100.8) 76 124.8 (165.6) -26.40 [ -70.14, 17.34 ]
Wong 2009 264 16.8 (19.8) 133 19.4 (29.2) -2.60 [ -8.11, 2.91 ]
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Analysis 2.1. Comparison 2 Metal clip-based VCD versus manual or mechanical compression (sheath size ≤
9 Fr), Outcome 1 Time to haemostasis (minutes).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 2 Metal clip-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 1 Time to haemostasis (minutes)
Study or subgroup VCD Compression
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ansel 2006 (1) 125 3.3 (2.6) 63 19.3 (5.7) 21.4 % -16.00 [ -17.48, -14.52 ]
Ansel 2006 (2) 118 5.5 (5.1) 56 22.3 (9.9) 17.2 % -16.80 [ -19.55, -14.05 ]
Hermiller 2005 135 1.46 (4.52) 72 15.47 (11.43) 17.2 % -14.01 [ -16.76, -11.26 ]
Hermiller 2006 184 7.95 (28.2) 91 20.06 (35.3) 5.3 % -12.11 [ -20.43, -3.79 ]
Perlowski 2011 39 2.98 (5.77) 42 19.53 (8.74) 15.7 % -16.55 [ -19.75, -13.35 ]
Sun 2009 469 3.2 (1.85) 271 15.46 (5.8) 23.2 % -12.26 [ -12.97, -11.55 ]
Total (95% CI) 1070 595 100.0 % -14.81 [ -16.98, -12.63 ]
Heterogeneity: Tau2 = 5.19; Chi2 = 31.53, df = 5 (P<0.00001); I2 =84%
Test for overall effect: Z = 13.33 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Metal clip-based VCD versus manual or mechanical compression (sheath size ≤
9 Fr), Outcome 2 Time to mobilisation (hours).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 2 Metal clip-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 2 Time to mobilisation (hours)
Study or subgroup VCD Compression
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ansel 2006 (1) 125 2.4 (3.3) 63 6 (5.2) -3.60 [ -5.01, -2.19 ]
Ansel 2006 (2) 118 3.4 (4.5) 56 7.6 (7) -4.20 [ -6.21, -2.19 ]
Hermiller 2005 131 2.72 (1.74) 70 4.49 (2.25) -1.77 [ -2.38, -1.16 ]
Sun 2009 469 4.84 (1.6) 271 20.3 (6.49) -15.46 [ -16.25, -14.67 ]
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Analysis 2.3. Comparison 2 Metal clip-based VCD versus manual or mechanical compression (sheath size ≤
9 Fr), Outcome 3 Major adverse event (any time).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 2 Metal clip-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 3 Major adverse event (any time)
Study or subgroup VCD Compression Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mortality
Hermiller 2005 0/136 0/72 Not estimable
Hermiller 2006 0/184 0/91 Not estimable
Perlowski 2011 0/39 0/42 Not estimable
Subtotal (95% CI) 359 205 Not estimable
Total events: 0 (VCD), 0 (Compression)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Vascular injury requiring vascular repair by surgical or non-surgical techniques
Deuling 2008 0/150 0/150 Not estimable
Hermiller 2005 0/136 0/72 Not estimable
Hermiller 2006 1/184 1/91 100.0 % 0.49 [ 0.03, 7.95 ]
Subtotal (95% CI) 470 313 100.0 % 0.49 [ 0.03, 7.95 ]
Total events: 1 (VCD), 1 (Compression)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
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Analysis 2.4. Comparison 2 Metal clip-based VCD versus manual or mechanical compression (sheath size ≤
9 Fr), Outcome 4 Infection.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 2 Metal clip-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 4 Infection
Study or subgroup VCD Compression Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Deuling 2008 0/150 0/150 Not estimable
Hermiller 2005 0/136 0/72 Not estimable
Hermiller 2006 0/184 0/91 Not estimable
Total (95% CI) 470 313 Not estimable
Total events: 0 (VCD), 0 (Compression)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Metal clip-based VCD versus manual or mechanical compression (sheath size ≤
9 Fr), Outcome 5 Groin haematoma.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 2 Metal clip-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 5 Groin haematoma
Study or subgroup VCD Compression Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Deuling 2008 17/150 14/150 41.1 % 1.24 [ 0.59, 2.62 ]
Hermiller 2005 1/136 1/72 4.3 % 0.53 [ 0.03, 8.53 ]
Hermiller 2006 8/184 7/91 29.7 % 0.55 [ 0.19, 1.55 ]
Sun 2009 4/469 6/271 25.0 % 0.38 [ 0.11, 1.36 ]
Total (95% CI) 939 584 100.0 % 0.79 [ 0.46, 1.34 ]
Total events: 30 (VCD), 28 (Compression)
Heterogeneity: Chi2 = 3.24, df = 3 (P = 0.36); I2 =7%
Test for overall effect: Z = 0.87 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Metal clip-based VCD versus manual or mechanical compression (sheath size ≤
9 Fr), Outcome 6 Pseudoaneurysm.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 2 Metal clip-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 6 Pseudoaneurysm
Study or subgroup VCD Compression Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ansel 2006 3/243 0/119 13.7 % 3.48 [ 0.18, 67.88 ]
Deuling 2008 1/150 1/150 20.6 % 1.00 [ 0.06, 16.14 ]
Hermiller 2005 0/136 0/72 Not estimable
Hermiller 2006 0/184 0/91 Not estimable
Perlowski 2011 0/39 0/42 Not estimable
Sun 2009 0/469 2/271 65.7 % 0.11 [ 0.01, 2.40 ]
Total (95% CI) 1221 745 100.0 % 0.76 [ 0.20, 2.89 ]
Total events: 4 (VCD), 3 (Compression)
Heterogeneity: Chi2 = 2.53, df = 2 (P = 0.28); I2 =21%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Metal clip-based VCD versus manual or mechanical compression (sheath size ≤
9 Fr), Outcome 7 Arterio-venous fistula.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 2 Metal clip-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 7 Arterio-venous ﬁstula
Study or subgroup VCD Compression Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hermiller 2005 0/136 0/72 Not estimable
Hermiller 2006 0/184 0/91 Not estimable
Perlowski 2011 0/39 0/42 Not estimable
Total (95% CI) 359 205 Not estimable
Total events: 0 (VCD), 0 (Compression)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Metal clip-based VCD versus manual or mechanical compression (sheath size ≤
9 Fr), Outcome 8 Deep vein thrombosis.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 2 Metal clip-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 8 Deep vein thrombosis
Study or subgroup VCD Compression Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hermiller 2005 0/136 0/72 Not estimable
Hermiller 2006 0/184 0/91 Not estimable
Total (95% CI) 320 163 Not estimable
Total events: 0 (VCD), 0 (Compression)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 2.9. Comparison 2 Metal clip-based VCD versus manual or mechanical compression (sheath size ≤
9 Fr), Outcome 9 Limb ischaemia.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 2 Metal clip-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 9 Limb ischaemia
Study or subgroup VCD Compression Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hermiller 2005 0/136 0/72 Not estimable
Hermiller 2006 0/184 0/91 Not estimable
Total (95% CI) 320 163 Not estimable
Total events: 0 (VCD), 0 (Compression)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Suture-based VCD versus manual or mechanical compression (sheath size ≤ 9
Fr), Outcome 1 Time to haemostasis (minutes).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 3 Suture-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 1 Time to haemostasis (minutes)
Study or subgroup VCD Compression
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Amine 1999 50 6 (10) 50 20 (6) 13.4 % -14.00 [ -17.23, -10.77 ]
Gerckens 1998 298 7.8 (4.8) 292 19.6 (13.2) 16.9 % -11.80 [ -13.41, -10.19 ]
Noguchi 2000 30 10 (3) 30 27 (9) 13.0 % -17.00 [ -20.39, -13.61 ]
Rickli 2002 96 7.1 (3.4) 97 22.9 (14) 14.2 % -15.80 [ -18.67, -12.93 ]
Sun 2009 183 4.57 (1.81) 271 15.46 (5.8) 18.1 % -10.89 [ -11.63, -10.15 ]
Tron 2003 91 8 (6) 76 25 (11) 14.5 % -17.00 [ -19.76, -14.24 ]
Wetter 2000 50 7.3 (3.2) 50 25.7 (17.4) 9.9 % -18.40 [ -23.30, -13.50 ]
Total (95% CI) 798 866 100.0 % -14.58 [ -16.85, -12.32 ]
Heterogeneity: Tau2 = 7.27; Chi2 = 44.39, df = 6 (P<0.00001); I2 =86%
Test for overall effect: Z = 12.60 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Suture-based VCD versus manual or mechanical compression (sheath size ≤ 9
Fr), Outcome 2 Time to mobilisation (hours).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 3 Suture-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 2 Time to mobilisation (hours)
Study or subgroup VCD Compression
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Amine 1999 50 5 (9) 50 24 (5) -19.00 [ -21.85, -16.15 ]
Carere 2000 50 7 (1.2) 50 15 (3.9) -8.00 [ -9.13, -6.87 ]
Gerckens 1998 298 4.5 (6.5) 292 17.8 (5) -13.30 [ -14.23, -12.37 ]
Noguchi 2000 30 2.2 (0.9) 30 11 (1.4) -8.80 [ -9.40, -8.20 ]
Rickli 2002 96 6.8 (5) 97 18.4 (2.1) -11.60 [ -12.68, -10.52 ]
Sun 2009 183 5.02 (1.57) 271 20.3 (6.49) -15.28 [ -16.09, -14.47 ]
Wetter 2000 50 6.2 (4.7) 50 18.3 (2.2) -12.10 [ -13.54, -10.66 ]
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Analysis 3.3. Comparison 3 Suture-based VCD versus manual or mechanical compression (sheath size ≤ 9
Fr), Outcome 3 Major adverse event (any time).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 3 Suture-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 3 Major adverse event (any time)
Study or subgroup VCD Compression Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mortality
Noguchi 2000 0/30 0/30 Not estimable
2 Vascular injury requiring vascular repair
Noguchi 2000 0/30 0/30 Not estimable
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Analysis 3.4. Comparison 3 Suture-based VCD versus manual or mechanical compression (sheath size ≤ 9
Fr), Outcome 4 Infection.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 3 Suture-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 4 Infection
Study or subgroup VCD Compression Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Amine 1999 0/50 0/50 Not estimable
Gerckens 1998 1/298 1/292 67.9 % 0.98 [ 0.06, 15.74 ]
Noguchi 2000 1/30 0/30 32.1 % 3.10 [ 0.12, 79.23 ]
Total (95% CI) 378 372 100.0 % 1.66 [ 0.22, 12.71 ]
Total events: 2 (VCD), 1 (Compression)
Heterogeneity: Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Suture-based VCD versus manual or mechanical compression (sheath size ≤ 9
Fr), Outcome 5 Groin haematoma.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 3 Suture-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 5 Groin haematoma
Study or subgroup VCD Compression Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Amine 1999 5/50 4/50 7.7 % 1.28 [ 0.32, 5.07 ]
Carere 2000 8/50 10/50 18.0 % 0.76 [ 0.27, 2.12 ]
Gerckens 1998 11/298 21/292 43.8 % 0.49 [ 0.23, 1.05 ]
Jensen 2008 3/22 1/24 1.8 % 3.63 [ 0.35, 37.83 ]
Noguchi 2000 4/30 10/30 18.6 % 0.31 [ 0.08, 1.13 ]
Sun 2009 3/183 6/271 10.2 % 0.74 [ 0.18, 2.98 ]
Total (95% CI) 633 717 100.0 % 0.65 [ 0.41, 1.02 ]
Total events: 34 (VCD), 52 (Compression)
Heterogeneity: Chi2 = 4.91, df = 5 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 1.86 (P = 0.063)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Suture-based VCD versus manual or mechanical compression (sheath size ≤ 9
Fr), Outcome 6 Retroperitoneal haemorrhage.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 3 Suture-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 6 Retroperitoneal haemorrhage
Study or subgroup VCD Compression Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martin 2008 0/63 1/67 0.35 [ 0.01, 8.73 ]
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Analysis 3.7. Comparison 3 Suture-based VCD versus manual or mechanical compression (sheath size ≤ 9
Fr), Outcome 7 Pseudoaneurysm.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 3 Suture-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 7 Pseudoaneurysm
Study or subgroup VCD Compression Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gerckens 1998 1/298 1/292 15.5 % 0.98 [ 0.06, 15.74 ]
Martin 2008 1/63 2/67 29.4 % 0.52 [ 0.05, 5.93 ]
Noguchi 2000 0/30 0/30 Not estimable
Rickli 2002 1/96 1/97 15.2 % 1.01 [ 0.06, 16.39 ]
Sun 2009 1/183 2/271 24.7 % 0.74 [ 0.07, 8.21 ]
Wetter 2000 1/50 1/50 15.1 % 1.00 [ 0.06, 16.44 ]
Total (95% CI) 720 807 100.0 % 0.79 [ 0.25, 2.53 ]
Total events: 5 (VCD), 7 (Compression)
Heterogeneity: Chi2 = 0.19, df = 4 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 Suture-based VCD versus manual or mechanical compression (sheath size ≤ 9
Fr), Outcome 8 Arterio-venous fistula.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 3 Suture-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 8 Arterio-venous ﬁstula
Study or subgroup VCD Compression Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Amine 1999 0/50 0/50 Not estimable
Gerckens 1998 0/298 1/292 100.0 % 0.33 [ 0.01, 8.02 ]
Martin 2008 0/63 0/67 Not estimable
Noguchi 2000 0/30 0/30 Not estimable
Total (95% CI) 441 439 100.0 % 0.33 [ 0.01, 8.02 ]
Total events: 0 (VCD), 1 (Compression)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 3.9. Comparison 3 Suture-based VCD versus manual or mechanical compression (sheath size ≤ 9
Fr), Outcome 9 Embolisation.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 3 Suture-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 9 Embolisation
Study or subgroup VCD Compression Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Noguchi 2000 0/30 0/30 Not estimable
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Analysis 3.10. Comparison 3 Suture-based VCD versus manual or mechanical compression (sheath size ≤ 9
Fr), Outcome 10 Limb ischaemia.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 3 Suture-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 10 Limb ischaemia
Study or subgroup VCD Compression Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gerckens 1998 0/298 1/292 76.2 % 0.33 [ 0.01, 8.02 ]
Martin 2008 1/63 0/67 23.8 % 3.24 [ 0.13, 81.01 ]
Total (95% CI) 361 359 100.0 % 1.02 [ 0.14, 7.22 ]
Total events: 1 (VCD), 1 (Compression)
Heterogeneity: Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 3.11. Comparison 3 Suture-based VCD versus manual or mechanical compression (sheath size ≤ 9
Fr), Outcome 11 Length of hospital stay (hours).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 3 Suture-based VCD versus manual or mechanical compression (sheath size≤ 9 Fr)
Outcome: 11 Length of hospital stay (hours)
Study or subgroup VCD Compression
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Carere 2000 50 11 (6.2) 50 22 (3.8) 39.7 % -11.00 [ -13.02, -8.98 ]
Noguchi 2000 30 52.8 (9.6) 30 74.4 (16.8) 32.4 % -21.60 [ -28.52, -14.68 ]
Tron 2003 91 39 (40) 76 40 (20) 27.8 % -1.00 [ -10.37, 8.37 ]
Total (95% CI) 171 156 100.0 % -11.66 [ -20.46, -2.85 ]
Heterogeneity: Tau2 = 49.73; Chi2 = 13.22, df = 2 (P = 0.001); I2 =85%
Test for overall effect: Z = 2.59 (P = 0.0095)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Collagen-based VCD versus metal clip-based VCD: AngioSeal versus StarClose,
Outcome 1 Major adverse event (any time).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 4 Collagen-based VCD versus metal clip-based VCD: AngioSeal versus StarClose
Outcome: 1 Major adverse event (any time)
Study or subgroup AngioSeal StarClose Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mortality
Rastan 2008 0/285 0/286 Not estimable
Subtotal (95% CI) 285 286 Not estimable
Total events: 0 (AngioSeal), 0 (StarClose)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Vascular injury requiring vascular repair by surgical or non-surgical techniques
Deuling 2008 0/150 0/150 Not estimable
Rastan 2008 0/285 1/286 100.0 % 0.33 [ 0.01, 8.22 ]
Subtotal (95% CI) 435 436 100.0 % 0.33 [ 0.01, 8.22 ]
Total events: 0 (AngioSeal), 1 (StarClose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
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Analysis 4.2. Comparison 4 Collagen-based VCD versus metal clip-based VCD: AngioSeal versus StarClose,
Outcome 2 Infection.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 4 Collagen-based VCD versus metal clip-based VCD: AngioSeal versus StarClose
Outcome: 2 Infection
Study or subgroup AngioSeal StarClose Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Deuling 2008 0/150 0/150 Not estimable
Veasey 2008 0/208 0/193 Not estimable
Total (95% CI) 358 343 Not estimable
Total events: 0 (AngioSeal), 0 (StarClose)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Collagen-based VCD versus metal clip-based VCD: AngioSeal versus StarClose,
Outcome 3 Groin haematoma.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 4 Collagen-based VCD versus metal clip-based VCD: AngioSeal versus StarClose
Outcome: 3 Groin haematoma
Study or subgroup AngioSeal StarClose Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Deuling 2008 15/150 14/150 67.9 % 1.08 [ 0.50, 2.32 ]
Rastan 2008 2/285 6/286 32.1 % 0.33 [ 0.07, 1.65 ]
Total (95% CI) 435 436 100.0 % 0.84 [ 0.43, 1.65 ]
Total events: 17 (AngioSeal), 20 (StarClose)
Heterogeneity: Chi2 = 1.71, df = 1 (P = 0.19); I2 =41%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours AngioSeal Favours StarClose
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Analysis 4.4. Comparison 4 Collagen-based VCD versus metal clip-based VCD: AngioSeal versus StarClose,
Outcome 4 Retroperitoneal haemorrhage.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 4 Collagen-based VCD versus metal clip-based VCD: AngioSeal versus StarClose
Outcome: 4 Retroperitoneal haemorrhage
Study or subgroup AngioSeal StarClose Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Veasey 2008 0/208 0/193 Not estimable
0.01 0.1 1 10 100
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Analysis 4.5. Comparison 4 Collagen-based VCD versus metal clip-based VCD: AngioSeal versus StarClose,
Outcome 5 Pseudoaneurysm.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 4 Collagen-based VCD versus metal clip-based VCD: AngioSeal versus StarClose
Outcome: 5 Pseudoaneurysm
Study or subgroup AngioSeal StarClose Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Deuling 2008 1/150 1/150 12.6 % 1.00 [ 0.06, 16.14 ]
Rastan 2008 3/285 7/286 87.4 % 0.42 [ 0.11, 1.66 ]
Veasey 2008 0/208 0/193 Not estimable
Total (95% CI) 643 629 100.0 % 0.50 [ 0.15, 1.66 ]
Total events: 4 (AngioSeal), 8 (StarClose)
Heterogeneity: Chi2 = 0.30, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.14 (P = 0.26)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours AngioSeal Favours StarClose
Analysis 4.6. Comparison 4 Collagen-based VCD versus metal clip-based VCD: AngioSeal versus StarClose,
Outcome 6 Arterio-venous fistula.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 4 Collagen-based VCD versus metal clip-based VCD: AngioSeal versus StarClose
Outcome: 6 Arterio-venous ﬁstula
Study or subgroup AngioSeal StarClose Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rastan 2008 1/285 0/286 3.02 [ 0.12, 74.47 ]
0.001 0.01 0.1 1 10 100 1000
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Analysis 4.7. Comparison 4 Collagen-based VCD versus metal clip-based VCD: AngioSeal versus StarClose,
Outcome 7 Limb ischaemia.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 4 Collagen-based VCD versus metal clip-based VCD: AngioSeal versus StarClose
Outcome: 7 Limb ischaemia
Study or subgroup AngioSeal StarClose Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Veasey 2008 0/208 0/193 Not estimable
0.01 0.1 1 10 100
Favours AngioSeal Favours StarClose
Analysis 4.8. Comparison 4 Collagen-based VCD versus metal clip-based VCD: AngioSeal versus StarClose,
Outcome 8 Technical failure of VCD.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 4 Collagen-based VCD versus metal clip-based VCD: AngioSeal versus StarClose
Outcome: 8 Technical failure of VCD
Study or subgroup AngioSeal StarClose Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Deuling 2008 2/150 9/150 17.3 % 0.21 [ 0.04, 1.00 ]
Rastan 2008 14/285 34/286 63.0 % 0.38 [ 0.20, 0.73 ]
Veasey 2008 6/208 10/193 19.7 % 0.54 [ 0.19, 1.53 ]
Total (95% CI) 643 629 100.0 % 0.38 [ 0.23, 0.64 ]
Total events: 22 (AngioSeal), 53 (StarClose)
Heterogeneity: Chi2 = 1.00, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 3.65 (P = 0.00026)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Collagen-based VCD versus suture-based VCD (sheath size ≤ 9 Fr), Outcome 1
Infection.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 5 Collagen-based VCD versus suture-based VCD (sheath size≤ 9 Fr)
Outcome: 1 Infection
Study or subgroup Collagen VCD Suture VCD Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kalsch 2008 0/212 0/154 Not estimable
0.01 0.1 1 10 100
Favours collagen VCD Favours suture VCD
Analysis 5.2. Comparison 5 Collagen-based VCD versus suture-based VCD (sheath size ≤ 9 Fr), Outcome 2
Groin haematoma.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 5 Collagen-based VCD versus suture-based VCD (sheath size≤ 9 Fr)
Outcome: 2 Groin haematoma
Study or subgroup Collagen VCD Suture VCD Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hattab 2012 5/50 3/50 12.6 % 1.74 [ 0.39, 7.71 ]
Jensen 2008 4/22 3/22 11.4 % 1.41 [ 0.28, 7.18 ]
Kalsch 2008 25/212 16/154 76.0 % 1.15 [ 0.59, 2.24 ]
Total (95% CI) 284 226 100.0 % 1.26 [ 0.71, 2.22 ]
Total events: 34 (Collagen VCD), 22 (Suture VCD)
Heterogeneity: Chi2 = 0.27, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 Collagen-based VCD versus suture-based VCD (sheath size ≤ 9 Fr), Outcome 3
Retroperitoneal haemorrhage.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 5 Collagen-based VCD versus suture-based VCD (sheath size≤ 9 Fr)
Outcome: 3 Retroperitoneal haemorrhage
Study or subgroup Collagen VCD Suture VCD Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martin 2008 1/70 0/63 2.74 [ 0.11, 68.51 ]
0.001 0.01 0.1 1 10 100 1000
Favours collagen VCD Favours suture VCD
Analysis 5.4. Comparison 5 Collagen-based VCD versus suture-based VCD (sheath size ≤ 9 Fr), Outcome 4
Pseudoaneurysm.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 5 Collagen-based VCD versus suture-based VCD (sheath size≤ 9 Fr)
Outcome: 4 Pseudoaneurysm
Study or subgroup Collagen VCD Suture VCD Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martin 2008 0/70 1/63 0.30 [ 0.01, 7.39 ]
0.001 0.01 0.1 1 10 100 1000
Favours collagen VCD Favours suture VCD
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Analysis 5.5. Comparison 5 Collagen-based VCD versus suture-based VCD (sheath size ≤ 9 Fr), Outcome 5
Arterio-venous fistula.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 5 Collagen-based VCD versus suture-based VCD (sheath size≤ 9 Fr)
Outcome: 5 Arterio-venous ﬁstula
Study or subgroup Collagen VCD Suture VCD Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martin 2008 0/70 0/63 Not estimable
0.01 0.1 1 10 100
Favours collagen VCD Favours suture VCD
Analysis 5.6. Comparison 5 Collagen-based VCD versus suture-based VCD (sheath size ≤ 9 Fr), Outcome 6
Technical failure of VCD.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 5 Collagen-based VCD versus suture-based VCD (sheath size≤ 9 Fr)
Outcome: 6 Technical failure of VCD
Study or subgroup Collagen VCD Suture VCD Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hattab 2012 4/50 6/50 33.5 % 0.64 [ 0.17, 2.41 ]
Jensen 2008 0/22 0/22 Not estimable
Kalsch 2008 0/212 9/154 66.5 % 0.04 [ 0.00, 0.62 ]
Total (95% CI) 284 226 100.0 % 0.24 [ 0.08, 0.69 ]
Total events: 4 (Collagen VCD), 15 (Suture VCD)
Heterogeneity: Chi2 = 3.80, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 2.64 (P = 0.0082)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Metal clip-based VCD versus suture-based VCD: StarClose versus PerClose,
Outcome 1 Time to haemostasis.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 6 Metal clip-based VCD versus suture-based VCD: StarClose versus PerClose
Outcome: 1 Time to haemostasis
Study or subgroup StarClose PerClose
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sun 2009 286 2.33 (1.24) 183 4.57 (1.81) -2.24 [ -2.54, -1.94 ]
-2 -1 0 1 2
Favours StarClose Favours PerClose
Analysis 6.2. Comparison 6 Metal clip-based VCD versus suture-based VCD: StarClose versus PerClose,
Outcome 2 Time to mobilisation.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 6 Metal clip-based VCD versus suture-based VCD: StarClose versus PerClose
Outcome: 2 Time to mobilisation
Study or subgroup StarClose PerClose
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sun 2009 286 4.72 (1.61) 183 5.02 (1.57) -0.30 [ -0.59, -0.01 ]
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Analysis 6.3. Comparison 6 Metal clip-based VCD versus suture-based VCD: StarClose versus PerClose,
Outcome 3 Groin haematoma.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 6 Metal clip-based VCD versus suture-based VCD: StarClose versus PerClose
Outcome: 3 Groin haematoma
Study or subgroup StarClose PerClose Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sun 2009 1/286 3/183 0.21 [ 0.02, 2.04 ]
0.002 0.1 1 10 500
Favours StarClose Favours PerClose
Analysis 6.4. Comparison 6 Metal clip-based VCD versus suture-based VCD: StarClose versus PerClose,
Outcome 4 Pseudoaneurysm.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 6 Metal clip-based VCD versus suture-based VCD: StarClose versus PerClose
Outcome: 4 Pseudoaneurysm
Study or subgroup StarClose PerClose Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sun 2009 0/286 1/183 0.21 [ 0.01, 5.24 ]
0.002 0.1 1 10 500
Favours StarClose Favours PerClose
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Analysis 6.5. Comparison 6 Metal clip-based VCD versus suture-based VCD: StarClose versus PerClose,
Outcome 5 Technical failure of VCD.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 6 Metal clip-based VCD versus suture-based VCD: StarClose versus PerClose
Outcome: 5 Technical failure of VCD
Study or subgroup StarClose PerClose Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sun 2009 6/286 11/183 0.34 [ 0.12, 0.92 ]
0.01 0.1 1 10 100
Favours StarClose Favours PerClose
Analysis 7.1. Comparison 7 Disc-based VCD versus suture-based VCD: Boomerang versus PerClose,
Outcome 1 Time to haemostasis (minutes).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 7 Disc-based VCD versus suture-based VCD: Boomerang versus PerClose
Outcome: 1 Time to haemostasis (minutes)
Study or subgroup Boomerang PerClose
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Chen 2013 30 40.07 (4.04) 30 8.02 (7.23) 32.05 [ 29.09, 35.01 ]
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Analysis 7.2. Comparison 7 Disc-based VCD versus suture-based VCD: Boomerang versus PerClose,
Outcome 2 Time to mobilisation (hours).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 7 Disc-based VCD versus suture-based VCD: Boomerang versus PerClose
Outcome: 2 Time to mobilisation (hours)
Study or subgroup Boomerang PerClose
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Chen 2013 29 2.05 (0.17) 29 2.09 (0.2) -0.04 [ -0.14, 0.06 ]
-0.5 -0.25 0 0.25 0.5
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Analysis 7.3. Comparison 7 Disc-based VCD versus suture-based VCD: Boomerang versus PerClose,
Outcome 3 Groin haematoma.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 7 Disc-based VCD versus suture-based VCD: Boomerang versus PerClose
Outcome: 3 Groin haematoma
Study or subgroup Boomerang PerClose Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chen 2013 4/30 0/30 10.36 [ 0.53, 201.45 ]
0.001 0.01 0.1 1 10 100 1000
Favours Boomerang Favours PerClose
170Vascular closure devices for femoral arterial puncture site haemostasis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 7.4. Comparison 7 Disc-based VCD versus suture-based VCD: Boomerang versus PerClose,
Outcome 4 Technical failure of VCD.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 7 Disc-based VCD versus suture-based VCD: Boomerang versus PerClose
Outcome: 4 Technical failure of VCD
Study or subgroup Boomerang PerClose Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chen 2013 2/30 1/30 2.07 [ 0.18, 24.15 ]
0.002 0.1 1 10 500
Favours Boomerang Favours PerClose
Analysis 8.1. Comparison 8 Collagen-based VCD versus collagen-based VCD: AngioSeal versus VasoSeal,
Outcome 1 Time to haemostasis (minutes).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 8 Collagen-based VCD versus collagen-based VCD: AngioSeal versus VasoSeal
Outcome: 1 Time to haemostasis (minutes)
Study or subgroup AngioSeal VasoSeal
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Michalis 2002 (1) 243 18.1 (5.8) 228 7 (3.2) 11.10 [ 10.26, 11.94 ]
Michalis 2002 (2) 47 19.8 (7.7) 52 7.8 (3.6) 12.00 [ 9.59, 14.41 ]
Shammas 2002 (3) 49 20.51 (4.36) 46 18.59 (11.57) 1.92 [ -1.64, 5.48 ]
Shammas 2002 (4) 28 24.23 (12.7) 27 19.57 (2.27) 4.66 [ -0.12, 9.44 ]
-10 -5 0 5 10
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(1) Diagnostic procedure
(2) Interventional procedure
(3) Diagnostic procedure
(4) Interventional procedure
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Analysis 8.2. Comparison 8 Collagen-based VCD versus collagen-based VCD: AngioSeal versus VasoSeal,
Outcome 2 Time to mobilisation (hours).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 8 Collagen-based VCD versus collagen-based VCD: AngioSeal versus VasoSeal
Outcome: 2 Time to mobilisation (hours)
Study or subgroup AngioSeal VasoSeal
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Michalis 2002 (1) 47 2.91 (1.04) 52 3.39 (0.81) 32.9 % -0.48 [ -0.85, -0.11 ]
Michalis 2002 (2) 243 1.88 (0.51) 228 2.36 (0.71) 39.4 % -0.48 [ -0.59, -0.37 ]
Shammas 2002 (3) 49 2.43 (2.07) 46 1.83 (1) 24.0 % 0.60 [ -0.05, 1.25 ]
Shammas 2002 (4) 28 10.12 (5.74) 27 8.11 (3.34) 3.7 % 2.01 [ -0.46, 4.48 ]
Total (95% CI) 367 353 100.0 % -0.13 [ -0.63, 0.37 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 14.20, df = 3 (P = 0.003); I2 =79%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
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Analysis 8.3. Comparison 8 Collagen-based VCD versus collagen-based VCD: AngioSeal versus VasoSeal,
Outcome 3 Major adverse event (any time).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 8 Collagen-based VCD versus collagen-based VCD: AngioSeal versus VasoSeal
Outcome: 3 Major adverse event (any time)
Study or subgroup AngioSeal VasoSeal Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mortality
Shammas 2002 (1) 0/28 0/27 Not estimable
Shammas 2002 (2) 0/49 0/46 Not estimable
Subtotal (95% CI) 77 73 Not estimable
Total events: 0 (AngioSeal), 0 (VasoSeal)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Vascular injury requiring vascular repair by surgical or non-surgical techniques
Shammas 2002 (3) 0/28 0/27 Not estimable
Shammas 2002 (4) 0/49 0/46 Not estimable
Subtotal (95% CI) 77 73 Not estimable
Total events: 0 (AngioSeal), 0 (VasoSeal)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 8.4. Comparison 8 Collagen-based VCD versus collagen-based VCD: AngioSeal versus VasoSeal,
Outcome 4 Infection.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 8 Collagen-based VCD versus collagen-based VCD: AngioSeal versus VasoSeal
Outcome: 4 Infection
Study or subgroup AngioSeal VasoSeal Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shammas 2002 (1) 0/49 0/46 Not estimable
Shammas 2002 (2) 0/28 0/27 Not estimable
Total (95% CI) 77 73 Not estimable
Total events: 0 (AngioSeal), 0 (VasoSeal)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours AngioSeal Favours VasoSeal
(1) Diagnostic procedure
(2) Interventional procedure
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Analysis 8.5. Comparison 8 Collagen-based VCD versus collagen-based VCD: AngioSeal versus VasoSeal,
Outcome 5 Groin haematoma.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 8 Collagen-based VCD versus collagen-based VCD: AngioSeal versus VasoSeal
Outcome: 5 Groin haematoma
Study or subgroup AngioSeal VasoSeal Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Michalis 2002 (1) 2/47 5/52 47.1 % 0.42 [ 0.08, 2.26 ]
Michalis 2002 (2) 3/243 5/228 52.9 % 0.56 [ 0.13, 2.36 ]
Shammas 2002 (3) 0/28 0/27 Not estimable
Shammas 2002 (4) 0/49 0/46 Not estimable
Total (95% CI) 367 353 100.0 % 0.49 [ 0.16, 1.47 ]
Total events: 5 (AngioSeal), 10 (VasoSeal)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 8.6. Comparison 8 Collagen-based VCD versus collagen-based VCD: AngioSeal versus VasoSeal,
Outcome 6 Retroperitoneal haemorrhage.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 8 Collagen-based VCD versus collagen-based VCD: AngioSeal versus VasoSeal
Outcome: 6 Retroperitoneal haemorrhage
Study or subgroup AngioSeal VasoSeal Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Michalis 2002 (1) 0/47 1/52 100.0 % 0.36 [ 0.01, 9.09 ]
Michalis 2002 (2) 0/243 0/228 Not estimable
Shammas 2002 (3) 0/49 0/46 Not estimable
Shammas 2002 (4) 0/28 0/27 Not estimable
Total (95% CI) 367 353 100.0 % 0.36 [ 0.01, 9.09 ]
Total events: 0 (AngioSeal), 1 (VasoSeal)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours AngioSeal Favours VasoSeal
(1) Interventional procedure
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Analysis 8.7. Comparison 8 Collagen-based VCD versus collagen-based VCD: AngioSeal versus VasoSeal,
Outcome 7 Pseudoaneurysm.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 8 Collagen-based VCD versus collagen-based VCD: AngioSeal versus VasoSeal
Outcome: 7 Pseudoaneurysm
Study or subgroup AngioSeal VasoSeal Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shammas 2002 (1) 0/49 1/46 100.0 % 0.31 [ 0.01, 7.71 ]
Shammas 2002 (2) 0/28 0/27 Not estimable
Total (95% CI) 77 73 100.0 % 0.31 [ 0.01, 7.71 ]
Total events: 0 (AngioSeal), 1 (VasoSeal)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 8.8. Comparison 8 Collagen-based VCD versus collagen-based VCD: AngioSeal versus VasoSeal,
Outcome 8 Arterio-venous fistula.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 8 Collagen-based VCD versus collagen-based VCD: AngioSeal versus VasoSeal
Outcome: 8 Arterio-venous ﬁstula
Study or subgroup AngioSeal VasoSeal Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shammas 2002 (1) 0/28 0/27 Not estimable
Shammas 2002 (2) 0/49 0/46 Not estimable
Total (95% CI) 77 73 Not estimable
Total events: 0 (AngioSeal), 0 (VasoSeal)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 8.9. Comparison 8 Collagen-based VCD versus collagen-based VCD: AngioSeal versus VasoSeal,
Outcome 9 Technical failure of VCD.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 8 Collagen-based VCD versus collagen-based VCD: AngioSeal versus VasoSeal
Outcome: 9 Technical failure of VCD
Study or subgroup AngioSeal VasoSeal Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Michalis 2002 (1) 2/47 4/52 14.7 % 0.53 [ 0.09, 3.06 ]
Michalis 2002 (2) 17/243 22/228 85.3 % 0.70 [ 0.36, 1.36 ]
Total (95% CI) 290 280 100.0 % 0.68 [ 0.37, 1.26 ]
Total events: 19 (AngioSeal), 26 (VasoSeal)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 Collagen-based VCD versus collagen-based VCD: AngioSeal versus Mynx,
Outcome 1 Major adverse event (any time).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 9 Collagen-based VCD versus collagen-based VCD: AngioSeal versus Mynx
Outcome: 1 Major adverse event (any time)
Study or subgroup AngioSeal Mynx Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vascular injury requiring vascular repair by surgical or non-surgical techniques
Fargen 2011 0/32 0/32 Not estimable
0.005 0.1 1 10 200
Favours AngioSeal Favours Mynx
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Analysis 9.2. Comparison 9 Collagen-based VCD versus collagen-based VCD: AngioSeal versus Mynx,
Outcome 2 Infection.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 9 Collagen-based VCD versus collagen-based VCD: AngioSeal versus Mynx
Outcome: 2 Infection
Study or subgroup AngioSeal Mynx Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fargen 2011 0/32 0/32 Not estimable
0.01 0.1 1 10 100
Favours AngioSeal Favours Mynx
Analysis 9.3. Comparison 9 Collagen-based VCD versus collagen-based VCD: AngioSeal versus Mynx,
Outcome 3 Groin haematoma.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 9 Collagen-based VCD versus collagen-based VCD: AngioSeal versus Mynx
Outcome: 3 Groin haematoma
Study or subgroup Favours AngioSeal Mynx Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fargen 2011 0/32 0/32 Not estimable
0.005 0.1 1 10 200
Favours AngioSeal Favours Mynx
180Vascular closure devices for femoral arterial puncture site haemostasis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 10.1. Comparison 10 Collagen-based VCD versus collagen-based VCD: AngioSeal versus Duett,
Outcome 1 Time to haemostasis (minutes).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 10 Collagen-based VCD versus collagen-based VCD: AngioSeal versus Duett
Outcome: 1 Time to haemostasis (minutes)
Study or subgroup AngioSeal Duett
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Michalis 2002 (1) 47 19.8 (7.7) 47 7.8 (3.6) 11.0 % 12.00 [ 9.57, 14.43 ]
Michalis 2002 (2) 243 18.1 (5.8) 234 7.5 (3.5) 89.0 % 10.60 [ 9.74, 11.46 ]
Total (95% CI) 290 281 100.0 % 10.75 [ 9.95, 11.56 ]
Heterogeneity: Chi2 = 1.13, df = 1 (P = 0.29); I2 =12%
Test for overall effect: Z = 26.10 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 10.2. Comparison 10 Collagen-based VCD versus collagen-based VCD: AngioSeal versus Duett,
Outcome 2 Time to mobilisation (hours).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 10 Collagen-based VCD versus collagen-based VCD: AngioSeal versus Duett
Outcome: 2 Time to mobilisation (hours)
Study or subgroup AngioSeal Duett
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Michalis 2002 (1) 47 2.91 (1.04) 47 3.23 (0.88) 7.5 % -0.32 [ -0.71, 0.07 ]
Michalis 2002 (2) 243 1.88 (0.51) 234 2.28 (0.71) 92.5 % -0.40 [ -0.51, -0.29 ]
Total (95% CI) 290 281 100.0 % -0.39 [ -0.50, -0.29 ]
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 7.22 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 10.3. Comparison 10 Collagen-based VCD versus collagen-based VCD: AngioSeal versus Duett,
Outcome 3 Groin haematoma.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 10 Collagen-based VCD versus collagen-based VCD: AngioSeal versus Duett
Outcome: 3 Groin haematoma
Study or subgroup AngioSeal Duett Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Michalis 2002 (1) 2/47 1/47 19.2 % 2.04 [ 0.18, 23.35 ]
Michalis 2002 (2) 3/243 4/234 80.8 % 0.72 [ 0.16, 3.25 ]
Total (95% CI) 290 281 100.0 % 0.97 [ 0.28, 3.40 ]
Total events: 5 (AngioSeal), 5 (Duett)
Heterogeneity: Chi2 = 0.51, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 10.4. Comparison 10 Collagen-based VCD versus collagen-based VCD: AngioSeal versus Duett,
Outcome 4 Retroperitoneal haemorrhage.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 10 Collagen-based VCD versus collagen-based VCD: AngioSeal versus Duett
Outcome: 4 Retroperitoneal haemorrhage
Study or subgroup AngioSeal Duett Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Michalis 2002 (1) 0/243 0/234 Not estimable
Michalis 2002 (2) 0/47 0/47 Not estimable
Total (95% CI) 290 281 Not estimable
Total events: 0 (AngioSeal), 0 (Duett)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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184Vascular closure devices for femoral arterial puncture site haemostasis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 10.5. Comparison 10 Collagen-based VCD versus collagen-based VCD: AngioSeal versus Duett,
Outcome 5 Technical failure of VCD.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 10 Collagen-based VCD versus collagen-based VCD: AngioSeal versus Duett
Outcome: 5 Technical failure of VCD
Study or subgroup AngioSeal Duett Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Michalis 2002 (1) 17/243 27/234 84.2 % 0.58 [ 0.31, 1.09 ]
Michalis 2002 (2) 2/47 5/47 15.8 % 0.37 [ 0.07, 2.03 ]
Total (95% CI) 290 281 100.0 % 0.54 [ 0.30, 0.99 ]
Total events: 19 (AngioSeal), 32 (Duett)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 2.01 (P = 0.045)
Test for subgroup differences: Not applicable
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Analysis 11.1. Comparison 11 Collagen-based VCD versus collagen-based VCD: VasoSeal versus Duett,
Outcome 1 Time to haemostasis (minutes).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 11 Collagen-based VCD versus collagen-based VCD: VasoSeal versus Duett
Outcome: 1 Time to haemostasis (minutes)
Study or subgroup VasoSeal Duett
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Michalis 2002 (1) 52 7.8 (3.6) 47 8.8 (6.7) 7.5 % -1.00 [ -3.15, 1.15 ]
Michalis 2002 (2) 228 7 (3.2) 234 7.5 (3.5) 92.5 % -0.50 [ -1.11, 0.11 ]
Total (95% CI) 280 281 100.0 % -0.54 [ -1.13, 0.05 ]
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.79 (P = 0.073)
Test for subgroup differences: Not applicable
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Analysis 11.2. Comparison 11 Collagen-based VCD versus collagen-based VCD: VasoSeal versus Duett,
Outcome 2 Time to mobilisation (hours).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 11 Collagen-based VCD versus collagen-based VCD: VasoSeal versus Duett
Outcome: 2 Time to mobilisation (hours)
Study or subgroup VasoSeal Duett
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Michalis 2002 (1) 228 2.36 (0.71) 234 2.28 (0.71) 87.0 % 0.08 [ -0.05, 0.21 ]
Michalis 2002 (2) 52 3.39 (0.81) 47 3.23 (0.88) 13.0 % 0.16 [ -0.17, 0.49 ]
Total (95% CI) 280 281 100.0 % 0.09 [ -0.03, 0.21 ]
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 11.3. Comparison 11 Collagen-based VCD versus collagen-based VCD: VasoSeal versus Duett,
Outcome 3 Groin haematoma.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 11 Collagen-based VCD versus collagen-based VCD: VasoSeal versus Duett
Outcome: 3 Groin haematoma
Study or subgroup VasoSeal Duett Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Michalis 2002 (1) 5/228 4/234 80.3 % 1.29 [ 0.34, 4.86 ]
Michalis 2002 (2) 5/52 1/47 19.7 % 4.89 [ 0.55, 43.52 ]
Total (95% CI) 280 281 100.0 % 2.00 [ 0.67, 5.95 ]
Total events: 10 (VasoSeal), 5 (Duett)
Heterogeneity: Chi2 = 1.06, df = 1 (P = 0.30); I2 =6%
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 11.4. Comparison 11 Collagen-based VCD versus collagen-based VCD: VasoSeal versus Duett,
Outcome 4 Retroperitoneal haemorrhage.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 11 Collagen-based VCD versus collagen-based VCD: VasoSeal versus Duett
Outcome: 4 Retroperitoneal haemorrhage
Study or subgroup VasoSeal Duett Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Michalis 2002 (1) 1/52 0/47 100.0 % 2.77 [ 0.11, 69.59 ]
Michalis 2002 (2) 0/228 0/234 Not estimable
Total (95% CI) 280 281 100.0 % 2.77 [ 0.11, 69.59 ]
Total events: 1 (VasoSeal), 0 (Duett)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
Test for subgroup differences: Not applicable
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Favours VasoSeal Favours Duett
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(2) Diagnostic procedure
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Analysis 11.5. Comparison 11 Collagen-based VCD versus collagen-based VCD: VasoSeal versus Duett,
Outcome 5 Technical failure of VCD.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 11 Collagen-based VCD versus collagen-based VCD: VasoSeal versus Duett
Outcome: 5 Technical failure of VCD
Study or subgroup VasoSeal Duett Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Michalis 2002 (1) 4/52 5/47 16.8 % 0.70 [ 0.18, 2.78 ]
Michalis 2002 (2) 22/228 27/234 83.2 % 0.82 [ 0.45, 1.48 ]
Total (95% CI) 280 281 100.0 % 0.80 [ 0.46, 1.38 ]
Total events: 26 (VasoSeal), 32 (Duett)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 12.1. Comparison 12 Collagen-based VCD versus collagen-based VCD: FemoSeal versus ExoSeal,
Outcome 1 Major adverse event (any time).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 12 Collagen-based VCD versus collagen-based VCD: FemoSeal versus ExoSeal
Outcome: 1 Major adverse event (any time)
Study or subgroup FemoSeal ExoSeal Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vascular injury requiring vascular repair by surgical or non-surgical techniques
Schulz-Schu¨pke 2014 0/1506 0/1509 Not estimable
0.005 0.1 1 10 200
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Analysis 12.2. Comparison 12 Collagen-based VCD versus collagen-based VCD: FemoSeal versus ExoSeal,
Outcome 2 Infection.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 12 Collagen-based VCD versus collagen-based VCD: FemoSeal versus ExoSeal
Outcome: 2 Infection
Study or subgroup FemoSeal ExoSeal Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schulz-Schu¨pke 2014 1/1509 0/1506 3.00 [ 0.12, 73.60 ]
0.001 0.01 0.1 1 10 100 1000
Favours FemoSeal Favours ExoSeal
Analysis 12.3. Comparison 12 Collagen-based VCD versus collagen-based VCD: FemoSeal versus ExoSeal,
Outcome 3 Groin haematoma.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 12 Collagen-based VCD versus collagen-based VCD: FemoSeal versus ExoSeal
Outcome: 3 Groin haematoma
Study or subgroup FemoSeal ExoSeal Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schulz-Schu¨pke 2014 65/1509 80/1506 0.80 [ 0.57, 1.12 ]
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Analysis 12.4. Comparison 12 Collagen-based VCD versus collagen-based VCD: FemoSeal versus ExoSeal,
Outcome 4 Pseudoaneurysm.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 12 Collagen-based VCD versus collagen-based VCD: FemoSeal versus ExoSeal
Outcome: 4 Pseudoaneurysm
Study or subgroup FemoSeal ExoSeal Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schulz-Schu¨pke 2014 22/1509 31/1506 0.70 [ 0.41, 1.22 ]
0.005 0.1 1 10 200
Favours FemoSeal Favours ExoSeal
Analysis 12.5. Comparison 12 Collagen-based VCD versus collagen-based VCD: FemoSeal versus ExoSeal,
Outcome 5 Arteriovenous fistula.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 12 Collagen-based VCD versus collagen-based VCD: FemoSeal versus ExoSeal
Outcome: 5 Arteriovenous ﬁstula
Study or subgroup FemoSeal ExoSeal Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schulz-Schu¨pke 2014 4/1509 8/1506 0.50 [ 0.15, 1.66 ]
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Analysis 12.6. Comparison 12 Collagen-based VCD versus collagen-based VCD: FemoSeal versus ExoSeal,
Outcome 6 Limb ischaemia.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 12 Collagen-based VCD versus collagen-based VCD: FemoSeal versus ExoSeal
Outcome: 6 Limb ischaemia
Study or subgroup FemoSeal ExoSeal Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schulz-Schu¨pke 2014 0/1509 0/1506 Not estimable
0.01 0.1 1 10 100
Favours FemoSeal Favours ExoSeal
Analysis 12.7. Comparison 12 Collagen-based VCD versus collagen-based VCD: FemoSeal versus ExoSeal,
Outcome 7 Technical failure of VCD.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 12 Collagen-based VCD versus collagen-based VCD: FemoSeal versus ExoSeal
Outcome: 7 Technical failure of VCD
Study or subgroup FemoSeal ExoSeal Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schulz-Schu¨pke 2014 80/1509 184/1506 0.40 [ 0.31, 0.53 ]
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Analysis 13.1. Comparison 13 PerClose ProGlide versus ProStar XL after percutaneous EVAR, Outcome 1
Time to haemostasis (minutes).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 13 PerClose ProGlide versus ProStar XL after percutaneous EVAR
Outcome: 1 Time to haemostasis (minutes)
Study or subgroup ProGlide ProStar
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Nelson 2014 50 9.8 (17) 51 13 (19) -3.20 [ -10.23, 3.83 ]
-20 -10 0 10 20
Favours ProGlide Fabours ProStar
Analysis 13.2. Comparison 13 PerClose ProGlide versus ProStar XL after percutaneous EVAR, Outcome 2
Time to mobilisation (hours).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 13 PerClose ProGlide versus ProStar XL after percutaneous EVAR
Outcome: 2 Time to mobilisation (hours)
Study or subgroup ProGlide ProStar
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Nelson 2014 50 17 (7.2) 51 16 (9.1) 1.00 [ -2.20, 4.20 ]
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Analysis 13.3. Comparison 13 PerClose ProGlide versus ProStar XL after percutaneous EVAR, Outcome 3
Major adverse event (any time).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 13 PerClose ProGlide versus ProStar XL after percutaneous EVAR
Outcome: 3 Major adverse event (any time)
Study or subgroup ProGlide ProStar Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mortality
Nelson 2014 0/50 1/51 0.33 [ 0.01, 8.38 ]
2 Vascular injury requiring vascular repair by surgical or non-surgical techniques
Nelson 2014 1/50 3/51 0.33 [ 0.03, 3.25 ]
0.001 0.01 0.1 1 10 100 1000
Favours ProGlide Fabours ProStar
Analysis 13.4. Comparison 13 PerClose ProGlide versus ProStar XL after percutaneous EVAR, Outcome 4
Infection.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 13 PerClose ProGlide versus ProStar XL after percutaneous EVAR
Outcome: 4 Infection
Study or subgroup ProGlide ProStar Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nelson 2014 0/50 0/51 Not estimable
0.01 0.1 1 10 100
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Analysis 13.5. Comparison 13 PerClose ProGlide versus ProStar XL after percutaneous EVAR, Outcome 5
Groin haematoma.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 13 PerClose ProGlide versus ProStar XL after percutaneous EVAR
Outcome: 5 Groin haematoma
Study or subgroup ProGlide ProStar Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nelson 2014 0/50 0/51 Not estimable
0.005 0.1 1 10 200
Favours ProGlide Fabours ProStar
Analysis 13.6. Comparison 13 PerClose ProGlide versus ProStar XL after percutaneous EVAR, Outcome 6
Arterio-venous fistula.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 13 PerClose ProGlide versus ProStar XL after percutaneous EVAR
Outcome: 6 Arterio-venous ﬁstula
Study or subgroup ProGlide ProStar Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nelson 2014 0/50 0/51 Not estimable
0.01 0.1 1 10 100
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Analysis 13.7. Comparison 13 PerClose ProGlide versus ProStar XL after percutaneous EVAR, Outcome 7
Deep vein thrombosis.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 13 PerClose ProGlide versus ProStar XL after percutaneous EVAR
Outcome: 7 Deep vein thrombosis
Study or subgroup ProGlide ProStar Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nelson 2014 2/50 1/51 2.08 [ 0.18, 23.73 ]
0.001 0.01 0.1 1 10 100 1000
Favours ProGlide Fabours ProStar
Analysis 13.8. Comparison 13 PerClose ProGlide versus ProStar XL after percutaneous EVAR, Outcome 8
Limb ischaemia.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 13 PerClose ProGlide versus ProStar XL after percutaneous EVAR
Outcome: 8 Limb ischaemia
Study or subgroup ProGlide ProStar Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nelson 2014 2/50 1/51 2.08 [ 0.18, 23.73 ]
0.001 0.01 0.1 1 10 100 1000
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Analysis 13.9. Comparison 13 PerClose ProGlide versus ProStar XL after percutaneous EVAR, Outcome 9
Technical failure of VCD.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 13 PerClose ProGlide versus ProStar XL after percutaneous EVAR
Outcome: 9 Technical failure of VCD
Study or subgroup ProGlide ProStar Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nelson 2014 0/50 0/51 Not estimable
0.01 0.1 1 10 100
Favours ProGlide Fabours ProStar
Analysis 13.10. Comparison 13 PerClose ProGlide versus ProStar XL after percutaneous EVAR, Outcome
10 Length of hospital stay (hours).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 13 PerClose ProGlide versus ProStar XL after percutaneous EVAR
Outcome: 10 Length of hospital stay (hours)
Study or subgroup ProGlide ProStar
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Nelson 2014 50 1.3 (0.7) 51 1.4 (0.9) -0.10 [ -0.41, 0.21 ]
-100 -50 0 50 100
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Analysis 14.1. Comparison 14 PerClose ProGlide ProStar XL versus suture-based closure after EVAR with
open exposure of CFA, Outcome 1 Time to haemostasis (minutes).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 14 PerClose ProGlide ProStar XL versus suture-based closure after EVAR with open exposure of CFA
Outcome: 1 Time to haemostasis (minutes)
Study or subgroup VCD Suture-based closure
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Nelson 2014 101 11.42 (17.93) 50 23 (23) -11.58 [ -18.85, -4.31 ]
-50 -25 0 25 50
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Analysis 14.2. Comparison 14 PerClose ProGlide ProStar XL versus suture-based closure after EVAR with
open exposure of CFA, Outcome 2 Time to mobilisation (hours).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 14 PerClose ProGlide ProStar XL versus suture-based closure after EVAR with open exposure of CFA
Outcome: 2 Time to mobilisation (hours)
Study or subgroup VCD Suture-based closure
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Nelson 2014 101 16.5 (8.19) 50 19 (16) -2.50 [ -7.21, 2.21 ]
-20 -10 0 10 20
Favours VCD Favours suture
199Vascular closure devices for femoral arterial puncture site haemostasis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 14.3. Comparison 14 PerClose ProGlide ProStar XL versus suture-based closure after EVAR with
open exposure of CFA, Outcome 3 Major adverse event (any time).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 14 PerClose ProGlide ProStar XL versus suture-based closure after EVAR with open exposure of CFA
Outcome: 3 Major adverse event (any time)
Study or subgroup VCD Suture-based closure Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mortality
Nelson 2014 1/101 0/50 1.51 [ 0.06, 37.67 ]
2 Vascular injury requiring vascular repair by surgical or non-surgical techniques
Nelson 2014 4/101 1/50 2.02 [ 0.22, 18.57 ]
0.001 0.01 0.1 1 10 100 1000
Favours VCD Favours suture
Analysis 14.4. Comparison 14 PerClose ProGlide ProStar XL versus suture-based closure after EVAR with
open exposure of CFA, Outcome 4 Infection.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 14 PerClose ProGlide ProStar XL versus suture-based closure after EVAR with open exposure of CFA
Outcome: 4 Infection
Study or subgroup VCD Suture-based closure Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nelson 2014 0/101 0/50 Not estimable
0.01 0.1 1 10 100
Favours VCD Favours suture
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Analysis 14.5. Comparison 14 PerClose ProGlide ProStar XL versus suture-based closure after EVAR with
open exposure of CFA, Outcome 5 Groin haematoma.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 14 PerClose ProGlide ProStar XL versus suture-based closure after EVAR with open exposure of CFA
Outcome: 5 Groin haematoma
Study or subgroup VCD Suture-based closure Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nelson 2014 0/101 0/50 Not estimable
0.005 0.1 1 10 200
Favours VCD Favours suture
Analysis 14.6. Comparison 14 PerClose ProGlide ProStar XL versus suture-based closure after EVAR with
open exposure of CFA, Outcome 6 Arterio-venous fistula.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 14 PerClose ProGlide ProStar XL versus suture-based closure after EVAR with open exposure of CFA
Outcome: 6 Arterio-venous ﬁstula
Study or subgroup VCD Suture-based closure Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nelson 2014 0/101 0/50 Not estimable
0.01 0.1 1 10 100
Favours VCD Favours suture
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Analysis 14.7. Comparison 14 PerClose ProGlide ProStar XL versus suture-based closure after EVAR with
open exposure of CFA, Outcome 7 Deep vein thrombosis.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 14 PerClose ProGlide ProStar XL versus suture-based closure after EVAR with open exposure of CFA
Outcome: 7 Deep vein thrombosis
Study or subgroup VCD Suture-based closure Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nelson 2014 3/101 3/50 0.48 [ 0.09, 2.47 ]
0.01 0.1 1 10 100
Favours VCD Favours suture
Analysis 14.8. Comparison 14 PerClose ProGlide ProStar XL versus suture-based closure after EVAR with
open exposure of CFA, Outcome 8 Limb ischaemia.
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 14 PerClose ProGlide ProStar XL versus suture-based closure after EVAR with open exposure of CFA
Outcome: 8 Limb ischaemia
Study or subgroup VCD Suture-based closure Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nelson 2014 3/101 2/50 0.73 [ 0.12, 4.54 ]
0.01 0.1 1 10 100
Favours VCD Favours suture
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Analysis 14.9. Comparison 14 PerClose ProGlide ProStar XL versus suture-based closure after EVAR with
open exposure of CFA, Outcome 9 Length of hospital stay (hours).
Review: Vascular closure devices for femoral arterial puncture site haemostasis
Comparison: 14 PerClose ProGlide ProStar XL versus suture-based closure after EVAR with open exposure of CFA
Outcome: 9 Length of hospital stay (hours)
Study or subgroup VCD Suture-based closure
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Nelson 2014 101 32.4 (19.2) 50 43.2 (57.6) -10.80 [ -27.20, 5.60 ]
-50 -25 0 25 50
Favours VCD Favours suture
A D D I T I O N A L T A B L E S
Table 1. Types of vascular closure devices
Types of vascular clo-
sure
devices (VCD) classi-
fied according to their
mechanism to achieve
haemostasis
Name Recommended sheath
size (Fr)
Extravascular haemo-
static agent
Intravascular compo-
nent
Balloon-based device Epiclose-T 6 Temporary extravascu-
lar haemostatic balloon,
which is withdrawn at
the end of the procedure
Temporary anchor bal-
loon, which is with-
drawn at the end of the
procedure
Disc-based device Cardiva Catalyst II 4 to 10 Temporary nitinol-
based wire with a niti-
nol braided mesh disc,
which is removed at the
end of the procedure
Plug-based device AngioSeal VIP, An-
gioSeal STS-Plus, An-
gioSeal Evolution
6, 8 Bovine collagenplug and
an absorbable traction
suture
Absorbable intra-arterial
anchor (co-polymers of
polylactic and polyg-
lycolic acids, absorbed
within 30 days)
203Vascular closure devices for femoral arterial puncture site haemostasis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Types of vascular closure devices (Continued)
VasoSeal VHD, ED,
Elite
5 to 8 Puriﬁed bovine collagen-
based plug
-
VasoSeal Low Proﬁle 4, 5 Puriﬁed bovine collagen-
based plug
-
Duett Pro, Duett 5 to 9 Thrombin with platelet
activation of collagen
Temporary anchor bal-
loon, which is with-
drawn at the end of the
procedure
6/7F Mynx, Mynx M5 5 to 7 Water-soluble, freeze-
dried polyethylene gly-
col (PEG) material
Temporary anchor bal-
loon, which is with-
drawn at the end of the
procedure
ExoSeal PGA (polyglycolic acid)
, a trusted non-collagen
plug material
-
Metal clip-based device StarClose 5, 6 Nitinol clip -
StarClose SE 5, 6 Nitinol clip -
Angiolink EVS 6 to 8 Titanium staple -
Suture-based device PerClose AT 5 to 8 Braided polyester suture -
PerClose ProGlide 5 to 8 Monoﬁlament
polypropylene suture
-
ProStar XL 8.5 to 10 Braided polyester suture -
X-Site 5, 6 Braided polyester suture -
SuperStitch 6 to 12 Polypropylene suture -
• Balloon-based device (Epiclose-T) (Kuraklio lu 2008): A temporary balloon-positioning catheter is inﬂated inside the arterial
puncture site, while a larger haemostasis balloon is inﬂated directly on the outer surface of the arteriotomy. The balloon applies direct
pressure on the arteriotomy site, thus allowing natural coagulation to occur. After a few minutes of device deployment, the anchor
balloon is pulled back into the distal end of the shaft, while the haemostasis balloon remains pressing against the arteriotomy site. At
the end of the haemostasis waiting period, the haemostasis balloon is deﬂated and the device is removed, leaving no foreign body in
the intraluminal nor the extraluminal space.
• Disc-based closure device (Cardiva Catalyst II) (Schwartz 2010): conformable nitinol-based wire with a temporary nitinol
braided mesh disc on a tether, which is deployed inside the artery to achieve haemostasis. Temporary placement of a low-proﬁle,
conformable disc against the intima creates site-speciﬁc compression of both the arteriotomy and the tract. The haemostatic
mechanism is based on the natural elastic recoil of the arteriotomy site back to its pre-dilated state, around the wire. In addition, a
biocompatible coating on the Catalyst II Wire assists the body’s natural haemostatic process and promotes ease of removal. After a few
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minutes of device deployment, the nitinol mesh disc and wire are removed, thus leaving no foreign body in the intraluminal nor
extraluminal space.
• Plug-based device (predominantly of collagen in composition) consisting of an extraluminal sealant with or without an
intraluminal anchor (VasoSeal VHD, ED, Elite, VasoSeal Low Proﬁle) (Bechara 2010). The intra-arterial anchor can be a temporary
balloon-positioning catheter that is removed at the end of the procedure (Duett Pro, Duett, 6/7F Mynx, Mynx M5) (Bechara 2010;
Scheinert 2007) or an absorbable intra-arterial anchor that is absorbed by the body in 30 days (AngioSeal VIP, AngioSeal STS Plus,
AngioSeal Evolution). Collagen-based devices without an intra-arterial anchor can undergo repeated puncture for angiography. A
commonly used extra-arterial sealant is a bovine biodegradable product that triggers a haemostatic cascade and physical expansion to
tamponade the puncture site and tissue tract.
• Metal clip-based device (StarClose, StarClose SE, Angiolink EVS) (Bechara 2010): devices that utilise metal clip-based
technology and deploy metal staple or clip that penetrates the vessel wall to achieve haemostasis. Upon deployment, the metal clip or
staple remains in situ over the vessel wall and forms a geometric conﬁguration that approximates adventitial vessel layers to close the
arterial hole. The metallic clips or staples do not undergo a bioresorption reaction, which therefore does not trigger signiﬁcant soft
tissue inﬂammatory response. Repeat puncture or surgical exploration of the artery can be done safely.
• Suture-based device (PerClose AT, PerClose ProGlide, ProStar XL, X-Site, SuperStitch) (Bechara 2010): Arterial haemostasis is
achieved by deploying sutures to form a knot to close the arteriotomy. The knot is tied by a built-in mechanism within the closure
device or is tied manually. No proteinaceous biomaterial is left behind in the puncture tract; therefore, no inﬂammatory soft tissue
reaction is associated with this closure technology. Consequently, repeat arterial access or surgical exploration of the same artery can
be performed safely.
A P P E N D I C E S
Appendix 1. CRS search strategy
Search run on Fri Apr 8 2015
#1 MESH DESCRIPTOR Endovascular Proce-
dures EXPLODE ALL TREES
5490
#2 MESH DESCRIPTOR Angiography
EXPLODE ALL TREES
5510
#3 MESH DESCRIPTOR Catheterization EX-
PLODE ALL TREES
8520
#4 MESH DESCRIPTOR Femoral Artery 723
#5 MESH DESCRIPTOR Groin 88
#6 MESH DESCRIPTOR Punctures 288
#7 vascular 23798
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(Continued)
#8 vessel 5372
#9 catheter* :TI,AB,KY 13346
#10 cannulat*:TI,AB,KY 1002
#11 endovascular:TI,AB,KY 920
#12 percutan*:TI,AB,KY 7724
#13 PTA or PTCA 1339
#14 angiograph*:TI,AB,KY 9659
#15 angioplasty:TI,AB,KY 5639
#16 arteriotom*:TI,AB,KY 52
#17 femoral:TI,AB,KY 5807
#18 groin:TI,AB,KY 487
#19 punctur*:TI,AB,KY 2580
#20 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #
7 OR #8 OR #9 OR #10 OR #11 OR #12 OR
#13 OR #14 OR #15 OR #16 OR #17 OR #18
OR #19
57621
#21 MESH DESCRIPTOR Wound Closure Tech-
niques EXPLODE ALL TREES
1506
#22 MESH DESCRIPTOR Surgical Instruments
EXPLODE ALL TREES
537
#23 compres*:TI,AB,KY 4491
#24 clamp*:TI,AB,KY 3663
#25 press*:TI,AB,KY 79983
#26 plug*:TI,AB,KY 367
#27 closure:TI,AB,KY 4668
#28 closing:TI,AB,KY 511
#29 weight*:TI,AB,KY 49193
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(Continued)
#30 clip*:TI,AB,KY 876
#31 seal*:TI,AB,KY 2741
#32 mynx:TI,AB,KY 1
#33 (starclose or star-close or prostar or tecstar or per-
close or boomerang or angioseal or proglide or
vasoseal or duett):TI,AB,KY
65
#34 MESH DESCRIPTOR Hemostasis 697
#35 hemostasis:TI,AB,KY 2687
#36 haemostasis:TI,AB,KY 615
#37 #21 OR #22 OR #23 OR #24 OR #25 OR #26
OR #27 OR #28 OR #29 OR #30 OR #31 OR
#32 OR #33 OR #34 OR #35 OR #36
137390
#38 #20 AND #37 16375
#39 (arterial or artery):TI,AB,KY 44222
#40 closure:TI,AB,KY 4668
#41 #39 AND #40 553
#42 #38 OR #41 16635
#43 * NOT SR-PVD:CC 910030
#44 #42 AND #43 15550
Appendix 2. Glossary
Ambulation: mobilisation
Arteriotomy: procedure in which a hole is made in an artery wall by a knife or a needleArteriovenous ﬁstula: abnormal connection
between an artery and a vein
EVAR: endovascular aneurysm repair
Haematoma: bruise
Haemostasis: process that causes bleeding to stop
Percutaneous: through the skin
Pseudoaneurysm: haematoma that occurs as a result of a leaking hole in an artery
6 to 8 Fr: French catheter scale used to measure the size of the sheath or catheter
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